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Résumé
Le trouble du déficit de l’attention/hyperactivité (TDA/H) est un des troubles 
comportementaux le plus commun chez les enfants. TDAH a une étiologie complexe et des 
traitements efficaces. Le médicament le plus prescrit est le méthylphénidate, un 
psychostimulant qui bloque le transporteur de la dopamine et augmente la disponibilité de 
la dopamine dans la fente synaptique. Des études précliniques et cliniques suggèrent que le 
cortisol peut potentialiser les effets de la dopamine. Un dysfonctionnement du système 
hypothalamo-hypophyso-surrénalien (HHS) est associé avec plusieurs maladies 
psychiatriques comme la dépression, le trouble bipolaire, et l’anxiété. Nous avons fait 
l’hypothèse que le cortisol influence l’efficacité du traitement des symptômes du TDAH 
par le méthylphénidate. 
L’objectif de cette étude est de mesurer les niveaux de cortisol le matin au réveil et 
en réponse à une prise de sang dans un échantillon d’enfants diagnostiqué avec TDAH âgé 
de 8 ans. Le groupe était randomisé dans un protocole en chassé croisé et en double aveugle 
avec trois doses de méthylphénidate et un placebo pour une période de quatre semaines. 
Les enseignants et les parents ont répondu aux questionnaires SWAN et à une échelle 
d’évaluation des effets secondaires.  
Les résultats ont démontrés qu’un niveau de cortisol élevé au réveil prédit les sujets 
qui ne répondent pas au traitement du TDAH, si on se fie aux rapports des parents. En plus, 
la réactivité au stress élevé suggère un bénéfice additionnel d’une dose élevée de 
méthylphénidate selon les enseignants. Aussi, les parents rapportent une association entre la 
présence de troubles anxieux co-morbide avec le TDAH et une meilleure réponse à une 
dose élevée.  
Cette étude suggère qu’une forte réactivité de l’axe HHS améliore la réponse 
clinique à des doses élevées, mais qu’une élévation chronique du niveau de cortisol pourrait 
être un marqueur pour les non répondeurs. Les résultats de cette étude doivent être 
considérés comme préliminaires et nécessitent des tests plus approfondis des interactions 
possibles entre les médicaments utilisés pour traiter le TDAH et l’axe HHS. 
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Abstract
ADHD is the most common behavioural disorder in children with complex 
aetiology and efficacious treatments. The most prescribed medication for ADHD is 
methylphenidate, a psychostimulant that blocks the dopamine transporter and increases 
dopamine availability in the synaptic cleft. Preclinical and clinical studies show that 
cortisol may enhance dopamine effects. Dysregulation of the hypothalamic-pituitary-
adrenal axis is also associated with many psychiatric disorders such as depression, bipolar 
disease, and anxiety. We hypothesized that cortisol has an influence on the efficacy of the 
treatment of ADHD symptoms with methylphenidate.  
The objective of this study was to measure the salivary level of cortisol in a sample 
of 8-year-old children with ADHD upon waking and in response to a venipuncture. The 
children were then randomized to three doses of methylphenidate and a placebo in a 
double-blind cross-over design. Teachers and parents rated the behaviour of the children 
using the SWAN and a side effect rating scale. 
The results showed that high morning cortisol is a good predictor of a non-
responder under active medication, as reported by parents. Also, the high stress reactivity 
group, but not the low stress reactivity group, demonstrated a greater benefit going to a 
higher dose of methylphenidate, according to teachers. In addition, parents demonstrated an 
association between anxiety comorbid disorders and a better response to a high dose of 
methylphenidate.    
This study suggests that a strong reactivity of the HPA axis improves the clinical 
response at high dose, but that chronically elevated cortisol might be a marker for non 
responders. The results of this study should be seen as preliminary and require further 
testing of the possible interactions between ADHD medication and HPA activity. 
Keywords : ADHD, cortisol, methylphenidate, stress, HPA axis, dopamine 
  
vi
 
Table des matières 
PAGE TITRE………………………………………………………………………………i 
IDENTIFICATION DU JURY………………………………………………...................ii 
SOMMAIRE………………………………………………………………………….……iii 
ABSTRACT……………………………………………………………………..…………v 
TABLE DES MATIERES………………………………………………………...............vi 
LISTE DES ABBREVIATIONS……………………………………………….................ix 
DEDICACE……………………………………………………………………..................xi 
REMERCIEMENTS………………………………………………………………..…….xii 
1. INTRODUCTION……………………………………………………………………....1 
   1.1 Attention deficit hyperactivity disorder……………………………………………….1 
1.1.1 Prevalence and comorbidity of ADHD……………………………………...1 
1.1.2 Diagnosis and symptoms………………………………………………………1 
            1.1.3 Aetiology of ADHD……………………………………………………….......3  
a) Family and twin studies………………………………………………....3 
b) Genetic studies………………………………………………………......3 
c) Risk factors……………………………………………………………....5 
d) Imaging studies……………………………………………………….....5 
e) Neuropsychology of ADHD……………………………………….........5 
f) Environmental causes…………………………………………………....6 
           1.1.4 Treatment……………………………………………………………………....7 
                    a) Stimulant medication: methylphenidate………………………………….....7 
                    b) Stimulant medication: amphetamine………………………………………10 
                    c) Non-stimulant medication: atomoxetine…………………………………...10 
                    d) Bupropion………………………………………………………………….11 
                    e) Other medications………………………………………………………….11 
                    f) Behavioral therapy………………………………………………………....12 
                    g) Alternative therapy………………………………………………………...14 
  
vii
 
           1.1.5 Anxiety disorder……………………………………………………………...16 
     1.2 Stress……...………………………………………………………………………...16 
          1.2.1 HPA axis……………………………………………………………………....16 
          1.2.2 Awakening cortisol response………………………………………………….18 
          1.2.3 Cortisol reactivity……………………………………………………………..18 
          1.2.4 Cortisol and DA interaction…………………………………………………..19 
                 1.2.4.1 Cortisol and cocaine interactions: preclinical studies………………….19 
                 1.2.4.2 Cortisol and cocaine interactions: clinical studies……………………..22 
      1.3 Research questions………………………………………………………………...25 
2. ARTICLE..……………………………………………………………………………..26 
3. DISCUSSION………………………………………………………………………….65 
3.1 Overall presentation………………………………………………………………..65 
3.2 Cortisol diurnal rhythm and morning level………………………………………...66 
          3.2.1 Influence of the circadian rhythm of cortisol with age…………………..…...66 
          3.2.2 SES and race…………………………………………………………….........67 
          3.2.3 Sampling day and gender effect…………..…………………………………..68 
      3.3 Cortisol reactivity……...…………………………………………………………...68 
          3.3.1 Cortisol reactivity: effect of age………………………………………………69 
          3.3.2 Gender and cortisol reactivity…………………………………………...........71 
          3.3.3 SES and race………………………………………………………………….71 
          3.3.4 Individual difference in DA activity………………………………………….71 
      3.4 Interaction between dopamine and norepinephrine……………………………......72 
      3.5 Interaction between NE and cortisol……………………………………………....74 
      3.6 Interaction between cortisol and serotonin………………………………………...76 
      3.7 Other predictors of the response to methylphenidate………………………………78 
      3.8 Clinical implications…………………………………………………………….…79 
     3.9 Limitations of the present study…………………………………………………....82 
4. CONCLUSION………………………………………………………………………....83 
  
viii
 
BIBLIOGRAPHIE….……………………………………………………………………84 
ANNEXES……………………………………………………………………………….xiii 
Annexe 1 SWAN-F Enseignants………………………………………………………...xiii 
Annexe 2 SWAN-F Parents……………………………………………………………..xvi 
Annexe 3 French versions of the strengths and weaknesses of ADHD symptoms and 
normal behaviours (SWAN-F) questionnaire…………………………………………xix 
 
  
ix
 
Liste des abréviations 
 
 
TCA- Tricyclic antidepressant 
DA- Dopamine 
NE- Norepinephrine  
MTA- Multimodal Treatment Approach 
HPA axis- Hypothalamic-Pituitary Adrenal axis 
ACR- Awakening Cortisol Response 
HVA- Homovanillic Acid 
MHPG- 3-methoxy-4-hydroxyphenylglycol 
TSST- Trier Social Stress Test 
MPH- Methylphenidate 
SWAN- Strengths and weaknesses of ADHD symptoms and Normal behaviours ratings 
Scale 
HHS- Hypothalamo-hypophyso-surrénalien 
TDAH- Trouble du déficit de l’attention/ hyperactivité 
CPRS- Conners Parents Rating Scale 
PET- Positron Emission Tomography 
DAT- Dopamine transporter 
LG- Licking and grooming 
cAMP- cyclic adenosine monophosphate 
HCN- Hyperpolarization activated cyclic nucleotide gated 
PFC- Pre-frontal cortex 
SES- Socioeconomic status 
PLC- Phospholipase C 
DAG- Diacylglycerol 
PKC- Protein Kinase C 
  
x
 
SNRT- Selective inhibitor of norepinephrine reuptake transporter 
CRF- Corticotropin releasing factor 
CRH- Corticotropin releasing hormone 
NRI- Norepineprine reuptake inhibitor 
5-HT- Serotonin 
SSRI- Serotonin selective reuptake inhibitor 
VNTR- Variable number tandem repeats 
DRD4- Dopamine receptor D4 
ICD-10- International classification of Diseases 
IQ- Intelligence quotient 
WISC- Wechster Intelligence Scale for children 
DISC 4.0- Diagnostic Interview Schedule for children 
SD- Standard deviation  
  
 
  
xi
 
Je dédie ce mémoire de maitrise à ma mère et 
à mon père qui m’ont appris la persévérance 
et la rigueur dans tout ce que j’entreprends. 
De  plus, je dédie ce mémoire à Aleksy 
Skvorc, pour son support et sa présence.
  
xii
 
 Remerciements 
Je voudrais remercier mon directeur de recherche, Dr Philippe Robaey pour son 
aide, ses précieux conseils et sa disponibilité tout au long de l’elaboration de mon travail.
 1. Introduction
 
1.1 Attention deficit hyperactivity disorder 
 
1.1.1 Prevalence and comorbidity of ADHD 
 
Attention deficit hyperactive disorder (ADHD) is a disorder that is commonly seen in 
children and it is a highly prevalent. It is estimated to affect 5-10% of children and 4% of 
adults (Biederman, 2005). There are many other disorders that are comorbid with ADHD 
such as oppositional defiant disorder, conduct disorder, mood disorders, anxiety disorders 
and learning disorders. Between 18 to 35% of children with ADHD have one or more 
associated psychiatric disorders such as anxiety disorder, oppositional defiant disorder and 
conduct disorder. Also up to 15 to 20% of children with ADHD have associated specific 
learning disorder (Karande, 2005). ADHD subjects had more lifetime psychopathology 
compared to non-ADHD subjects; 87% had one psychopathology and 56% had at least two 
psychopathology compared to 64% and 27% respectively (McGough, 2005). Anxiety 
disorder has been found to co-occur with ADHD in 10-40% of children. The comorbidity 
of ADHD with mood disorders such as major depression is 15-75%. The rate of childhood 
ADHD in adults with bipolar disorder is estimated in the 10-20% range; however, the 
reverse is not true, follow-up studies of children with ADHD have not showed that they are 
at increased risk of developing classic bipolar disorder in adulthood. Consequently, this 
disorder is highly comorbid with other psychiatric disorder which makes it more complex 
and harder to find the optimal treatment.  
 
 
1.1.2 Diagnosis and symptoms 
 
ADHD is the most commonly diagnosed neuropsychiatric disorder in children (Karande, 
2005). The most common symptoms are inattention, impulsiveness and hyperactivity. The 
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diagnosis of ADHD is based on the Diagnostic and Statistical Manual (DSM-IV). The 
diagnosis of ADHD divides the disorder into three specific groups based on their 
predominant symptoms; the inattentive type, the impulsive/hyperactive type and the 
combined type.  
 
The diagnosis of ADHD is based on clinical findings and the criteria for children’s specific 
behaviours in the DSM-IV. These criteria describe the three subtypes of ADHD. To meet 
the diagnostic criteria for ADHD, a child needs to have at least six of the nine specific 
behaviours in the inattentive type or at least six of the nine behaviours in the 
hyperactive/impulsive type or at least nine behaviours described in both domains for the 
combined type. Also these behaviours need to be occurring often for the past six months to 
a degree that is maladaptive. Some impairment from the symptoms is present in two or 
more settings. In addition, these symptoms need to be present before seven years of age and 
there must be clear evidence of clinically significant impairment in academic or social 
functioning. As well, these symptoms should not be better explained by other psychiatric 
disorders. These core symptoms of ADHD are identified by informants (parents, teachers), 
by the patient or by direct observation of the behaviour of the patient. Structured interviews 
or a structured questionnaire are essential for the diagnosis of ADHD.  
 
Differences exist in the diagnosis process. The primary care physician generally sees the 
child and attempts to assess his physical and developmental development through a series 
of office visits. The American Academy of Pediatrics (AAP) prepared guidelines for 
physicians for the evaluation of children between the ages of six to twelve years (Kirby, 
2001). These guidelines are specific for children that present the symptoms of inattention, 
impulsiveness, hyperactivity and behavioural problems. They are used in order to assist in 
decision making for the physicians. However, they should always refer to the criteria in the 
Diagnostic and Statistical Manual for diagnosis. The guidelines emphasize the use of 
assessment tools in different settings such as school and home. Also, the use of teacher 
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assessment data is essential for the diagnosis of the children. In addition, the AAP indicates 
the importance of the detection of comorbid conditions for children that have been 
diagnosed for ADHD. As discussed earlier, ADHD is highly comorbid with other 
psychiatric disorders. 
 
1.1.3 Aetiology of ADHD 
 
ADHD is a complex and heterogeneous disorder. Both genetic and environmental 
factors contribute to the risk of ADHD. The aetiology of this disorder can be divided in 
biological and environmental causes. In terms of biological justifications, it can be further 
divided into genetics, brain structure and their influence on neuropsychology. In terms of 
environmental terms, it can be explained by parenting and diet among other possible 
causes. 
 
a) Family and twin studies  
The data from family studies suggest that there is a two to eightfold increase in the 
risk for ADHD in parents or siblings of children with ADHD. The heritability of ADHD 
was estimated mainly from twin studies. Heritability is a genetic measure used to establish 
the influence of genetic factors on the disorder (Biederman, 2005). According to twin and 
adoption studies from Australia, Sweden, the UK and many sites in the USA, the average 
heritability is estimated to 0.76. This implies that genes are very important in ADHD. The 
estimates of heritability from 1973 until 2004 have not changed, despite changes in the 
diagnostic systems. The high heritability observed for ADHD reveals a large influence of 
genetics on the aetiology of this disorder (Biederman, et al. 2005)  
 
b) Genetic studies 
Molecular genetic studies show that the genetic architecture of this disorder is 
complex. Genes with large effects are unlikely to exist. Many candidate genes studies have 
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used association to examine if biologically relevant gene variants affect the susceptibility of 
being diagnosed with ADHD. For the sake of clarity, we will only present two examples of 
association with candidate genes (DRD4 and DAT1). 
 
Among the candidate genes, the dopamine genes have been a large focus by 
researchers. These genes are important for the susceptibility of this disorder because 
dopamine plays an important role in attention and motivation. The dopamine receptor D4 
gene contains a highly polymorphic 48 base pair variable number of tandem repeats 
sequence. (48 bp VNTR) This polymorphism varies between two and seven copies but the 
four and the seven repeats allele are the most common number of repeats found in the 
population. The seven repeats allele is proven to show a blunted intracellular response to 
dopamine and to exhibit a lower affinity to antagonists in vitro (Asghari et al., 1995; Van 
Tol et al., 1992)  
 
There are four sets of pooled or meta-analyses that convincingly show that the 7 
repeats allele is associated with ADHD (Faraone, Doyle, Mick, & Biederman, 2001; 
Faraone et al., 2005; Li, Sham, Owen, & He, 2006; Maher, Marazita, Ferrell, & Vanyukov, 
2002). The odds ratio reported in these studies ranged from 1.13 (1.03 to 1.24) to 1.9 (1.5 to 
2.2). This is the range of odds ratio found for venous thrombosis when taking oral 
contraceptives or risk of for cardiovascular disease in passive smokers, after adjustment for 
confounding variables. 
 
The dopamine transporter (DAT) gene has been studied because it is the principal 
target of the first-line medications for ADHD (stimulant). The stimulant, and especially 
methylphenidate, inhibit the activity of dopamine transporter and diminish the symptoms of 
this disorder. If the first meta-analysis reported an association (Maher et al., 2002; Faraone 
et al., 2005), subsequent ones show no association (Li et al., 2006; Purper-Ouakil et al., 
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2005). This may be due to the heterogeneity of the polymorphism as well as to gene-
environment interactions (Brookes et al., 2006). 
 
c) Risk factors 
Neurobiology of ADHD is not known but imbalances in the dopaminergic and 
noradrenergic systems are likely to be involved in the symptoms of this disorder. Several 
environmental biological factors contribute to ADHD such as food additives, cigarette and 
alcohol exposure, low birth weight and maternal smoking during pregnancy (Biederman, 
2005).  
  
d) Imaging studies 
Neuroimaging suggest that dysfunctions in the fronto-subcortical pathways are related to 
the core ADHD symptoms (Biederman, 2005). Structural brain imaging found evidence for 
a smaller volume in the frontal cortex, cerebellum and subcortical structures. Functional 
imaging studies support a dysfunction in the fronto-subcortical pathways. These pathways 
are rich in catecholamines which are involved in the mechanism of action of ADHD 
medication. For example, when completing a Go/No-go task, children with ADHD do not 
activate frontostriatal regions as efficiently as children without this disorder. Instead, these 
children activate a more diffuse network of regions in the brain including more posterior 
and dorsolateral prefrontal regions compared to the control subjects (Booth et al., 2005; 
Schulz et al., 2004; Smith, Taylor, Brammer, Toone, & Rubia, 2006). This deficit in striatal 
activation is supported by the observation that dopamine D2 receptor level in the striatum 
predicts the reinforcing effects of the psychostimulant. Levels of the receptors were highly 
correlated (r=0.82) with the rating of drug-liking (Volkow et al., 1999; Volkow et al., 
2002b). 
 
f) Neuropsychology of ADHD 
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In contrast to the dominant view explained above, some researchers suggest that 
ADHD is not characterized by cognitive dysregulation but as a motivational style. ADHD 
is viewed as a functional response by the child aiming at avoiding delay. When the child 
has control over his environment, he can choose to minimize the time by acting 
impulsively. When the child is not in control of his environment, he will choose to distract 
himself from the passing of time. For example, in a classroom, the child will distract 
himself by daydreaming or by fidgeting. Based on these findings, some researchers 
proposed the dual pathway model of ADHD. This model suggests two possible routes 
between biology and ADHD behaviour. One pathway is via cognitive dysregulation and the 
other one via motivational style. This model is viewed clinically to target different sub-
types with different treatments (Sonuga-Barke, 2002; Sonuga-Barke, 2003). Also this 
model could allow the development of novel interventions such as using delay fading, a 
technique to reorganize the child’s delay experience in order to increase tolerance to delay 
and reduce ADHD symptoms (Sonuga-Barke, 2004). 
g) Environmental causes 
Parenting and diet were the 2 possible ways proposed to explain how the 
environment affects a child. ADHD is then viewed as the result of a gene-environment 
interaction. If a child has the genetic predisposition of ADHD, he will express the disorder 
but only if he is put in the pathogenic environment such as chaotic parenting. The best 
evidence for the effect of parenting on ADHD symptoms comes from intervention studies 
where parents were taught alternative parenting skills. The results of these studies show that 
the influence of parenting is important for the child. The relationship between ADHD and 
parenting may result from the negative effects of the child on the parent’s behaviour and 
the negative effects of the parents influencing the child’s behaviour (Bor, 2002). 
 
Diet is another environmental influence on children with this disorder. Bad diets 
such as food additives, refined sugars and fatty acid deficiencies have been associated with 
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ADHD symptoms. In a large randomized controlled trial, researchers studied the influence 
of food coloring and benzoate preservatives on preschool hyperactivity. The results showed 
an adverse effect of food coloring and benzoate preservatives on the behaviour of these 
children. However, these results were based on parental reports but not on simple clinical 
assessment. The improvement of diet has an impact on the health of the children and 
overall behaviour (Bateman et al., 2004; McCann et al., 2007; Schab & Trinh, 2004). 
 
1.1.4 Treatment 
 
There are three treatments that are efficacious for ADHD. The first treatment is 
using medications; the second treatment available is behavioural therapy and the third 
treatment for this disorder consists of the combination of the two above treatments. The 
management of ADHD by medication is proven to achieve amelioration of the core 
symptoms of this disorder. The two most common medications given for children are 
stimulants and atomoxetine. The use of medication is proven to be a superior for the control 
of symptoms compared to behavioural therapy (Karande, 2005). The medication given for 
the treatment of ADHD is mostly the stimulants. The most commonly prescribed stimulant 
is methylphenidate. Some subjects are non-responsive or respond badly to stimulants and 
they are given the non-stimulants drugs such as atomoxetine. Further, other drugs can be 
used for ADHD treatment such as antidepressants and alpha-adrenergic antagonists.  
 
a) Stimulant medication: methylphenidate 
Amphetamine and methylphenidate are the most commonly prescribed medication for 
the treatment of children with ADHD. Both these drugs are rapidly acting stimulants and 
their effects are seen within 30 to 45 minutes of their oral administration. Their behavioural 
effects peak within 2 to 4 hours after ingestion. Their effect will dissipate within 3 to 7 
hours. These drugs have a short half-life so they must be taken 2 to 3 times per day. This 
dosing schedule causes inconvenience for children and parents. These medications are 
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available in slow-release doses to reduce the number of times the medication has to be 
taken. The improvement in behaviour for children taking one of these two drugs occurs in 
sustained attention, impulse control and reduction of task-irrelevant activity. There are 
other drug-related improvement such as in self-esteem, aggression, handwriting, academic 
productivity, persistence in effort, working memory, peer relations, emotional control and 
participation in sports. Individually tailored doses of methylphenidate improved attentional 
functioning of children with ADHD. These differences were mostly of small or medium 
size, but the children with ADHD who were on methylphenidate treatment were still 
considerably impaired (Dafny & Yang, 2006). The effects of the medications are 
idiosyncratic, with some children having maximal improvement at lower doses and other 
children show maximal improvement at higher doses. Mild insomnia and appetite reduction 
are the most common side effects of stimulants (Barkley, 2004). 
 
Methylphenidate hydrochloride is a central nervous system stimulant that is closely 
related to the structure of dextroamphetamine, an isomer of amphetamine. The drug was 
first synthesized in 1944 and was used as an analeptic for numerous barbiturate-induced 
comas. Later, it was used to improve memory in depressed and elderly patients. Since then, 
it has been used to improve the alertness in children with emotional, behavioural and 
learning difficulties. MPH is metabolized via de-esterification to ritalinic acid and released 
in the urine within 48 hours. Brain concentrations of this drug exceed those of plasma as 
MPH passes through the blood brain barrier easily. The therapeutic effect of MPH has been 
attributed to its ability to bind to the DAT in the presynaptic terminal and block the 
reuptake of DA. This blockade causes an increase in DA in the synaptic cleft which is the 
effect that is linked to the reinforcing properties of MPH (Dafny et al., 2006). MPH does 
not stimulate catecholaminergic receptors but facilitates the action of DA. It slows down 
dopamine reuptake from the extracellular space. Its behavioural effects are seen within 30 
min of oral administration of the drug and its effects last for three to five hours. The daily 
dose should be individualized by titration and monitored for children. The doses 
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recommended are between 5 to 20 mg two to three times daily. Side effects include 
anorexia, stomach-ache, headache, irritable mood, tics and sleep difficulties. However, 
these side effects are mild and disappear after continuous use of this medication. Side 
effects increase with the increase of the dose. In some children, methylphenidate has 
slowed their physical growth during the first to third year of their administration. In 
addition, long acting methylphenidate is available for a better compliance of the 
medication. The long acting dose is taken once daily and its action is on a period up to 10 
hours (Karande, 2005). 
 
Methylphenidate is the drug of choice for treating ADHD and it is effective in 60-70% 
of individuals. There exist individual differences in the actions of methylphenidate which 
are not completely elucidated. This explains the different doses required to achieve the 
clinical response in ADHD subjects. Positron emission tomography (PET) was used to 
image the blockade of dopamine in real time after the administration of the drug. Cocaine is 
a dopamine transporter (DAT) ligand and raclopride is a dopamine D2 receptor ligand and 
competes with dopamine to bind the receptor. Cocaine radioligand is used to assess the 
level of DAT blockade with methylphenidate. Raclopride radioligand is used to measure 
methylphenidate induced changes in extracellular dopamine. Hence the two radioligands 
were used to determine the effects of methylphenidate on the DAT and on extracellular 
dopamine (Volkow et al., 2002b). 
 
There exist differences in dopamine cell activity that cause the inter-subject variability 
of methylphenidate. Methylphenidate is a DAT blocker and its ability to block this 
transporter is a function of the level of DAT blockade but also of dopamine cell activity. 
Dopamine (DA) release is dependent on DA cell activity. If a subject has a high dopamine 
cell activity, dopamine will be released faster in the synapse. Homovanilic acid (HVA) 
which is the principal metabolite of dopamine serves as a marker for dopamine activity in 
the cerebrospinal fluid. Hence, DA cell activity may cause the variability of 
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methylphenidate observed between subjects with ADHD. It is estimated that 15-30% of 
subjects do not respond to methylphenidate. This non responsiveness could reflect very low 
dopamine activity because the rate of DA released is determined by DA cell activity. Using 
PET scans, subjects were tested before and after the dose of methylphenidate to estimate 
the DAT occupancy with cocaine or raclopride as radioligands. Methylphenidate 
significantly blocked DAT and increased extracellular dopamine in the brain. However, the 
correlation between DAT blockade and dopamine increase was not significant. This leads 
to the conclusion that individual differences in DAT blockade are not the only source of 
this variability seen in the effect of the drug. Hence the variability in the effects of the drug 
is seen for an equivalent level of DAT blockade, methylphenidate would induce smaller 
dopamine changes in subjects with low dopamine cell activity (Volkow et al., 2002a). 
 
 
b) Stimulant medication: amphetamine 
Amphetamine is another psychostimulant. It acts on the central nervous system as a 
direct sympatomimetic. Its mode of action is via the release and reuptake inhibition of NE 
and DA. The activity of amphetamine on the vesicular monoamine transporter is crucial in 
the release process of the monoamines except serotonin. Amphetamine is responsible for 
releasing DA in the nucleus accumbens. The reinforcing effects of stimulants are mediated 
by the increase in DA in this region of the brain (Hearn et al., 2004). The beneficial effect 
for the treatment of ADHD include improved impulse control, improved concentration, 
decreased sensory overstimulation and decreased irritability. The side effects are the same 
as for methylphenidate but the effects on appetite and sleep tend to be stronger for 
amphetamine. Also amphetamines last longer in the body than methylphenidate. Its half life 
is between 10 to 13 hours.  
 
c) Non-stimulant medication: Atomoxetine 
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Atomoxetine blocks the reuptake of noradrenaline selectively. This is a new drug and 
represents an important advance in the pharmacological management of ADHD. This 
medication shows an efficacy similar to methylphenidate. It consists of a daily dose. Its 
main side effects are nausea, vomiting, decreased appetite and weight loss (Karande, 2005).  
 
Atomoxetine is highly specific for the presynaptic norepinephrine transporter with 
minimal affinity for other noradrenergic receptors or other neurotransmitter transporters or 
receptors. Methylphenidate, placebo or atomoxetine were used in a double-blind study in a 
total of 291 children. Atomoxetine efficacy was different from placebo and it was an 
effective drug for the treatment of ADHD. Also atomoxetine was shown to be safe and well 
tolerated in patients treated for a period of nine weeks (Spencer et al., 2002). Three 
different doses of atomoxetine were examined in children and adolescent with ADHD. The 
results obtained with the lowest dose 0.5 mg/kg/day showed an intermediate efficacy 
between the placebo and the two higher doses. The two higher doses 1.2 and 1.8 mg/kg/day 
are associated with superior outcomes compared to placebo but were not different between 
each other (Michelson, 2001). Atomoxetine was also tested in the adult population that has 
ADHD. The researchers found that it appears to be an efficacious treatment for adult 
ADHD (Michelson, 2003). 
 
d) Bupropion
Bupropion is another antidepressant that also was found effective in treating ADHD. 
Bupropion affects the noradrenergic and dopaminergic system. Bupropion produces 
improvements in ADHD symptoms but is not as efficacious as stimulant medications. It 
reduces the symptoms of ADHD. The side effects include oedema, rashes, irritability, loss 
of appetite and insomnia (Barkley, 2004). 
 
e) Other medications 
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Other drugs can also be used to treat ADHD. Examples of such drugs antidepressant 
and alpha-adrenergic antagonist have been used for the treatment of ADHD as a substitute 
to stimulants. Tricyclics antidepressants (TCA) have been found effective to treat ADHD 
patients. These drugs act by increasing the levels of norepinephrine in the brain, as 
atomoxetine, and result in a positive response from 70-90% of children with ADHD. 
Examples of TCA are imipramine, nortriptyline, desipramine and amitriptyline. Less is 
known about the pharmacokinetics and behavioural effects of these drugs on children with 
ADHD than with stimulants. These medications are given twice a day and their action is 
longer than stimulants. The most common side effects are drowsiness, dry mouth, 
constipation, and flushing. The TCA’s are recommended to be used as a treatment for 
ADHD in the case that stimulants and atomoxetine are not effective. Also, clinicians need 
to evaluate the cardiac functioning of children before starting the treatment with TCA and 
then monitoring it during the course of the treatment. TCA have risks of impairing cardiac 
functioning (Barkley, 2004). 
 
Alpha-adrenergic drugs such as clonidine and guanfacine have shown positive effects 
on the symptoms of ADHD (Kirby, 2001). These drugs act as an alpha-2 adrenergic 
receptor agonist. However, the scientific literature on the efficacy of these drugs is limited 
(Karande, 2005). From the limited research available, clonidine is less effective than 
stimulants in improving inattention and school productivity but equally effective in 
reducing hyperactivity and moodiness. The common side effects are drowsiness, dizziness, 
weakness and occasional sleep disturbance (Barkley, 2004). 
 
f) Behavioural therapy 
During behaviour therapy, parents are taught by psychologist how to achieve consistent 
and positive interactions with their children. They are taught how to reinforce positive 
behaviours, how to extinguish negative behaviours and how to effectively punish a child for 
wrong behaviour. Psychoeducational intervention at school such as seating the child beside 
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the teacher to minimize distractions by other students or assigning a specific teacher daily 
to review with the child his homework is an effective way to improve the academic 
achievement of these children (Karande, 2005).  
 
The combined therapy is the optimal treatment for ADHD children. Although it does 
not does not achieve better symptoms control than the medication alone, it helps reduce the 
total daily dose of medication and helps achieve positive functioning outcomes for peer 
interactions and parents-child interactions (Karande, 2005). The Multi-modal treatment 
study of ADHD (MTA) compared the efficacy of the use of medication alone, psychosocial 
intervention and the combination of both methods. The results of the MTA study showed 
that medical management alone was more effective for the core symptoms of ADHD than 
psychosocial treatment alone. Also, psychosocial intervention did not significantly improve 
the result when it is combined with medical treatment (Jensen, 1999). 
 
There are a number of concerns for the use of psychostimulants for children especially 
young children. One concern of the use of this medication regards the ethical objections to 
utilize medication to change child’s behaviour. Other concerns for the long-term use of the 
psychostimulants are the lack of evidence of long-term effectiveness of psychostimulants. 
Also research showed that pre-school children are at high risk of developing short-term side 
effects (Greenhill et al., 2006; Swanson et al., 2006). There is also a lack of evidence of the 
long-term consequence on the physical and neurological development of pre-school 
children. In addition, sub-group analysis of the MTA study indicated a large effect of 
psychosocial intervention in certain groups and settings. For example, 75% of the patients 
assigned for the behavioural group were successfully maintained without medication for 14 
months. Also, the combined group had the same outcome as the medical treatment group 
but this was achieved with a 20% reduction of the dose of medication used in long-term 
treatment. The behavioural intervention mediates improvements in the parent-reported 
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comorbid anxiety, in the negative parenting and ineffective discipline and in decreasing 
parental conflicts (Vitiello et al., 2007; Swanson et al., 2002; Barkley, 2000).  
 
 
g) Alternative therapy 
For treating ADHD, alternative therapies such as diets have been used. It is sought as a 
natural method to control the symptoms of ADHD. Diets are the most common alternative 
treatment to stimulant therapy. The Feingold diet is based on the elimination of food 
additives, preservatives (Kirby, 2001). This diet is based on the theory that some children 
are sensitive to dietary salicylates and artificial added colors, flavours and preservatives. 
Some recent meta-analyses and controlled double-blind placebo studies seem to support the 
value of the Feingold diet (Bateman et al., 2004; McCann et al., 2007; Schab et al., 2004).   
Another dietary intervention is eliminating all sugars from the diet. This diet is based on 
the belief that sugars causes hyperactivity. These claims have not been supported. Some 
theories of a relation between sugar, mood and behaviour were proposed in the early 
1990’s. It was suggested that these states of anxiety and frustration were reported at the 
same time as intake of sweeteners was increased. The belief that avoiding sugar would help 
a child with ADHD comes from this theory. The studies so far showed weak and 
conflicting clinical evidence so this hypothesis needs yet to be validated (Marcason, 2005). 
Vitamins and supplements is another hypothesis for the symptoms of ADHD. Zinc is 
another dietary supplement that is involved in the regulation of dopamine. Hence there are 
zinc supplements sold for the treatment of ADHD. However, zinc supplementation should 
be monitored because of zinc’s possible toxicity in higher doses than normal (Kirby, 2001). 
Supplementation with high doses of vitamins and minerals is another option that has 
been proposed. The hypothesis for this theory is from the observation that some people 
have genetic abnormalities that result in increased requirements for vitamins and minerals. 
However, there is a lack of scientific evidence for this treatment. In addition, the American 
Psychiatric Association and the American Academy of Pediatrics have concluded that the 
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use of megavitamins and minerals to treat behavioural and learning problems is not 
justified by clinical evidence (Marcason, 2005). 
 
Another intervention is the use of fatty acids (EFA) supplementation for ADHD. 
Numerous studies have reported that children with ADHD have low levels of EFA and 
supplementation would be beneficial for them. However, the studies with EFA 
supplementation have not established for all behavioural characteristics of ADHD. More 
research needs to be done for the use of EFA supplementation as a treatment option 
(Marcason, 2005). 
 
Herbal treatments are another option for ADHD. Calming herbs such as chamomile, 
lemon balm, valerian are some herbs that are used to treat the symptoms of sleepiness and 
restlessness often found in children with ADHD. However, the lack of clinical trials to 
prove the side effects of these herbs requires physicians to be cautious in recommending 
this alternative for ADHD patients. Another natural herb such as ginkgo biloba has shown 
to have a beneficial effect on concentration and cognition. Evening primrose oil is another 
herb that contains important essential fatty acids that could be used for ADHD. However, it 
is important to understand that there are no clinical trials that prove the efficacy of these 
alternative treatments for ADHD (Kirby, 2001). Hence, clinicians should advise parents 
that want to use natural herbs as an alternative treatment should be cautious in 
administrating these herbs to their child.   
 
Overall there are many different treatment options for ADHD. It is not a simple task to 
find a good treatment that works for every person with ADHD. The treatment needs to be 
updated with current research findings and also it needs to be adapted to accommodate each 
child or person’s individual needs. The multimodal treatment option remains a very 
successful choice including medication, parent/school counselling and behavioural therapy. 
More research needs to be done on dietary interventions in order to fully assess the impact 
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of this alternative treatment. Improved study design and clinical trials need to be expanded 
for more precise and accurate results on the treatment options.  
 
1.1.5 Anxiety disorders 
Anxiety disorders are comorbid with ADHD in approximately 50% of ADHD 
children (Bowen et al., 2008). Children with ADHD tend to worry about competence, 
future events and they show a great need of reassurance. Anxiety disorders as a comorbid 
condition may affect the functioning and treatment outcome of children with ADHD. The 
presence of comorbid anxiety increases the risk for interpersonal deficits, difficulties 
interacting with peers and self-esteem problems. The presence of both these disorders is 
associated with more attentional problems, school fears and lower levels of social 
competence compared to the ADHD only group. Data from studies suggest that anxiety is 
often a precursor to mood and substance disorders and among children with ADHD, the 
pathway to depression is often via anxiety. Therefore, treatment of ADHD children with 
comorbid anxiety is more complex and an array of symptoms need to be considered in the 
intervention.  
1.2 Stress 
The high proportion of children having anxiety disorders with ADHD suggested a 
possible disruption of the hypothalamic pituitary adrenal (HPA) axis. As ADHD is thought 
to be primarily a dopamine system disorder, improved by dopaminergic drugs, the 
relationship between cortisol and dopamine is of interest. The stress system is a complex 
network composed of cells that release hormones that act as mediators for survival. This 
large network of cells is regulated by negative and positive feedback.  
1.2.1 HPA axis 
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The HPA axis is a complex set of direct influences and feedback interactions 
between the hypothalamus, the pituitary gland and the adrenal gland. These interactions are 
important to maintain homeostasis. They are a major part of the neuroendocrine system that 
controls reactions to stress and regulates various body processes such as digestion, the 
immune system, mood and sexuality, and energy usage.  
 
Cortisol is a hormone secreted by the adrenal glands in response to a stressful 
situation. It helps the body to adapt to the new environment. Cortisol is secreted by the 
activation of the hypothalamic-pituitary-adrenal axis. The hypothalamus is related to the 
pituitary by the portal blood system. Therefore the releasing factors liberated by the 
hypothalamus reach quickly the pituitary where a mediator is again released. Then that 
hormone reaches the adrenal glands and causes the secretion of cortisol. In addition, when 
cortisol concentrations are high, it negatively feedback to the hypothalamus and the 
pituitary to stop releasing the hormones that causes its secretion from the adrenal glands. 
Hence this system is composed of many hormones that act together in response to stress.  
 
Cortisol has widespread actions to help restore homeostasis following stress. It acts 
as a physiological antagonist to insulin by promoting gluconeogenesis, breakdown of lipids 
and proteins, mobilization of extra hepatic amino acids and ketone bodies. This results to 
increased blood glucose concentrations. It also increases blood pressure, lowers the activity 
of the immune system and bone formation. Cortisol has also effects on brain cells. Long-
term exposure to cortisol leads to damage to cells in the hippocampus. This damage impairs 
learning. However, short-term exposure to cortisol helps to create memories. This 
mechanism for memory storage is called flash bulb memories. This type of memory is 
stored with great detail during a highly personally significant event or a shocking event.  
 
The formation of glucocorticoids hormones is the final step of the hypothalamic 
pituitary adrenal axis that allows the human to respond to environmental stressors. 
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Glucocorticoid hormones formation is characterized by a circadian rhythm. The levels of 
these hormones are at their peak in the morning and are their lowest level during the night. 
Also the secretion of these hormones is increased during stressful situations, as an adaptive 
response of the body to stress. It helps the body to adjust during these stressful situations by 
increasing heart rate, lipolysis and glyconeogenesis. The two latter effects increase blood 
glucose and help the body to cope with stressful situations by increasing the amount of 
energy available (Marinelli & Piazza, 2002). 
 
1.2.2 Awakening cortisol response  
The awakening cortisol response consists of a rapid and a marked rise of cortisol 
and ACTH after awakening and continues for about 60 minutes, detectable in about 75% of 
healthy subjects (Buckley & Schatzberg, 2005). The ACR is independent of the mode of 
awakening, naturally or with an alarm. ACR is distinct from the cortisol rhythm and it is 
defined as the increase in cortisol concentration by 50 to 75% in a period of 30 to 45 
minutes following awakening. The transition from sleep to awake is essential for the 
presence of the ACR. It appears to be a true response to awakening superimposing on the 
circadian cycle, and not the continuation of the increasing level of cortisol in the second 
half of the night (Wilhelm, 2007). ACR has been measured in many patients and control 
subjects. ACR was increased in relation with perceived stress (Pruessner, Hellhammer, 
Pruessner, & Lupien, 2003; Schlotz, Hellhammer, Schulz, & Stone, 2004), with 
neuroticism (Portella, Harmer, Flint, Cowen, & Goodwin, 2005), depressive symptoms 
(Pruessner et al., 2003), even in recovered depressed patients (Bhagwagar, Hafizi, & 
Cowen, 2003). However, ACR was decreased after poor sleep due to primary insomnia, 
chronic fatigue syndrome (Roberts, Wessely, Chalder, Papadopoulos, & Cleare, 2004), 
post-traumatic stress disorder (Rohleder, Joksimovic, Wolf, & Kirschbaum, 2004), early 
loss experience (Meinlschmidt & Heim, 2005). Thus, ACR is an important measure that 
indicates whether HPA axis functioning is normal or abnormal.  
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1.2.3 Cortisol reactivity 
Perceived stress activates the central nervous system, causing the release of 
corticotrophin releasing hormone from the hypothalamus which causes the release of 
adrenal corticotrophic hormone from the anterior pituitary and results in cortisol secretion 
from the adrenal glands (Burke, 2005). Elevations of cortisol will act on the hypothalamus 
and anterior pituitary to inhibit the HPA system via negative feedback in the hippocampus. 
The dynamics of the HPA system consists of three phases described by the unstimulated 
basal activity which is the non-stressed HPA activity, the stress reactivity phase in which 
cortisol increase from baseline following the onset of a stressor and a stress recovery phase 
in which cortisol levels return to baseline following the offset of the stressor. Each of these 
phases are described by different physiological processes with mineralocorticoid receptors 
regulating cortisol levels during periods of low HPA activity and glucocorticoid receptors 
regulating cortisol responses to stress and cortisol levels during periods of high HPA 
activity. Thus, cortisol reactivity will be examined in ADHD children for its possible role 
with methylphenidate treatment. 
 
1.2.4 Cortisol and DA interaction 
 
1.2.4.1 Cortisol and cocaine interactions: preclinical studies  
There are many examples in preclinical studies of interactions between the 
dopamine systems and the HPA axis. They have been reviewed briefly in the introduction 
of the presented paper. The role of the HPA axis in cocaine reinforcement will be reviewed 
more in detail, using the intravenous self-administration model. Cocaine share with 
psychostimulant the same mechanism of action (blockade of the dopamine transporter in 
the presynaptic neuron). Therefore, the interaction between cocaine and dopamine in the 
self-administration procedure might inform us about the possible relations between 
psychostimulant and cortisol while using them as medication for ADHD.  
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The first phase of cocaine self-administration is the acquisition phase. During this 
phase, the rat learns to make the response that delivers cocaine, which in turn reinforces the 
response. Different forms of social stress increase cocaine or stimulant self administration: 
social isolation (Schenk, Lacelle, Gorman, & Amit, 1987), rats seeing other rats receiving 
footshocks (Ramsey & Van Ree, 1993), males rats housed with female rats (Lemaire, 
Deminiere, & Mormede, 1994),  exposure to threat or attack (Haney, Maccari, Le, Simon, 
& Piazza, 1995; Tidey & Miczek, 1997; Miczek & Mutschler, 1996).  
 
Physical stress can also influence the acquisition phase of cocaine self-
administration. The effects on the acquisition phase of cocaine self-administration of 
exposure to footshocks either when the rat presses a lever that delivers food or regardless of 
whether or not it has pressed the food delivering lever have been studied. In the former 
condition, there was a conflict between obtaining food and avoiding pain, while in the latter 
condition, there was no conflict as obtaining food and avoiding pain were unrelated. In the 
contingent condition, the animal had some control over the stressor while in the non 
contingent condition, the animal had none. In control rats that did not receive any electric 
footshock and pressed the food delivering level, the dose-response curve followed a typical 
inverted U shape during the acquisition phase. Rats exposed to the non contingent 
condition (uncontrollable stress) demonstrated higher drug self-administration by session 
for the same dose of cocaine, as compared with those in the contingent condition. However, 
this shift upward and to the left of the dose-response curve was only observed in the 
ascending limb of the dose-response curve. For higher dose of cocaine infusion, the 
condition no longer influenced cocaine self-administration (Goeders & Guerin, 1994). Rats 
exposed to the contingent condition did not show a different dose-response curve as 
compared to control animals.  
 
Stress-induced increases in plasma corticosterone were positively associated with 
the ability of non-contingent electric footshocks to shift the ascending limb of the 
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acquisition dose-response curve upwards and to the left. Accordingly, rats treated with 
repeated exogenous injections of corticosterone during the two preceding weeks prior the 
start of the self-administration procedure in order to mimic the HPA activation during the 
uncontrollable footshock condition, also showed a leftward shift of the ascending limb of 
the dose-response curve (Goeders & Guerin, 1996b). Surgical removal of the adrenal gland 
completely flattened the dose-response curve, as compared with sham-operated controls, 
although there were no differences between these two groups for the food delivery level 
responding (Goeders & Guerin, 1996a). Similarly, rats treated with repeated injection of 
high dose of dexamethazone during the two weeks preceding the self-administration 
procedure did not acquire cocaine administration, at any dose tested (Goeders et al., 1996a). 
As high dose of dexamethasone practically suppressed corticosterone secretion by the 
adrenal gland, it realised a pharmacological adrenalectomy and replicated the results of the 
surgical removal of the adrenal glands. Glucocorticoid thus seems necessary for the 
acquisition of cocaine self-administration and it does not occur unless corticosterone level 
is increased above a threshold level.  
 
The activity of the HPA axis is also critical during the maintenance phase, once the 
animal has learned the behaviour that is reinforced by cocaine infusion. Ongoing cocaine 
self-administration can be decreased by drugs that reduce the corticosterone secretion, but 
this effect is only observed for low dose of cocaine infusion. Metapyrone blocks the 11 
beta-hydroxylation and ketoconazole both the 11 beta- and 18-hydroxylation, reducing the 
corticosterone synthesis. Pre-treatment with ketoconazole reduced self-administration of 
low dose of cocaine without affecting the food-reinforced behaviour and led to extinction 
of cocaine self-administration (Goeders, Peltier, & Guerin, 1998). Cocaine self-
administration was also decreased by a drug that blocked the central CRH receptors, but 
this effect was not dose-dependent (Goeders & Guerin, 2000). This further reinforces the 
role of the HPA axis in cocaine self-administration, as cocaine might influence the HPA 
axis at the level of hypothalamic CRH.  
  
22
 
 
Once the cocaine self-administration is stable, extinction is obtained by no longer 
reinforcing the responding by the delivery of the drug. Once the extinction is obtained, 
various manipulations can re-instate the self-administration behaviour. Exposure to non-
contingent electric footshocks is a form of stress that can reinstate cocaine self-
administration. However, pre-treatment with ketoconazole prior to exposure to the stressor 
prevented this re-instatement (Mantsch & Goeders, 1999).   
 
To conclude, the HPA axis is involved in the acquisition, the maintenance and the 
re-instatement of cocaine self-administration. The fact that cocaine can induce anxiogenic-
like responses in rats could have led to the opposite prediction that corticosterone would 
antagonize the reinforcing effect of cocaine. However, pressing the cocaine delivery lever 
is under the control of the animal and the reinforcement by cocaine infusion makes the 
effects of pressing the lever controllable and predictable. The controlled and predictable 
effects of the activation of the HPA axis may result in an internal state of motivated 
behaviour whereby the animal actually seeks out specific sensations in an internal state that 
might be compared with that of individual who engage themselves in thrill-seeking 
activities. If we extrapolate the results of these experiments to humans treated with 
stimulant, it is tempting to propose that the individuals who have a strong HPA response to 
a stressor could demonstrate a stronger sensitivity to stimulant medication and respond to 
lower dose of stimulant, or continue to respond at higher dose, reproducing the upward and 
left shift of the dose-response curve observed during the acquisition phase. Also, 
individuals with higher level of basal HPA activity would have a decreased sensitivity to 
stimulant medication, reproducing the effect of pre-treatment by high dose of 
dexamethasone.  
 
 
1.2.4.2 Cortisol and cocaine interactions: clinical studies 
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In healthy volunteers receiving intravenous injection of methamphetamine in a 
double-blind randomized cross-over design, pre-treatment by repeated injection of 
hydrocortisone over 7 consecutive days did not affect the expected decrease in prolactin 
level in the plasma. As prolactin is under tonic inhibitory control of dopamine neurons from 
the zona incerta in the hypothalamus, prolactin level was expected to decrease since 
methamphetamine increases dopamine release. Pre-treatment neither affected the increased 
subjective mood rating nor the performance on a task of sustained attention, which have 
been showed to be sensitive markers of changes in dopamine levels (Hearn et al., 2004). 
This lack of effect may be due to the type of glucocorticoid regimen, the lack of sensitivity 
of the individuals tested, as those individuals with a greater vulnerability to addiction 
would have altered regulation of HPA system. In another study, the subjective effects of 
intravenous injection methamphetamine were evaluated in humans with previous 
experience of methamphetamine injection in two opposite conditions. In the first condition, 
cortisol levels were directly increased by administering orally hydrocortisone while in the 
second condition, the cortisol response was blocked with the cortisol synthesis inhibitor 
oral metyrapone. Neither raising cortisol level nor blunting cortisol response altered the 
pleasurable effects of methamphetamine (Harris, Reus, Wolkowitz, Mendelson, & Jones, 
2003). However, homovanillic acid (HVA) levels were greater after hydrocortisone or 
metyrapone pre-treatment, as compared to placebo. Moreover, 3-methoxy-4-
hydroxyphenylglycol (MHPG) levels were greater after metyrapone pre-treatment. 
Hydrocortisone pre-treatment diminished HVA and MHPG increases after 
methamphetamine (perhaps explaining the lack of expected increase in pleasurable effects), 
but metyrapone did not. Thus, raising cortisol concentration did affect the cathecholamine 
response to methamphetamine, but blocking cortisol synthesis did not produce opposite 
effects (Harris et al., 2006). 
 
Positron emission tomography (PET) can be used to measure extracellular 
dopamine release in the brain, with [11C]raclopride as D2 receptor radioligand. 
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[11C]raclopride competes with endogenous dopamine for the D2 receptors, and a stronger 
fixation of the radioligand indicates smaller release of extracellular dopamine (Volkow et 
al., 2002b). By measuring also the HPA activity, it is thus possible to assess directly in 
humans the possible interactions between cortisol and dopamine levels. In healthy human 
volunteers, a greater dopamine release in several regions of the striatum was also associated 
with stronger positive effects of amphetamine. Dopamine release in ventral striatum by 
amphetamine was positively correlated with cortisol increase in response to the same dose 
of amphetamine (Oswald et al., 2005). The subjects with a stronger cortisol response also 
reported more positive subjective effects with amphetamine, i.e. ‘high, rush, drug liking, 
good effects and desire for drug’. Although the cortisol levels in response to amphetamine 
were greater in magnitude than the cortisol responses to placebo, a significant correlation 
was found between the cortisol levels in response to the amphetamine and the placebo 
sessions. The individuals with greater cortisol reactivity in response to amphetamine were 
also higher cortisol producers in response to placebo. The high responders would thus have 
a larger HPA activation in response to the placebo, and amphetamine would further 
increase this already enhanced response. These individuals may have a sensitized HPA axis 
and/or a sensitized dopaminergic mesolimibic pathway. In another study, the amphetamine-
induced dopamine release in ventral striatum was also found positively correlated with the 
cortisol response to an acute standardized psychosocial stressor measured independently 
(Trier Social Stress Test), again in human healthy volunteers (Wand et al., 2007). This 
suggests that high dopamine releasers in response to amphetamine may have a sensitized 
HPA axis across various types of stressors. In fact, an acute social stressor (a mental 
arithmetic task was set to be too difficult in the stress session, accompanied by negative 
comments) can also directly induce dopamine release. Overall, this dopamine release was 
also correlated with the cortisol response to the acute psychosocial stressor. All subjects 
also rated their perceived levels of parental care and protection and were divided into low 
and high groups. The increase in dopamine release during the mental arithmetic task as 
compared to a rest session was only significant in the low care group. Similarly, the cortisol 
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response increase in the stress condition, as compared to rest, was larger in the low than in 
the high care group (Pruessner, Champagne, Meaney, & Dagher, 2004).  
 
 
1.3 Research questions: 
 
Based on the interaction between cortisol and dopamine released observed both in 
preclinical and in clinical studies, this research aimed at testing four hypotheses. 
1. The dose-response curve will depict an overall linear relation between ADHD 
symptoms and methylphenidate doses, although the increase in symptom 
improvement may be larger going from placebo to low dose, as compared to 
medium to high dose. 
2. Children with higher level of salivary cortisol in response to a venipuncture will 
exhibit a steeper slope in the dose-response curve, as they would be more sensitive 
to the effects of methylphenidate. The same change in dose-response will be 
observed in children with comorbid anxiety problems.  
3.  Children with a higher level of salivary cortisol upon waking will exhibit a 
flattened dose-response curve, as they would be more resistant to the effects of 
methylphenidate.  
4. Side-effects of medication are expected to reflect the same trend as symptoms, with 
more side effects in children with a high salivary cortisol in response to the 
venipuncture and fewer side effects in children with a high level of salivary cortisol 
upon waking.  
In order to test these hypotheses, we used a double blind placebo control prospective study 
in children diagnosed with ADHD, with three different doses of MPH to assess the 
response to MPH over a week. Salivary sample was obtained just after waking and before 
and after a standard stress (venipuncture) in order to assess HPA axis.   
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Abstract 
 
Pre-clinical studies support the hypothesis of the hypothalamic-pituitary-adrenal (HPA) 
axis as predictor of the stimulant response for ADHD-like behaviors. A double blind 
placebo control prospective study was used with three different doses of MPH to assess the 
response to MPH over a week. Salivary sample was obtained just after waking and before 
and after a standard stress (venipuncture) in order to assess HPA axis. The therapeutic 
effect of increasing doses and the side effect severity were function of the level of cortisol 
upon waking according to parents’ ratings, resulting in decreasing efficacy at higher doses 
and increased side effects at lower doses. However, the effect of dose assessed by the 
teacher was unaffected by the level of cortisol upon waking. With regard to the cortisol 
stress reactivity, the teachers, but not the parents, reported an additional benefit of a high 
versus a medium dose only in children with a high reactivity level. However, a similar 
benefit was described by the parents, but not by the teachers, when the presence of an 
anxiety comorbid condition was used instead of a high cortisol stress response. Cortisol 
stress reactivity was not related to any side effect rating.
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Introduction 
 
Predicting which children with ADHD will respond favorably to stimulant medication 
has been proved challenging. In their review Gray & Kagan (2000), concluded that «despite 
considerable effort by capable and creative investigators, predicting response to 
methylphenidate (MPH) has been perhaps most remarkable for its lack of success».
However, some conclusions can be drawn. Generally, the response to stimulant medication 
is increased at younger age and when symptoms (Efron, Jarman, & Barker, 1997a; Gray & 
Kagan, 2000) or cognitive deficits, especially inhibitory control or attention (Barkley, 
1976), are more severe before treatment, although the relations are weak. Age and severity 
are not independent as ADHD symptoms and associated deficits tend to decrease with age. 
However, the better response at younger age may not hold for children below the age of 6.  
In preschool-age children, the effect size of stimulant medication is smaller than for school-
age children, the optimal dosage lower (Greenhill et al., 2006) and adverse effect of 
stimulant more frequent (Wigal et al., 2006). With regard to severity, it should be stressed 
that response to stimulant is also lower in children with comorbid conditions (Ghuman et 
al., 2007; DuPaul, Barkley, & McMurray, 1994; MTA Cooperative Group, 1999; Owens et 
al., 2003). In order to predict a better response, severity might have to be restricted to 
ADHD symptoms. Among the Multimodal Treatment Study of Children with ADHD 
participants, those diagnosed with the ICD-10 criteria for Hyperkinetic Disorder (i.e., no 
anxious or depressive comorbidities; symptom threshold met for hyperactivity, 
impulsiveness and inattention; pervasiveness across school and home setting, and 
impairment endorsed) responded better to medication than those with ADHD failing to 
meet these ICD-10 more stringent criteria (Owens et al., 2003; Santosh et al., 2005). The 
predictive power of symptom severity may not always be unequivocal. ADHD symptom 
severity was showed to predict a poorer not a better response, but only in those children 
with a parent afflicted with a relatively high level of depressive symptoms (Owens et al., 
2003). Similarly, if ADHD-specific cognitive deficits predicted a better response to 
  
30
 
stimulant, broader deficits captured by an IQ below 50 were associated with a less 
favorable response to MPH (Aman, Buican, & Arnold, 2003). Beyond clinical 
characteristics, some physiological measures have been tested as predictor of the response 
to stimulant. Homovanillic acid (HVA) is the major dopamine metabolite. Its cerebrospinal 
fluid concentration has been showed to be correlated with the rating of hyperactivity and 
with the response to stimulant: higher HVA predicted a modest portion (up to 25% on some 
measures) of better drug response (Castellanos et al., 1996). The present study aimed at 
testing the role of the functioning of the hypothalamic-pituitary-adrenal axis (HPA axis) as 
a predictor of the stimulant response. 
There are many pre-clinical studies that support the hypothesis of the HPA axis as 
predictor of the stimulant response for ADHD-like behaviors. Rats can be divided into high 
and low responders according to spontaneous difference in levels of locomotor activity in a 
novel environment (Piazza, Deminiere, Le Moal M., & Simon, 1989).  High responders 
differ from low responders in their behavioral response to psychostimulants. High 
responders show more locomotor activation in response to psychostimulants (Piazza et al., 
1990), develop stronger contextual conditioning to drug effects (Jodogne, Marinelli, Le, & 
Piazza, 1994), develop behavioral sensitization more readily than do low responders (Pierre 
& Vezina, 1997) and are more likely to acquire and maintain psychostimulant self-
administration (Piazza et al., 1989; Pierre et al., 1997). These high responders also showed 
a higher corticosterone response after exposure to novelty (Piazza et al., 1991). Moreover, 
glucocorticoids affect the response to stimulants. Glucocorticoids have a facilitatory effect 
on acute stimulant-induced locomotor activity (Marinelli et al., 1997; Cador, Dulluc, & 
Mormede, 1993), which can not be accounted by a drug-induced increase of 
glucocorticoids (Marinelli et al., 1997). Stimulant-induced sensitization is increased in 
psychomotor effects of psychostimulants after repeated injections. Suppression or reduction 
of circulating glucocorticoids reduce the expression of sensitization, although it cannot 
prevent its development (Marinelli et al., 1997). It also decreases the reinforcing effects of 
psychostimulants as measured by self-administration. These effects are reversed dose-
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dependently by exogenous administration of glucocorticoids (Deroche, Marinelli, Le Moal 
M., & Piazza, 1997). The psychomotor effects of psychostimulant drugs may increase 
under stressful conditions (stress-induced sensitization). The stress-induced sensitization 
depends on the glucocorticoid level increase induced by the stressor (Deroche et al., 1992; 
Deroche, Piazza, Casolini, Le Moal M., & Simon, 1993; Deroche, Piazza, Le, & Simon, 
1994; Prasad, Ulibarri, & Sorg, 1998). Stress also increases psychostimulant self-
administration, and this increase also depends on stress-induced glucocorticoid secretion 
(Piazza & Le Moal, 1998). To conclude, in rats, higher behavioral response to novelty is 
associated with higher glucocorticoid response; the behavioral response to novelty predicts 
the behavioral response to stimulants and glucocorticoid level influences the response to 
stimulants. It is thus tempting to hypothesize that the response to stimulant medication in 
patients with hyperactivity would depend on their cortisol level. 
However, findings from human studies have not been very consistent with the 
preclinical literature. In healthy human volunteers, sub-chronic hydrocortisone 
administration had no effect on methamphetamine-induced subjective mood changes and 
objective performance on a task of sustained attention (Hearn et al., 2004). Acute 
hydrocortisone pretreatment did not affect any of the physiological, behavioral, or 
subjective effects of d-amphetamine (Wachtel, Charnot, & de Wit, 2001). Blocking cortisol 
response with the cortisol synthesis inhibitor, metyrapone, did not produce significant mean 
changes in most subjective effects of intravenous methamphetamine in humans (Harris, 
Reus, Wolkowitz, Mendelson, & Jones, 2003). One explanation for this discrepancy is that 
repeated exposure to stress levels of glucocorticoids may be necessary for the association 
between glucocorticoid and dopamine to develop. During early repeated stress situations, 
the repeated increases in glucocorticoid hormones and dopamine would render the subject 
durably more responsive to stimulant.  
Therefore, it was predicted that among the children with ADHD, those with an 
enhanced salivary cortisol level in response to a stressor would have a better response to 
stimulant medication. As children with comorbid anxious problems exhibited greater 
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cortisol reactivity to the same stressor used in this study  (Hastings, Fortier, Utendale, 
Simard, & Robaey, 2008), they were expected to show an enhanced response to stimulants. 
Higher basal level of cortisol are generally associated with smaller reactivity to a stressor, 
and high level of cortisol over sustained period of time are often associated with comorbid 
mixed mood/anxiety symptoms (Nestler et al., 2002).  As in humans, glucocorticoids are 
low during inactivity period at night and increase to reach a peak after waking up, it was 
predicted that high morning levels of cortisol upon waking would be associated with worse 
response to stimulant on the core ADHD symptoms. 
In order to test these hypotheses, we used a double blind placebo control prospective 
study in children diagnosed with ADHD, with three different doses of MPH to assess the 
response to MPH over a week. Salivary sample was obtained just after waking and before 
and after a standard stress (venipuncture) in order to assess HPA axis. We thus followed 
with Taylor’s design criteria for the prediction of stimulant response: blindness and placebo 
control, reliability, compliance, flexible dosage, and prospective design (Taylor et al., 
1987), as well as the additional criteria proposed by Gray and Kagan: accurate diagnosis, 
predictor is not a proxy for age or IQ (Gray et al., 2000). 
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Material and methods 
  
 
Subjects 
 
 Children between 6 and 12 years of age referred by their physician with a suspected 
diagnosis of ADHD were recruited for a MPH titration procedure through the 
Interdisciplinary Research Program on Hyperactivity at Sainte-Justine Hospital, a 
university-based pediatric hospital in Montreal, Canada. One parent was administered the 
French version of the Diagnostic Interview Schedule for Children (DISC4.0) by a trained 
interviewer. The DISC4.0 is a structured computerized interview that is used for the 
diagnosis of psychiatric disorders in children such as ADHD, ODD, CD, tic disorders and 
Tourette’s syndrome (Shaffer, Fisher, Lucas, Dulcan, & Schwab-Stone, 2000). This 
interview allowed the classification of the children among three ADHD subtypes: 
inattentive, hyperactive/impulsive or combined. A French-language version of the DISC4.0 
was obtained through iterative translation and back-translation by bilingual health 
professionals in collaboration with the DISC4.0 authors. The Wechsler Intelligence Scale 
for Children (WISC-III) was administered to all children (Wechsler, 1991): M IQ = 100.19, 
SD = 16.39. A structured questionnaire addressed to a parent was used to collect 
information on age (M age = 8.35, SD = 1.37), sex (44 males. 8 females), parent’s 
education (27.1% of the fathers and 40.4% of the mothers had a college degree), previous 
MPH use (57.7% used psychostimulant before the trial, with mean daily dosage of 19.8 mg, 
SD: 7,6 mg, range 10-40 mg), as well as the family income (40.4% less that CAN $55,000 
per year) and structure (11.5% reconstituted families). Children with an IQ lower than 70, 
born prematurely (<35 weeks of gestation), with severe learning and language retardation, 
any neurological disease, Obsessive Compulsive Disorders, and Tourette’s disorders as a 
diagnosis were not eligible to participate in the study. 
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Medication trial 
 
 The medication trial was developed based on the titration process of the MTA 
study. The procedure consisted of a double-blind, placebo-controlled crossover trial with 
randomized dose schedule. The 4 week trial was done after the 3 days pre-test with MPH at 
increasing doses. During the trial, children either took placebo or one of the three doses of 
immediate-release MPH. Low, medium and high doses were 15, 25 and 35 mg per day. For 
children who weighted 25 kg or more the high dose was 50 mg/day. Each daily dose was 
distributed in 3 intakes, at 8 am, noon and 4 pm. Each dose or the placebo was taken for 
one week of the 4-week trial. A code number was allocated by the research pharmacist to 
the recruited patients. Each number corresponded to a random treatment schedule except 
that the higher dosage (35 or 50 mg) could not be assigned for the first week. Parents, 
children, teachers, research assistants and investigators were all blinded to the MPH dose 
given throughout the study. A written consent was obtained from the children, their parents 
and teachers before the beginning of the study. This study was approved by the Research 
Ethic Board of Sainte-Justine Hospital Research Center.  
 
 
Cortisol sampling and procedures 
 
Prior to a scheduled family visit to the ADHD clinic, parents were instructed in how 
to use the salivettes with their child. A sample upon waking was collected from each child 
on the morning of the scheduled clinic visit, within 15 minutes of waking and prior to 
eating, drinking or brushing teeth. Out of the 52 children who participated in the titration 
process, 43 parents brought waking samples, and 35 had enough saliva to perform assays of 
cortisol. Among these 35 children, 17 were diagnosed with combined type ADHD, 3 with 
the Hyperactive-Impulsive subtype and 15 with the Inattentive subtype. An anxiety 
problem was diagnosed using the DISC4.0 in 9, 1 and 4 of the ADHD subjects, within each 
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respective subtype category. Each family attended a 3-hour testing session at the clinic. 17 
(39.5%) families were seen in the morning (9 AM to 11 AM start-time), and 26 (59.5%) 
were seen in the afternoon (1 PM to 3 PM start time). Parents completed the DISC4.0 and 
other questionnaires not relevant for the present study in one room of the clinic, while the 
child was assessed in another room. The WISC-III was administered to the child, along 
with other procedures and measures not pertinent to the current analyses. Two hours after 
arriving at the clinic, a second saliva sample was collected from the child (Pre-stress). The 
child was then told that a nurse needed to collect a blood sample1. A topical analgesic was 
applied to the child’s arm, which the child was told would make the needle not hurt. The 
child and interviewer then went to the phlebotomy clinic, where a nurse drew the blood. 
The child and interviewer returned to the ADHD clinic, and 20 minutes after the 
venipuncture, a third saliva sample (Post-stress) was obtained. Among the 52 children who 
participated in the titration process, 10 refused the blood draw. Thus 42 pre- and the post-
stress saliva samples were collected. Of the 42 pre- and the post-stress saliva samples 
collected, 41 were usable. Among these 41 children for which pre- and post-samples were 
usable, 20 were diagnosed with combined type ADHD, 4 with the Hyperactive-Impulsive 
subtype and 17 with the Inattentive subtype. An anxiety problem was diagnosed using the 
DISC4.0 in 11, 1 and 4 of them, within each respective subtype category.  The 10 boys who 
refused to provide pre- or post-stress samples did not differ from the other children in 
prevalence of anxiety problems.  
Saliva samples were stored in a -80C medical freezer, then shipped to the 
Pennsylvania State University Behavioral Endocrinology Laboratory (Salimetrics ™) to be 
thawed, centrifuged, and have 50 l of clear samples pippetted into test-wells for enzyme-
immunoassay of cortisol. All samples were tested in duplicate; samples that varied by more 
than 5% across duplicates were re-tested; correlation across duplicates r = .99. Mean values 
of duplicates were used in analyses, in units of microgram per deciliter (g/dL). Raw 
                                                 
1 The broader protocol for this study included a blood draw for the purpose of genotyping, which also 
provided an opportunity to examine the physiology of stress reactivity. 
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cortisol data were leptokurtic and positively skewed, therefore log-transformations were 
used to establish normality. The transformations corrected the skew and eliminated outliers; 
therefore, log-transformed data were used in all analyses. Untransformed data are reported 
in text for ease of interpretability. In order to assess cortisol response to the blood draw 
stressor, while controlling for individual differences in the pre-stress level, linear 
correlations were computed between log-transformations of pre- and post-stress sample 
dosages and the residuals were retained for further analyses. The increases in salivary 
cortisol levels in response to venipuncture were larger when the blood draw was done later 
in the day (Pearson’s correlation: 0.409; p=0.008). However, in a larger sample (N=151) 
the salivary cortisol levels in response to venipuncture were similar in the morning and in 
the afternoon (Hastings et al., 2008). Also, the increases in salivary cortisol levels in 
response to venipuncture increased with age (Pearson’s correlation: 0.402; p=0.009). 
 
Outcome measures 
 
 The French version of the Strengths and Weaknesses of ADHD-symptoms and 
Normal-behaviors ratings Scale (SWAN-F) (Robaey, Amre, Schachar, & Simard, 2007) 
was completed daily by teachers (5 days/week) and parents (7 days/week) throughout the 
trial. The SWAN (Strengths and Weaknesses of ADHD-symptoms and Normal-behaviors 
ratings Scale - SWAN) is a scale where the informant is asked to assess the strength 
opposite to the ADHD symptoms (Swanson et al., 2005). Without changing the content, 
each item of the SNAP-IV rating scale (Swanson et al., 2001) was re-worded in order to 
capture the strength corresponding to the weakness. For example: “Often does not seem to 
listen when spoken to directly” becomes “Listen when spoken to directly” and is rated from 
“far below average” (-3) to “far above average” (+3) relative to children of the same age. 
This approach yielded a normal distribution of ADHD scores (Hay, Bennett, Levy, 
Sergeant, & Swanson, 2007). The SWAN-F scores were averaged across the 18 DSM-IV 
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ADHD symptoms each day and then averaged for the placebo week and each MPH dose 
week for parents and teachers separately.  
 Medication side effects were evaluated daily by parents and teachers using the Side 
Effect Rating Scale (SERS; (Barkley, McMurray, Edelbrock, & Robbins, 1990). The SERS 
is composed of a variety of side effects experienced by stimulant medications and it is used 
to measure the prevalence and severity of the side effects in several treatment studies. The 
teacher’s form included 14 items while the parents form included 3 additional items that 
rated appetite, insomnia and nightmares. Each item was scored using a 10 point scale 
reflecting side effect intensities ranging from 0 to 9 (0=absent, 1-3=mild, 4-6=moderate, 7-
9=severe). Scores were averaged to give the total side effect score.  
 To ensure compliance by the parents and teachers in the filling out of the 
questionnaires, they were contacted weekly. Also parents and teachers had to maintain a 
daily diary for the recording of the medication intake.  
 
Statistical analyses 
 
 Repeated-measures of analyses of variance were conducted. The outcomes analyzed 
were the parent or teacher-rated SWAN-F and SERS global scores under placebo and the 
three doses of MPH. The main effect of dose (within subject factor with four levels) and the 
effect of the cortisol upon waking or cortisol reactivity (used as covariate) were tested. 
When testing cortisol reactivity, age and time of the blood draw were also used as 
covariate. When the covariate was significant, the effect of a between-group factor was 
tested using the median as cut-off point, and the different between increasing doses were 
test in each subgroup. The analyses were performed using the statistical software 
SPSS16.0. 
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Results 
 
1. Effect of raters. 
 
Globally, teachers rated the ADHD behavior as more severe than the parent did 
(Rater: F (1,50)= 5.041; P=0.029). However, there was no difference between the rating of 
the effect of increasing MPH doses at school and at home. Correlations between SWAN 
rating of parents and teacher were generally low and non significant, ranging from 0.15 to 
0.19 (0.25 to 0.29 after controlling for cortisol level). With regard to side effects, the 
teachers differ from the parents in their reports of the dosage (Rater x Dose: F (3,150)= 
4.831; P=0.003), but paradoxically they reported more side effects under placebo than 
under active medication (Dose: F (1,51)= 23.426; P<0.001). Pearson correlations between 
side effects rated by parents and teachers were very low (<0.15) and insignificant, the 
stronger coefficient being obtained for the somatic symptoms under placebo (Pearson 
correlation: 0,246, ns; 0.297, ns, after controlling for cortisol level). 
 
The correlation between cortisol level upon waking and cortisol stress reactivity 
was low and non significant (Pearson correlation: 0.-119; ns). However, when correlation 
were computed for the participants below the median waking cortisol and equal or above 
separately, the correlation were in opposite directions, although still non significant: 
Pearson correlations: 0.294 and -0.361, respectively. However, the difference in correlation 
was significant (dr= 0.655; z= 1.75827; p=0.0394), which suggest that going from the low 
to the high cortisol upon waking group, the cortisol reactivity tend to increase, then to 
decrease with increasing morning cortisol level.  
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2. Effect of cortisol level upon waking (Figure 1 p: 57-58) 
MPH therapeutic effects 
 
According to the parents, increasing the MPH doses significantly improved ADHD 
global scores (Dose; F(2.5, 125.9) = 22.344; P<0.001,  = 0.823). This dose effect was no 
longer significant when the level of cortisol upon waking used as covariate. The 
improvement in ADHD score with increasing doses tended to depend on the level of 
cortisol upon waking (Dose x Waking; F(3, 99) = 2.351; P= 0.077). Specifically, under 
high dose of MPH, the global ADHD ratings by the parents were negatively correlated with 
the cortisol upon waking (Pearson correlation -0.357; P=0.035), as was the difference 
between the high dose and the placebo (Pearson correlation -0.347; P=0.041). In order to 
further analyze these effects, we divided the children into two groups, below the median 
level of cortisol upon waking, and equal or above. The correlation with the SWAN scores 
under high dose of MPH was strong in those with a cortisol upon waking above the group 
median (Pearson correlation -0.597; P=0.019), but almost null for those beyond (Pearson 
correlation -0.010; ns). Similarly, the correlation between the difference in total scores on 
high dose and placebo and the cortisol level was high in the high cortisol group (Pearson 
correlation -0.467; P=0.080) and almost null in the low cortisol group (Pearson correlation -
0.069; ns). 
A clinical consequence of the decrease of the pharmacological effect with 
increasing cortisol levels upon waking is that a high cortisol level is a good predictor of 
being a non-responder under active medication, whatever the dose. We defined a responder 
by two conditions. First, the parents had to rate the ADHD symptoms as improved under 
active medication, whatever the dose, as compared to placebo. Second, one of these ratings 
had to be above - 0.6, which is considered the lower limit for the normal range (Robaey et 
al, 2007). A receiver operating characteristic (ROC) analysis showed a cortisol level upon 
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waking above .37g/dL allowed identifying the non-responders with a sensitivity of 0.75 
and specificity of 0.87 (Area under the curve = 0.855; P=0.023). 
Similar to parents’, teacher’s ratings showed a very significant effect of increasing 
doses on the ADHD global scores: Dose; F(2.5, 128.3) = 46.154; P<0.001,  = 0.839. 
However, contrary to the parents, the dose effect assessed by teachers did not interact with 
the level of cortisol upon waking when used as a covariate. 
 
MPH side effects 
 
In parent ratings, the side effect total score was low (0.48 ± 0.59) and did not 
increase with dose. However, when the level of cortisol upon waking was used as a 
covariate, side-effects globally increased with MPH doses (Dose; F(2.1, 68.1) = 3.775; 
P=0.027,  = 0.688) and the effect of the dosage depended on the level of cortisol upon 
waking (Dose x Waking; F(2.1, 68.1) = 4.834; P=0.010,  = 0.688). The covariate effect on 
the global side-effect level was also significant (Waking; F(1,33) = 7.538; p=010). 
Specifically, the level of salivary cortisol upon waking was positively correlated with the 
parents’ ratings of side effect under placebo (Pearson correlation: 0.511; P=002) and under 
a low dose of MPH (Pearson correlation: 0.504; P=002). 
By using the separation into two groups, below the median level of cortisol upon 
waking, and equal or above, side effects were higher in the high waking cortisol group than 
in the low cortisol group (mean 0.73 ± 0.68 vs. 0.34 ± 0.44). Within the low cortisol group, 
escalating MPH doses increased the side effect severity (Dose; F(1.5, 28.5) = 4.536; 
P=0.028,  = 0.500), while in the high cortisol group, side effect rating was not influenced 
by escalating MPH doses  (Dose; F(2.0, 27.3) = 0.230; P=0.790,  = 0.650). As for the 
therapeutic effects, the cortisol level upon waking predicted the side effect rating in the 
placebo condition in the high cortisol group (Pearson correlation 0.515; P=0.049), but not 
in the low cortisol group (Pearson correlation 0.054; ns).  
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In teachers ratings, the total score for side effect varied with dose (Dose; F(2.6, 
131.8)= 9.575; P<0.001,  = 0.862). It showed a quadratic trend (F(1,51)= 8.652; p=005), 
decreasing from the placebo (0.97 ± 0.94) to low dose (0.67 ± 0.78) and to medium dose 
(0.54 ± 0.59), with an small increase at high dose (0.62 ± 0.66).  However, when the level 
of cortisol upon waking was used as covariate, the effect of dose decreased and was no 
longer significant and neither was its interaction with the covariate. Correlations between 
side effects rating and cortisol upon awakening were almost null.  
 
 
2. Effect on cortisol stress reactivity (figure 2 p: 59-60) 
MPH therapeutic effects 
In school, the effect of increasing doses on the total ADHD scores improvement 
was significant (Dose; F(2.5, 128.3) = 46.154; P<0.001,  = 0.839). When the cortisol stress 
reactivity was used as covariate, the effect of increasing doses depended on the cortisol 
stress reactivity (Dose x Stress; (F (3, 117) = 3.760; p=0.013). When the time of the blood 
draw was also used as covariate, the interaction remained significant (Dose x Stress; (F (3, 
111) = 2.861; p=0.040). When age was also used as covariate, the effect of increasing dose 
was related to cortisol stress reactivity (Dose x Stress; (F (3, 111) = 3.563; p=0.017), to age 
(Dose x Age; (F (3, 111) = 4.954; p=0.003), as well to the combined effect of both age and 
cortisol response (Dose x Stress x Age; (F (3, 111) = 2.943; p=0.036). 
In order to describe this effect of the cortisol response to a stressor, we divided the 
sample into two groups: below and equal or above the median cortisol stress reactivity in 
order to make a trend analysis. In addition to the linear trend across doses in both groups, 
only children with low cortisol stress reactivity showed a significant quadratic trend (Dose; 
F(1, 19) = 8.318; P<0.010), with an inverted J-shaped dose-response curve.  
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Further, we compared the improvement in ADHD global ratings in children with 
low and high stress cortisol reactivity for each increase in MPH dose. For the low dose, as 
compared the placebo, improvement in global ADHD ratings was significant both in the 
high (t = -2.36; df = 20; p= 0.028) and in the low reactivity groups (t = -4.53; df = 19; p< 
0.001). Going from low to medium dose, global ADHD ratings again significantly 
improved in both the high (t = -2.47; df = 20; p= 0.023) and the low reactivity groups (t = -
3.54; df = 19; p= 0.002). However, further increasing MPH from medium to high dose did 
improve ADHD behavior in the high reactivity group (t = -2.193; df = 20; p= 0.040), but 
not in the low reactivity group (t = 0.302; df = 19; ns).  The same results held for more 
extreme subjects with regard to cortisol stress reactivity, when comparing those below the 
percentile 30 and above the percentile 70: going from medium to high MPH dose yielded 
an additional improvement on ADHD global rating in the very high reactivity group (t = -
2.275; df = 13; p= 0.040), but not in the very low reactivity group (t = 0.054; df = 11; ns).   
At home, the effect of increasing dose on parent’s ADHD global ratings was very 
significant (Dose; F(2.5, 125.9)= 22.344; P<0.001,  = 0.823).  However, this effect of 
doses was still significant when the cortisol stress reactivity was used as covariate and did 
not interact with the covariate. 
 
Anxiety disorders 
 We found that boys’ comorbid anxiety diagnoses and problems were consistently 
associated with exaggerated cortisol reactivity. We found that out of 52 subjects, 19 also 
had a diagnosis of anxious disorder. Their cortisol stress reactivity was increased by 
38.85%, which was not statistically significant. When the presence of any anxiety comorbid 
disorder was used as between-subjects factor, the parents reported that the improvement 
with dose of the ADHD global ratings differed according the anxiety status (Dose X Anx: F 
(2.6, 130.5) = 6.975; P<0.001; = 0.870). We compared the improvement in ADHD global 
ratings with increasing dose in children with or without anxiety comorbid condition. 
Improvement in global ADHD ratings was significant for the low dose, as compared the 
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placebo, both in the anxious (t = -2.28; df = 18; p= 0.035) and in the non anxious groups (t 
= -2.75; df = 32; p= 0.035). Going from low to medium dose, global ADHD ratings again 
significantly improved in both anxious (t = -2.83; df = 18; p= 0.011) and non anxious 
groups (t = -2.07; df = 32; p= 0.047). However, further increasing MPH from medium to 
high dose tended to improve ADHD behavior in the anxiety comorbid group (t = -1.934; df 
= 18; p= 0.069), but not the group without anxiety disorder (t = - 0.067; df = 32; p= 0.947).  
However, for teacher’s global ADHD ratings, this interaction between dose effect 
and anxiety status did not reach the statistical significance level (Dose X Anx: F (2.5, 
124.9) = 1.821; P=0.156; = 0.833).    
MPH side effects 
There was no effect of stress cortisol reactivity and the rating of side effects 
observed by neither the parents nor the teachers. 
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Discussion 
 
The benefit of the medication on ADHD symptoms progressively decreased with 
increasing morning cortisol levels, up to the point that the children with the highest 
morning cortisol levels could be defined as non responders to stimulant. This result can be 
linked to previous demonstrated predictors of the response to psychostimulant. Parental 
depression is one of the main factors that has been showed to decrease the rate of favorable 
outcome on ADHD symptoms, following well monitored treatment with MPH (Owens et 
al., 2003). Depressive symptoms in the parent were supposed to interfere with the primary 
caregiver’s involvement in the treatment and consequently with the child ability to benefit 
from the treatment. However, the child inability to benefit from treatment could not only be 
the consequence of the lack of parental involvement in the treatment, but also be related to 
another characteristic specific to the child with a depressed parent. Maternal depression at 2 
month post-partum was found to be associated with higher and more variable morning 
cortisol in 13-year-old adolescent offspring. Mothers with post-natal depression were also 
more likely to experience further depression in the following years (Halligan, Herbert, 
Goodyer, & Murray, 2004). Moreover, elevated morning cortisol at 13 years mediated the 
association between postnatal depression in the mother and depressive symptoms at 16 
years, over and above 13-year depressive symptom levels and other possible confounding 
factors (Halligan, Herbert, Goodyer, & Murray, 2007). The sensitive period for the 
influence of maternal depression on elevated cortisol in offspring may extend over the first 
or even the second year after birth, and can be detected in 7-8 year- and even 4.5 year-old 
children (Ashman, Dawson, Panagiotides, Yamada, & Wilkinson, 2002; Essex, Klein, Cho, 
& Kalin, 2002). Increased waking salivary cortisol level has been proposed to be a stable 
endophenotype in individuals at risk of depression (Mannie, Harmer, & Cowen, 2007). 
Thus the dysfunction of the HPA axis in poor MPH responders with a depressive parent 
could have been acquired earlier in life in response to already present depressive symptoms 
of their mother. Those children with ADHD who have a high cortisol level and depressive 
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parent are themselves at risk of depression.  Stimulant medication have been showed to 
potentially increase mood problems: 7- to 9-year-old children with ADHD showed initial 
increases in their Children’s Depression Inventory (CDI) scores after 5 weeks of MPH 
treatment, followed by a significant decrease in CDI scores after 6 months of treatment 
with MPH (Hechtman et al., 2004). In preschool children ages 3–5.5 years, parent rated 
depression and dysthymia as worsened by methylphenidate during a 4-week double-blind 
placebo controlled trial similar to the one we used (Abikoff et al., 2007). A significant 
increase in emotional outburst and crying with MPH compared to placebo was also found 
in the titration phase of the same study (Hechtman et al., 2004; Wigal et al., 2006). ADHD 
children at risk for depression, identified by high level of morning salivary cortisol, would 
exhibit more readily mood-related features under MPH treatment. These depressive 
symptoms can constitute a halo which could hinder the rating of the improvement of 
ADHD symptoms themselves. We did not include mood assessment in this study. The 
hypothesis of aggravation of mood symptoms secondary to treatment initiation attenuating 
treatment outcome in some children with high morning cortisol level has to be further 
investigated.  
Alternatively to this hypothesis of treatment-related mood symptoms hindering the 
improvement of ADHD symptoms, a high level of cortisol upon waking acquired early in 
life could identify a subset of patients whose ADHD syndrome comprises features that are 
usually considered as side effects but are in fact part of a form of ADHD that would be 
more resistant to stimulant treatment. These symptoms associated with a high morning 
level of salivary cortisol would be primarily observed by the parents because they would be 
more readily observable when the child is waking up. Some children with ADHD have 
difficulty getting out of bed; some are slowed down or agitated during morning, starring 
into space when expected to do the morning routine. In adult, poor rest and recovery from 
work was associated with high levels of morning cortisol. The strongest relationships  with 
high cortisol levels emerged for questions about feeling “thoroughly rested”, “energetic”, 
“very tired”, “had sufficient sleep” with the early morning cortisol level (Gustafsson, 
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Lindfors, Aronsson, & Lundberg, 2008). In preschool-age children, disruptive behaviors 
were found to be associated with more negative affect, higher afternoon cortisol levels, and 
a smaller decrement in cortisol from morning to afternoon (Ward, Gay, Alkon, Anders, & 
Lee, 2008). Parents could thus report poorer response to treatment and more symptoms 
under placebo in the high-cortisol subgroup of children with poorer rest and recovery, and 
marked psychomotor retardation or activation after waking. This specificity to the morning 
home setting could explain why the teachers were blind to the effect of the morning 
cortisol. 
The influence of cortisol on the dose-response curve for side effects also contributed 
to define poor responder. When the cortisol level upon waking was used as a covariate, the 
cortisol level was significantly associated with increasing side effects as rated by the 
parents, and increasing MPH doses worsened side effects. In addition, the cortisol level 
influenced the side effects ratings, but only for the placebo or the low dose of MPH: The 
higher the cortisol level, the worse the side effects. The most parsimonious explanation for 
both the presence of side effects under placebo or low dose of MPH and the increase in side 
effect with higher MPH doses is that what is usually described as side effects are in fact a 
mixture of symptoms that are part of the ADHD syndrome and real MPH-related side 
effects. The latter symptoms are aggravated by increasing MPH doses. The former 
symptoms are expressed by the children with high level of morning cortisol and did not 
seem to improve with treatment. However, their relation with the cortisol level is observed 
for the placebo and low dose of MPH only, when the real side-effects are low.  
The observation of paradoxical stimulant side effects on placebo has already been 
reported. A study on side effect that used a double blind cross-over design to compare the 
side effect profile of MPH and dexamphetamine also concluded that in more than 50% of 
the children, parents reported during the initial baseline symptoms (irritability, anxiousness, 
proneness to crying, sadness/unhappiness, trouble sleeping, daydreaming) that improved 
significantly on stimulant (Efron, Jarman, & Barker, 1997b). These authors suggested that 
these symptoms may represent features of the behavioral phenotype of ADHD. 
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Alternatively, they suggested that the high rating of side effects could be due to a halo 
effect of a globally negative view of the child, especially during the baseline before 
treatment. However, this latter explanation is not supported by the high frequency of side 
effects under placebo (especially staring, sadness, irritable, euphoria, anxiousness, 
proneness to crying and insomnia) also reported by parents in the validation study on the 
Stimulant Drug Side Effect Rating Scale that used a placebo-controlled design (Barkley et 
al., 1990). In teachers’ ratings, staring, sadness and anxiety also declined with increasing 
doses of medication (Barkley et al., 1990). In the present study, the severity of the side 
effects reported by the parents under placebo or low dose of methylphenidate was predicted 
by the level of salivary cortisol upon waking. Hypersecretion of cortisol is one of the most 
often reported findings in depression (Nestler et al., 2002). Side effects associated with high 
level of cortisol may be depression-related features (such as psychomotor retardation or 
activation symptoms, sleep problems, lack of interactiveness, psychosomatic symptoms, 
etc.) associated with ADHD that are more prominent under placebo or low dose of 
stimulant. The level of cortisol upon waking predicted the level of side effects, especially 
for the placebo or the low dose condition, but only in the subgroup of children at or above 
the 50th percentile for morning salivary cortisol. In this subgroup, side effects are not 
worsened with increasing MPH doses, but increased in severity with the cortisol level, 
which suggests that they are part of a broader ADHD syndrome that they may help to 
recognize. Thus both SWAN and SERS rating by the parents tend to support the hypothesis 
of a broader ADHD syndrome more resistant to stimulant medication, in relation with the 
morning cortisol level. 
On the other hand the teachers did report that the children with ADHD who showed 
the highest reactivity salivary cortisol to the venipuncture stressor also showed a different 
dose-response curve. More specifically, they reported an additional improvement in ADHD 
behavior when going from a medium to a high dose of MPH in the children with the larger 
cortisol response to the stress of the blood draw, while those with a lower response did not 
show any additional gain. It should be noted that this additional improvement could only be 
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detected by a strength-based questionnaire like the SWAN. The average rating to a high 
MPH dose in high reactivity cortisol participants was slightly positive (0.14) and thus 
included some ratings above zero. A symptom-based instrument would likely be less 
sensitive by not rating strength but only the absence of symptoms as zero (Robaey et al., 
2007). This influence of cortisol reactivity might increase with age, and the time of the day, 
but this suggestion has to be confirmed in independent studies and may be due to a sample 
effect.  
In a previous paper, we showed that boys with comorbid anxious disorders and 
problems exhibited greater cortisol reactivity to the same venipuncture procedure (Hastings 
et al., 2008). Remarkably, parents reported the same effect of an additional benefit of a high 
MPH dose, but in relation with comorbid anxious disorders and problems. Parents would 
thus be more sensitive to the anxious symptoms while teacher would be more sensitive to 
coping with stress. Using the State- Trait Anxiety Inventory for Children (STAIC), higher 
anxiety in children with ADHD predicted better outcome after 10 weeks of MPH or 
combined MPH- multimodal behavior therapy in teacher ratings (Van der Oord, Prins, 
Oosterlaan, & Emmelkamp, 2008). Pre-treatment comorbid anxious symptoms did not 
predict a clinically significant attenuation of response to MPH in children with both ADHD 
and chronic multiple tic disorder, at least with regard to the core features of ADHD. On the 
contrary, when the contribution of oppositional behavior was controlled, there was some 
evidence suggesting anxiety symptoms at intake were associated with a more favorable 
response of hyperactive and inattentive behaviors to medication (Gadow, Nolan, Sverd, 
Sprafkin, & Schwartz, 2002). In the Multimodal Treatment Study of Children with ADHD 
(MTA), no adverse effect of anxiety on medication response for core ADHD or other 
outcomes was demonstrated. To the contrary, a robust response to optimal medication 
management was found in anxious subjects with teacher-reported inattention (March et al., 
2000). A further examination of predictors of treatment response in the MTA study, using a 
categorical measure of ‘‘excellent response’’ rather that a continuous outcome measure, 
comorbid anxiety was not a predictor (Owens et al., 2003). A few other studies concluded 
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to a weaker response in children with ADHD and comorbid anxiety, but not conclusively. 
Prediction of the response to a relatively low dose of MPH (10 mg bid) in a 4-week trial 
was only possible for recovery at home and at school: lower rating of anxiety at home (as 
measured by the anxiety subscale of the Conners Parent Rating Scale, CPRS) was a 
predictor, but behind a  higher Full Scale IQ, more inattentiveness at school, younger age, 
and lower severity of the disorder (Van der Oord et al., 2008; Buitelaar, van der Gaag, 
Swaab-Barneveld, & Kuiper, 1995). Children with ADHD and Overanxious Disorder were 
found to have a decreased response to MPH for inattention/overactivity, as compared to the 
non anxious group. However, but this interaction was mostly due to an improvement of the 
comorbid group while on placebo and another decline on drug. For the non anxious group, 
the baseline and the placebo were not different from each other but were significantly 
worse than the low and high drug condition, which were in turn not different from each 
other (Pliszka, 1989). Other studies (Taylor et al., 1987; DuPaul et al., 1994) have included 
anxiety symptoms into a broader spectrum of internalizing or emotional problems and can 
not specifically assess the effect of anxiety, independently of mood symptoms.  
Methylphenidate effects are in part due to increase in extracellular dopamine 
secondary to blockade of dopamine transporter that recaptures the dopamine into the pre-
synaptic neuron. Positron emission tomography (PET) allows to measure extracellular 
dopamine using [11C]raclopride as D2 receptor radioligand that competes with endogenous 
dopamine. PET studies showed that MPH increased dopamine release in the brain. 
However, individual differences in dopamine increases are not due to differences in DAT 
blockade, as measured in PET using [11C]cocaine as DAT radioligand, but more likely to 
individual differences in DA activity (Volkow et al., 2002). Other studies looked at 
individual differences that could account for individual differences in dopamine activity or 
release by MPH. In healthy human volunteers, dopamine release in ventral striatum by 
amphetamine is increased in the subjects who showed a stronger cortisol increase in 
response to amphetamine; these high cortisol response subjects also reported liking more 
the drug effect (Oswald et al., 2005). Although the cortisol increase in response to 
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amphetamine was larger than the raise in cortisol in responses placebo, significant 
correlations were found in cortisol levels between amphetamine and placebo sessions.  The 
amount dopamine released by amphetamine is thus related to the amplitude of the cortisol 
response in response to a drug challenge, but also to the experimental situation itself. 
Amphetamine-induced dopamine release in ventral striatum was also found positively 
correlated with the cortisol response to an acute standardized psychosocial stressor 
measured independently (Trier Social Stress Test), again in human healthy volunteers 
(Wand et al., 2007). Subjects with a stronger dopamine response to amphetamine may thus 
have a stronger cortisol response to both pharmacological and social stressors. Conversely, 
an acute social stressor (a mental arithmetic task set to be too difficult and accompanied by 
negative comments) can directly induce dopamine release in the ventral striatum. This 
dopamine release was positively correlated with the cortisol response to the same acute 
psychosocial stressor. All subjects also rated their perceived levels of parental care and 
protection and were divided into low and high groups. The increase in dopamine release 
during the mental arithmetic task as compared to a rest session was only significant in the 
low care group. Similarly, the cortisol response increase in the stress condition, as 
compared to rest, was larger in the low than in the high care group  (Pruessner, Champagne, 
Meaney, & Dagher, 2004). Thus both enhanced cortisol and dopamine release in response 
to stress seems more strongly associated in the subject with a lower level of perceived 
parental protection and care. In the present study, the children with a higher cortisol 
response to the blood draw also showed a larger decrease in ADHD behaviors using a high 
dose of stimulant. It is most likely that cortisol elevations to venipuncture are primarily 
attributable to emotional arousal than physical stress or pain (Hubert, Moller, & Nieschlag, 
1989; Bellitti, Valeriano, Gasperi, Sodini, & Barletta, 1994; Meeran, Hattersley, Mould, & 
Bloom, 1993). It is thus possible that children with ADHD and a stronger cortisol response 
to stress would have a higher increase in dopamine release in response to high dose of 
methylphenidate, which would in turn account for the larger improvement in behaviour. 
Teacher reported more accurately the enhanced clinical response in children with a stronger 
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cortisol response to the venipucture. Both the hospital and school situations require 
responding to a demand outside the family circle. Parent would report more accurately the 
better response associated with manifest anxiety symptoms as their children would report 
them more easily at home, such as separation anxiety or specific phobia.  
Limitations: The prediction of cortisol was limited to a one week-period during the 
titration trial; it needs to be replicated and validated in an independent sample followed 
longitudinally. The cortisol morning level was expected to reflect the circadian rhythm, as 
the early morning peak in cortisol is reliably established at three months of age (Price, 
Close, & Fielding, 1983). However, as the saliva samples were collected up to 15 minutes 
after waking, it could also capture part of the awakening cortisol response (ACR). ACR is a 
discrete and distinctive part of the cortisol circadian cycle. In healthy adults salivary free 
cortisol concentrations increase by between 50 and 160% in the first 45 min immediately 
post-awakening and is thus rising during the first 15 minutes upon waking (Clow, Thorn, 
Evans, & Hucklebridge, 2004). However, a delay between waking and sampling below 15 
minutes was not found to have a significant influence on cortisol level (Dockray, 
Bhattacharyya, Molloy, & Steptoe, 2008). How the cortisol response to a blood draw can be 
generalized to psychosocial stressor, as well as the role of the stimulant-induced rise in 
cortisol have also to be established in further studies. The relatively small number of 
subjects did not allow exploring whether all ADHD subtypes are equally sensitive to 
cortisol levels. Further studies are also needed to establish whether the side-effects 
correlated with the morning cortisol and those related to increasing dose of stimulant are 
distinguishable or not, as this would help identifying potential non responders. Specific 
measures of mood, anxiety, and sleep problems would also be important in future studies to 
tackle this issue. However, despite its limitations, this first study using a double blind 
placebo controlled trial in a well defined ADHD group, and a standard stressor, provided 
evidence that the HPA axis circadian rhythm and reactivity is likely to be a strong predictor 
of the response to stimulant medication. Given the relative lack of success of previous 
studies, it is worth pursuing in further investigations. 
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Figure 1 legend: Correlations between Log of cortisol upon waking (x-coordinate) and ADHD global 
rating at high dose (circles/y-coordinate) and total side effects with placebo (triangles/y-coordinate) in 
the low (upper panel) and high (lower panel) cortisol upon waking groups. In the high awakening 
group, Pearson’s correlation was -0.60 (P=0.019) with the ADHD score and +0.53 (P=0.044) with the 
total side effect score. 
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Figure 2 legend: SWAN ADHD scores by parents and teacher under the placebo, the low, 
medium and high dose of MPH in each low vs. high stress cortisol or no diagnosis vs. any 
anxiety diagnosis groups. 
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3. Discussion 
3.1 Overall presentation 
The present study demonstrated differences in effects of dose of methylphenidate in 
children with ADHD according to their morning cortisol or cortisol reactivity levels. The 
results obtained suggest that the effect of methylphenidate treatment should be considered 
in relation with cortisol levels. Children with ADHD and high morning cortisol are poor 
responders to methylphenidate while those with high cortisol reactivity continue to improve 
with higher doses of methylphenidate. Thus cortisol can partially predict the response to 
treatment of methylphenidate. In addition, children with comorbid anxiety disorders 
displayed similar results as the children with high cortisol reactivity. This is in line with 
previous results showing that children with ADHD and anxiety disorders have stronger 
cortisol response to stressor than children with ADHD alone. Conversely, low level of 
morning cortisol was not a marker of anxiety level. These findings have important clinical 
implications for the most prescribed medication in child psychiatry for the treatment of 
children with ADHD; stimulants such as methylphenidate or amphetamine salts. However, 
they raise different issues in order to fully understand the implications for treatment. First, 
it is primordial to examine if these results could be generalized to all age groups, as diurnal 
cortisol rhythm and cortisol reactivity is affected by age. Furthermore, other factors could 
affect cortisol levels such as gender, socioeconomic status, race, etc. Such factors have 
been found to influence cortisol levels and hence may have an effect on the efficacy of the 
stimulant medication.  
 
Also, the influence of cortisol level and reactivity on the response to other medications 
used in children with ADHD should be examined. Cortisol-norepinephrine or cortisol-
serotonin interactions will be discussed in relation with the cortisol-dopamine interactions. 
In addition, there are differences in individual dopamine activity that may have an effect on 
the treatment of ADHD. Lastly, we will review the limitations and the general clinical 
implications of the present study.   
  
66
 
3.2 Cortisol diurnal rhythm and morning level 
 
3.2.1. Influence of the circadian rhythm of cortisol with age 
It is typically at three months that the early morning peak is clearly established at an 
individual level, although it is detectable as early as at six weeks in group average. The 
circadian rhythm is characterized by a decrease of cortisol throughout the day. A significant 
decrease in salivary cortisol levels has been consistently observed between the sample 
obtained approximately 30 minutes after wake up and the sample obtained within 30 
minutes of bedtime, from 3 to 36 months (Gunnar & Donzella, 2002). However, the 
expected smaller decrease from mid-morning to mid-afternoon is not reliably observed 
before 48 months. This diurnal change at 48 months may be related to the development of a 
mature sleep/wake pattern over this period. Cortisol level also decreased during the nap and 
its decrease from morning to afternoon predicted the duration of the nap in preschoolers. 
The basal activity of the HPA axis continues to mature until the late preschool years, in 
relation with changes in daytime napping.  
The development of the circadian rhythm of cortisol is also changing later in life. There is 
consistent evidence of an age-related phase advance (i.e., to an earlier phase) in the timing 
of the biological cycle. This was shown with circadian rhythm markers such as the sleep-
wake cycle, melatonin cycle, body temperature and cortisol cycles. A phase difference of 
about one hour is typically found between young and old subjects such that older adults 
have an earlier phase than younger adults (Monk, 2005). Hence older adults tend to wake 
up and sleep earlier. Nocturnal exercise is capable of delaying the circadian melatonin 
rhythm in older adults who have advanced sleep-wake cycle and of restoring synchrony of 
the sleep-wake cycle with the external environment (Baehr et al., 2003). Napping in the 
evening is common in older adults and it is related to early morning awakening. Evening 
napping could thus be a manifestation of advanced circadian rhythm. This is partly 
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supported by the finding that older adults with evening naps showed a more advanced 
acrophase melatonin excretion than those without evening naps. 
In the elderly, humans also show an attenuation of diurnal rhythm of cortisol and ACTH 
secretion, resulting in higher evening cortisol (Deuschle et al., 1997; Van Cauter E., 
Leproult, & Kupfer, 1996) since other studies confirmed that ACTH and cortisol level are 
higher in the evening than in younger subjects (Giordano et al., 2005). The basal HPA 
activity was also enhanced during sleep in the elderly, as indicated by significantly elevated 
nadirs of plasma cortisol and ACTH concentrations during early nocturnal sleep (Dodt, 
Theine, Uthgenannt, Born, & Fehm, 1994).   
The clinical response to stimulant could thus be more predictable when the circadian 
rhythm is reliably established. However, in practice, stimulants are not prescribed in 
children less than 4 years. Older adults could have a better response to methylphenidate due 
to the lower morning cortisol levels.  
 
3.2.2 SES (socioeconomic status) and race 
 Cortisol waking responses were positively associated with high job demands, but this 
effect was attenuated by higher SES. Gender may also interact with SES and job demand, 
as over the remainder of the day were elevated in lower SES female participants who 
experienced high job demands (Kunz-Ebrecht, Kirschbaum, & Steptoe, 2004). In children, 
the basal salivary cortisol level in the morning was significantly higher in low family 
income, and this effect emerges at age 6 (Lupien, King, Meaney, & McEwen, 2000). 
Children from low family income may thus be at higher risk to not respond to 
psychostimulant medication, due to chronically elevated levels of cortisol.  
 
Afro-American people also showed a higher evening salivary cortisol, and thus a flatter 
rhythm at the end of the day. This association was independent of SES and could not be 
explained by behavioral, social, or emotional mediators (Cohen et al., 2006).  Conversely, 
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whites with higher education had a steeper awakening response as compared to other 
groups, after adjustment for relevant covariates (Bennett, Merritt, & Wolin, 2004).  
Interactions have also been described between SES and gender: For example, cortisol 
concentration was greater in lower than higher grade men but was more elevated in higher 
than lower grade women, which may reflect the higher stress experienced by women in 
high-status occupation (Steptoe et al., 2003). 
 
3.2.3 Sampling day and gender effect  
Salivary cortisol levels on waking did not differ between work and weekend days. 
However, the cortisol awakening response (defined as the difference between waking and 
30 min later) was greater on work than weekend days (Kunz-Ebrecht, Kirschbaum, 
Marmot, & Steptoe, 2004; Thorn, Hucklebridge, Evans, & Clow, 2006) Although salivary 
cortisol levels on waking did not differ by gender, women showed a larger cortisol 
awakening response (defined as the difference between waking and 30 min later) on work 
days but not on weekend days (Bennett et al., 2004; Kunz-Ebrecht et al., 2004). The 
anticipation of the day could thus play a role in morning cortisol level and these findings 
could have lead to hypothesize that girls would be more likely to be non responders to 
stimulant treatment on stressful days since their morning cortisol would be increased 
compared to men. This is also true in lower primates, as a study in female monkeys showed 
that age had a significant effect on the diurnal pattern of cortisol so that older monkeys had 
lower morning cortisol levels and higher evening cortisol levels (Gust et al., 2000).  
 
3.3 Cortisol reactivity 
Cortisol reactivity is defined as the amount of cortisol secreted when faced with a stress. 
Like cortisol rhythm, cortisol reactivity is affected by many factors such as age, gender, 
race, and dopamine activity.  
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3.3.1 Cortisol reactivity: effect of age 
In the newborn, the cortisol response to stressor is high from the first week of life up to 
10-11 weeks. However, the cortisol response quickly habituates. A separation of 30 
minutes from the parents in the presence of an unknown non engaging babysitter only 
produces small increase of cortisol at 9 months of age (Gunnar, Larson, Hertsgaard, Harris, 
& Brodersen, 1992), but by 13 months the cortisol increase was not significant (Gunnar & 
Nelson, 1994). Using immunization inoculation as standard stressors, cortisol responses 
were large in 2-to-6 month-infants, but by 12 months and up to 18 months, significant 
increases were no longer observed for most infants (Gunnar, Brodersen, Krueger, & 
Rigatuso, 1996). The dampening of the cortisol response is not tightly linked to the 
expression of emotional distress and does not decrease for the average toddler, 12- to 18- 
months of age. This dampening of the cortisol response seems to persist throughout 
toddlerhood and in preschool age. Mean cortisol values for 3-to 5-year old children during 
the early weeks in the nursery school were not elevated over levels obtained at home 
(Gunnar, Tout, de, Pierce, & Stansbury, 1997). This lack of overall cortisol reactivity 
should not hide individual differences that can be detected across different contexts. For 
example, the cortisol response in children with an insecure attachment and temperamentally 
fearful was larger at 15 months, than the average response of all 6-month-old infants 
(Gunnar et al., 1996). At 18 months, elevation of cortisol in the Ainsworth Strange 
Situation was only found for toddlers with insecure attachment (Nachmias, Gunnar, 
Mangelsdorf, Parritz, & Buss, 1996). Thus quality of care can prevent the cortisol rise in 
potentially stressful situations, even in children at risk, although the nature of the most 
important aspects of care for regulating children’s cortisol response to challenge remains to 
be studied. 
 
In rat, normally occurring differences in maternal care quality (as measured by the 
frequency of pup licking and grooming or LG) during the first week of life are associated 
with individual differences in the adult offspring. As compared to high LG mother, 
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offspring of low LG mother show increased HPA response to stress (Liu et al., 1997). The 
maternal effects on HPA response to stress partly depend on epigenetic programming of 
gene expression. The non-coding exon 1 region of the hippocampal glucocorticoid receptor 
(GR) includes a promoter region, exon I7, containing a binding site for nerve growth factor-
inducible protein A (NGFl-A, a transcription factor). In adult offspring of low LG mother, 
hypermethylation of exon I7 GR contributes to the decrease in expression of GR, and hence 
in higher cortisol response to stress (Weaver et al., 2004). Increased level of cortisol 
reactivity is a potential adaptive advantage in an adverse environment. For example, adult 
offspring of low LG mother showed enhanced memory relative to offspring of high LG 
mother, but only when tested in a hippocampal-dependent, contextual fear-conditioning 
paradigm (Champagne et al., 2008). This epigenetic process imprints environmental 
experience on the fixed genome, resulting in stable alteration of the phenotype. Children 
inherit not only genes but also an environment. However, the signalling pathway that 
informs the genome on the level of environmental demand is mediated by the caring 
behaviour of the parent. The microenvironment of the parent-child relationship can also 
considerably alter the nature of the larger environment. The cost of this adaptation is the 
increase of the risk of stress-related disorders, brain-based or cardio-vascular and 
metabolic, especially in environment that require opposite adaptive strategies later in life. 
   
By using the Trier Social Stress Test, the response pattern of free cortisol measure in 
saliva did not differ between children and younger adults and older adults (Kudielka, 
Buske-Kirschbaum, Hellhammer, & Kirschbaum, 2004). However, in elderly humans, 
prolonged basal cortisol level correlate strongly with reduced hippocampal volume and 
deficits in hippocampus-dependent memory tasks (Lupien et al., 1998). Individual 
differences in hippocampal damage could thus emerge with age as a decrease in 
glucocorticoid receptor expression could be responsible for abnormal cortisol response 
(Nichols, Zieba, & Bye, 2001).   
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3.3.2 Gender and cortisol reactivity 
ACTH and total plasma cortisol response using the Trier Social Stress Test appeared 
enhanced in younger men and decreased with age in men only. Younger females have a 
greater adrenal sensitivity to ACTH stimulation, but this effect could be accounted for by 
differences in corticosteroid binding globulin (CBG) and/or sex steroids, like estrogens. 
Women in the luteal phase have comparable saliva cortisol stress responses compared to 
men whereas women in the follicular phase or taking oral contraceptives show significantly 
lower free cortisol responses (Kudielka et al., 2004). This may account for fluctuations in 
responsiveness to methylphenidate treatment in adult ADHD.  
 
 
 
3.3.3 SES (socioeconomic status) and race 
Using the Trier Social Stress Test Caucasian participants showed a greater HPA axis 
response than Afro-American participants. These differences remain significant after 
adjustment for potential social and psychological confounders (Chong, Uhart, McCaul, 
Johnson, & Wand, 2008). However, such racial related difference are absent for cortisol 
response following physical stimuli, as exercise, at least in females (Giannopoulou, 
Carhart, Sauro, & Kanaley, 2003; Yanovski et al., 2000).   
  
3.3.4 Individual difference in DA activity 
In normal humans, usual therapeutic dose of methylphenidate (0.5 mg/kg) increased 
extracellular dopamine in the striatum (including the nucleus accumbens) by blocking the 
DAT transporter (Volkow et al., 2002). However, the level of DAT blockade by 
methylphenidate could not predict the DA increase; individual differences in DA neuron 
tonic firing rate are likely to be the main source of individual differences in DA 
methylphenidate-induced increase, and therapeutic effects (Volkow et al., 2002). There was 
also a significant association between methylphenidate induced DA increases in the 
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striatum and the interest and motivation for the task (Volkow et al., 2004) or the subject’s 
expectation of a positive experience (Volkow et al., 2006). Individual difference in DA 
activity could thus modulate the antagonistic effect of high morning cortisol on the 
response to stimulants.
 
3.4. Interaction between dopamine and norepinephrine 
Many neuroimaging and neuropsychological studies support the hypothesis of prefrontal 
cortex (PFC) abnormalities in ADHD. The PFC is an important brain structure for 
executive functions such as inhibition of the processing of irrelevant stimuli, sustaining 
attention over long delays, coordinating attention, all functions that were showed to be 
deficient in children with ADHD and responsible for their symptoms. DA modulated PFC 
functions through D1 (D1, D5) and D2 (D2, D3, D4) families of dopamine receptors. D1 
dopamine receptor agonists infused in the PFC of rats produces an inverted U dose-
response curve on their ability to sustain and divide attention (Granon et al., 2000) or keep 
spatial information in working memory (Zahrt, Taylor, Mathew, & Arnsten, 1997). Using 
spatial working memory task, modest levels of D1 agonist suppressed delay-related firing 
for nonpreferred spatial directions (i.e., increased “spatial tuning” and decreased “noise”) at 
a cellular level. On the contrary, higher levels of D1 stimulation reduced delay-related 
firing for all directions, eroding spatial tuning (Williams & Goldman-Rakic, 1995; 
Vijayraghavan, Wang, Birnbaum, Williams, & Arnsten, 2007). D1 receptors are also 
critical for spatial working memory performance in humans (Muller, von Cramon, & 
Pollmann, 1998).   
 
As for dopamine, modest levels of NE are critical to proper PFC functions and high levels 
released during stress are impairing PFC functions. Postsynaptic alpha-2A adreno-receptors 
(and not presynaptic receptors reducing NE release as previously thought) mediate the 
enhancing effects of alpha2-agonist on PFC functions. Alpha-2A agonist guanfacine 
improves both lateral and ventro-medial prefrontal cortex functions, and thus potentiates 
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both sensory-motor and emotional responses. In contrast to D1 agonist that decreased noise, 
NE alpha2A agonist increased delayed-related firing for the preferred spatial direction (i.e., 
increased signal). Pyramidal cells of the PFC form reverberating microcircuits through 
mutual connection for axons to the dendritic spines of neurons sharing the same spatial 
preferences. Stimulation of alpha-2A adreno-receptors inhibits the production of cAMP 
through G-couple receptors, which closes Hyperpolarization-activated Cyclic Nucleotide-
gated (HCN) channels and increase the efficacy of synaptic input, strengthening the 
functional connectivity of PFC microcircuits (Wang et al., 2007). At the opposite high level 
of stimulation of G-couple D1 receptors would activate cAMP production, open HCN 
channels and shunt synaptic input, rendering the PFC functionally disconnected 
(Vijayraghavan et al., 2007).  
 
In contrast to the enhancing effects of modest levels of NE, higher levels of NE (e.g., 
during stress) impair PFC function and this impairment is mediated by alpha1-
adrenoreceptors. Alpha1-adrenoreceptors are coupled to G proteins that activates 
phospholipase C (PLC) releasing diacylglycerol (DAG) which subsequently binds to and 
activates protein kinase C (PKC). Thus NE indirectly activates PKC. High levels of PKC 
activity in prefrontal cortex, as seen for example during stress exposure, markedly impair 
behavioral performance in a working memory test and decreased delayed related activity 
for the preferred spatial direction (Birnbaum et al., 2004). Lithium and valproate are 
common treatments for patients with bipolar disorder. Although disparate in many of their 
actions, both agents attenuate PKC activity; both lithium and valproate protected prefrontal 
cortical cognitive function from alpha1 adrenergic receptor-induced impairment (Birnbaum 
et al., 2004). Most atypical antipsychotic also are potent alpha1 receptor blockers. At dose 
that reduce locomotor activity in male Sprague-Dawley rats, methylphenidate produces a 
substantial increase of NE and DA efflux within the PFC, (Berridge et al., 2006) and the 
hippocampus (Kuczenski & Segal, 2002), but not in other regions of the brain, especially 
not in the nucleus accumbens. This may be explained by the efficient uptake of DA by the 
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NE transporter in the PFC, similar to the efficiency of NE uptake (Bymaster et al., 2002). 
2 antagonist and the D1 antagonist were able in male rats to reverse the cognitive 
enhancing effects of methylphenidate in the spatial delayed alternation task (Arnsten & 
Dudley, 2005).  Methylphenidate may thus improve performance by increasing the 
availability of NE and DA in the PFC, which in turn stimulate 2 and D1 receptors. 
 
3.5. Interaction between NE and cortisol 
Animal studies (McGaugh, 2004) have shown that the amygdala (especially the 
basolateral complex of the amygdala) mediates the memory-modulating effects of adrenal 
stress hormones. The availability of NE in the amygdala appears to be a prerequisite for this 
effect. To examine this interaction NE-cortisol interaction in humans, a group of healthy 
subjects were shown emotional stimulating images. Results showed that endogenous 
cortisol level interacted with Ne activation within the amygdala. Subjects with high cortisol 
levels showed significantly more amygdala activation during emotional pictures than in the 
low cortisol group. Hence a significant interaction of the endogenous cortisol with the 
activation of the amygdala was proven. Emotional stimuli lead to activation of the 
amygdala, an effect that is Ne dependent (van Stegeren et al., 2007). Thus, endogenous 
cortisol amplifies the noradrenergic effect in humans. This interaction can also be studied in 
patients treated for ADHD with noradrenergic drugs.   
   
Clonidine (Catapres®) is an alpha2-agonist that has been used off label as a potential 
treatment for ADHD. It has relatively high affinity for the three subtypes of alpha2 
adrenoreceptors (A, B, C). All three subtypes are found on the post-ganglionic sympathetic 
neurons. The hypotensive effect is likely to be due to stimulation of post-synaptic alpha2-
adrenoreceptors of inhibitory neurons within the caudal ventro-lateral medulla in the 
brainstem. The sedative effects arise from various effects, including presynaptic alpha2A 
and alpha 2C autoreceptors on locus coeruleus neurons as well as postsynaptic receptors 
throughout the cortex and in the thalamus (alpha2B). Clonidine is used to treat not only 
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ADHD symptoms, but also tic and explosive behaviours. As the more common side effects 
are sedation, hypotension and dizziness, many physicians are also prescribing clonidine at 
bedtime for its sedative effects. In combination with methylphenidate, clonidine was well 
tolerated in children with ADHD only (Tourette's Syndrome Study Group, 2002) or with 
ADHD and tics (Palumbo et al., 2008; Daviss et al., 2008). Clonidine was supposed to 
decrease the severity of the tics through activation of adrenergic receptors and negative 
feedback on the HPA axis. The same reasoning could be applied to guanfacine (Tenex®), 
another alpha2-agonist that could be used in the treatment of ADHD (Posey & McDougle, 
2007). Guanfacine is much less sedating than clonidine, and its pre-synaptic inhibition of 
NE release in locus coeruleus neurons is also much weaker. However, the use of alpha2-
agonist was limited by the need to re-dose throughout the day. On June 24, 2007, the U.S. 
Food and Drug Administration (FDA) gave an approval letter for Intuniv (guanfacine) 
extended release tablets. The combination of guanfacine IR and a stimulant has not yet 
been evaluated.  
 
The involvement of brain catecholamine in the regulation of the pineal gland hormone 
secretion, especially through the action of alpha-adrenergic agonist has long been 
recognized. The clonidine test has been proposed in 1979 to test for the growth hormone 
reserve in children evaluated for short stature (Gil-Ad, Topper, & Laron, 1979).   In 
children, 30 minutes after oral administration of clonidine, ACTH and cortisol decreased in 
the plasma reaching lowest values at 90 min. This suggests the existence of alpha2-
adrenergic receptors in the pineal gland, as in lower vertebrates, and an inhibitory alpha2-
adrenergic influence on the HPA axis (Munoz-Hoyos et al., 2000). The same effect is 
observed using guanfacine (Dura et al., 1996). 
 
Atomoxetine is a selective inhibitor of norepinephrine reuptake transporter (SNRI) and 
constitutes a non-stimulant alternative in the treatment of ADHD. Norepinephrine reuptake 
inhibitor atomoxetine blocks the transporters, which causes accumulation of endogenous 
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NE, which in turn leads the alpha2-adrenoreceptor to shut down firing activity. The 
administration of atomoxetine in healthy male volunteers also led to significant increases in 
salivary cortisol. The time course of the response corresponded to approximately the 
pharmacokinetics of the drug, peaking 1 to 2 hours after oral dosing. Thus, norepinephrine 
is thought to augment HPA axis function by increasing CRF secretion in the paraventricular 
nucleus of the hypothalamus (Chamberlain, Muller, Cleary, Robbins, & Sahakian, 2007). 
The findings are consistent with previous studies (Nutt, Middleton, & Franklin, 1987) that 
used other less selective NE reuptake inhibitors such as tricyclic antidepressants 
(desipramine, imipramine, clomipramine, maprotiline). Reboxetine is a novel 
antidepressant drug that selectively inhibits norepinephrine reuptake, with a very similar 
pharmacological profile to atomoxetine. It also has been showed to be effective and safe in 
the long-term treatment of ADHD (Toren et al., 2007). A transient increase in ACTH and 
cortisol release after acute administration of reboxetine was observed in healthy volunteers 
(Schule et al., 2004) or in volunteer scoring high for depression but not clinically depressed 
(Hennig, Lange, Haag, Rohrmann, & Netter, 2000). This increase is likely caused by 
enhancing NE concentration and stimulating CRH via hypothalamic alpha1-
adrenoreceptors. However, the long-term effects of norepinephrine reuptake inhibitor 
(NRIs) appeared opposed to the acute effects. In patients treated for major depressive 
episode with reboxetine, the combined dexamethasone suppression/corticotrophin releasing 
hormone challenge showed that HPA axis decreased in activity. This decreased was largest 
after 5 weeks of treatment, especially in the patients who showed a clinical response to the 
treatment (Schule et al., 2006). The results also showed a significant decrease in the 
baseline level of cortisol, before the CRH injection.  
 
3.6. Interaction between cortisol and serotonin 
Stress is an important precipitant factor in depression, and many changes that occur in 
depression are similar to those observed in response to stress .Many symptoms of ADHD 
are overlapping with symptoms found in depression, such as the inability to concentrate, or 
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impulsiveness. In addition many mood symptoms are usually found in children with ADHD 
such as emotional lability. Mood and anxiety disorder are also frequently comorbid with 
ADHD, as well as mood symptoms of Oppositional Defiant Disorder (touchy and easily 
annoyed, angry and resentful, loses temper). Serotoninergic neurons in the dorsal raphe 
nuclei do not increase firing rate in response to stress, but the synthesis and outflow of 5-
HT increases in the raphe and its projections area (for a review see (Lanfumey, Mongeau, 
Cohen-Salmon, & Hamon, 2008). This effect seems to be mediated by the stimulatory 
influence of adrenal steroid hormones on tryptophan hydroxylase, and hence on 5-HT turn-
over (Singh, Corley, Phan, & Boadle-Biber, 1990).  
 
On the other hand, 5-HT receptors are central to the antidepressant effects of serotonin 
selective reuptake inhibitors (SSRIs). SSRIs by blocking 5-HT reuptake produce an 
increase in brain levels of extracellular 5-HT within minutes following their administration. 
However, this increase in cancelled by the negative feedback mediated by the activation of 
5-HT1A autoreceptors at the 5-HT cell body/dendrite level in the dorsal raphe nuclei.  
However, after prolonged SSRI treatment, 5-HT1A autoreceptors desensitize, which 
inactivates the 5-HT inhibitory feedback control. Extracellular 5-HT concentration raises 
markedly as in projection areas of 5-HT fibres, In turn this change has an effect on cortisol 
levels. Increase in plasma cortisol after two hours was observed in healthy volunteers after 
a single dosage of 20 mg of the SSRI citalopram, as compared to the placebo condition 
(Chamberlain et al., 2007; Hennig & Netter, 2002) or after receiving 20 mg of the SSRI 
paroxetine (Kojima et al., 2003). Another study tested the effect of oral citalopram but on 
salivary cortisol levels in healthy volunteers. The results demonstrated an increase in 
salivary cortisol and hence an increase in HPA activity (Nadeem, Attenburrow, & Cowen, 
2004). However, a gradual downregulation of HPA axis hyperactivity was demonstrated by 
serial Dexamethasone/CRH tests in depressed patients treated with the SSRI paroxetine 
(Nickel et al., 2003).   
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3.7 Other predictors of the response to methylphenidate 
In addition to the interaction between the HPA axis and the different medication used to 
treat children with ADHD, genetic factors may play a role in difference in the clinical 
response. For example, twice higher doses were required for symptom improvement for 
children possessing a DRD4 7R allele, a common polymorphism found in 44.4% of the 
sample (Hamarman, Fossella, Ulger, Brimacombe, & Dermody, 2004). An excess 
transmission of DRD4-7 allele was also more likely in methylphenidate responders than in 
non responders, as defined in an open titration procedure (Tahir et al., 2000). A positive but 
not significant trend was found between the presence of one or two DRD4 7 repeat allele 
and a higher response rate of methylphenidate, as reported by parents during treatment (van 
der Meulen et al., 2005). However, in Korean children where the 7 repeat allele is rare, it is 
the 2-repeat allele at DRD4 that may be associated with poor outcome of methylphenidate 
treatment, while the children homozygous for the 4-repeat allele showed a better response 
(Cheon, Kim, & Cho, 2007). However, no association between the 48-bp VNTR 
polymorphism at the D4 dopamine receptor (DRD4) and response to methylphenidate have 
also been reported (Zeni et al., 2007; Winsberg & Comings, 1999). 
 
Other clinical characteristics may also influence the response to stimulant medication is 
increased at younger age and when symptoms (Efron, Jarman, & Barker, 1997; Gray & 
Kagan, 2000) or cognitive deficits, especially inhibitory control or attention (Barkley, 
1976), are more severe before treatment, although the relations are weak. Age and severity 
are not independent as ADHD symptoms and associated deficits tend to decrease with age. 
However, the better response at younger age may not hold for children below the age of 6.  
In preschool-age children, the effect size of stimulant medication is smaller than for school-
age children, the optimal dosage lower (Greenhill et al., 2006) and adverse effect of 
stimulant more frequent (Wigal et al., 2006). With regard to severity, it should be stressed 
that response to stimulant is also lower in children with comorbid conditions (DuPaul, 
Barkley, & McMurray, 1994; Ghuman et al., 2007; MTA Cooperative Group, 1999; Owens 
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et al., 2003). In order to predict a better response, severity might have to be restricted to 
ADHD symptoms. Among the Multimodal Treatment Study of Children with ADHD 
participants, those diagnosed with the ICD-10 criteria for Hyperkinetic Disorder (i.e., no 
anxious or depressive comorbidities; symptom threshold met for hyperactivity, 
impulsiveness and inattention; pervasiveness across school and home setting, and 
impairment endorsed) responded better to medication than those with ADHD failing to 
meet these ICD-10 more stringent criteria (Santosh et al., 2005). The predictive power of 
symptom severity may not always be unequivocal. ADHD symptom severity was showed 
to predict a poorer not a better response, but only in those children with a parent afflicted 
with a relatively high level of depressive symptoms (Owens et al., 2003). Similarly, if 
ADHD-specific cognitive deficits predicted a better response to stimulant, broader deficits 
captured by an IQ below 50 were associated with a less favourable response to MPH 
(Aman, Buican, & Arnold, 2003). Beyond clinical characteristics, some physiological 
measures have been tested as predictor of the response to stimulant. Homovanillic acid 
(HVA) is the major dopamine metabolite. Its cerebrospinal fluid concentration has been 
showed to be correlated with the rating of hyperactivity and with the response to stimulant: 
higher HVA predicted a modest portion (up to 25% on some measures) of better drug 
response (Castellanos et al., 1996).  
 
3.8 Clinical implications 
This review of the interaction between the cortisol secretion and the various ADHD drug 
suggest that the NE and DA interacting systems are involved in treating the ADHD 
symptoms. The efficacy of the different types of drugs may differ according to the balance 
between these systems have in the expression of the ADHD symptoms. To summarize, the 
dopamine is crucial for creating habit memories in striatal loops though a reward brain 
circuit which is the basis for motivated behaviours. Norepinephrine plays a crucial role in a 
less enduring form of memory creation: working memory which depends primarily on the 
prefrontal cortex and maintains information in a temporary buffer that is constantly updated 
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according to cognitive demand. Executive functions depend critically on working memory 
which is the basis for an interactive aroused behaviour. NE cells of the locus coeruleus fire 
according to levels of arousal, with low levels of both tonic and phasic firing under drowsy 
conditions, moderate tonic firing and clear phasic firing in response to relevant stimuli 
when animals are alert, and high tonic firing and poor phasic firing when animals are 
stressed (Aston-Jones & Cohen, 2005). Similarly DA cells in the ventral tegmental area 
may fire according to the level of motivation, with low levels of both tonic and high phasic 
firing under non motivating state, with interest for irrelevant stimuli, moderate tonic firing 
and clear phasic firing in response to relevant stimuli when the subject is motivated, and 
high tonic firing and poor phasic firing when animals are too strongly motivated and 
stressed.  
 
The medications used to treat ADHD symptoms modulate the firing balance of the DA 
and NE cells. Methylphenidate may thus improve performance by increasing the 
availability of NE and DA in the PFC, which in turn stimulate alpha2 and D1 receptors. But 
methylphenidate also increases extracellular dopamine in the striatum (including the 
nucleus accumbens) by blocking the DAT transporter. By increasing the tonic rate of DA 
cell, methylphenidate improves the motivational state, decreasing irrelevant responding and 
enhancing the interest of the relevant behaviors. When the motivational factors are relevant 
for the expression of ADHD symptoms, subjects are likely to respond well to stimulant 
medication. However, if a chronically high level of stress is the most relevant factor in the 
expression of ADHD symptoms (impairing executive functions), methylphenidate may 
have a reduced therapeutic effect. In fact it may even have a negative effect if the tonic 
activation of alpha2 and D1 receptors is already increased. A high level of cortisol would 
be a marker of a chronically elevated stress level. This would explain why children with 
high morning cortisol were more likely to be classified as non responders. NE medication 
may be a better choice, as they would reduce NE cell tonic firing in the locus coeruleus and 
restore a normal and more adapted level of alertness. Long term treatment may also 
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desensitize the HPA axis and restore a normal diurnal rhythm of cortisol. This 
normalization of the stress level could in turn restore the effect of methylphenidate on the 
motivational state, as NRI (especially atomoxetine) do not change DA level in the striatum 
(Bymaster et al., 2002).  
 
It is thus possible that alpha2 adrenergic drug could potentiate the effect of 
methylphenidate in those with a high level of morning cortisol. A long term treatment using 
atomoxetine could also be an alternative in order to decrease the HPA axis activity and 
restore the responsiveness to stimulant if necessary. Other NRIs such as tricyclic 
antidepressants (desipramine, imipramine, clomipramine, maprotiline) are likely to have the 
same effect.  Although selective serotonin reuptake inhibitors are not effective in 
decreasing ADHD symptoms, augmenting stimulant treatment with SSRI could also 
potentiate the effect of stimulant medication, through desensitizing the HPA axis.  
 
Beyond the capacity to predict the response to stimulant, these results point to the 
heterogeneity of ADHD and the need to better define the symptoms, by including more 
systematic assessment of what is considered nowadays as side effect of the medication but 
are likely to be further defined as part of the ADHD symptoms. It is also important to better 
define the co-mordid conditions, especially stress-related disorder, as some but not all of 
them may hinder the efficacy of the treatment. High doses of stimulant may be beneficial 
for children with ADHD and with a high level of cortisol reactivity or with ADHD and 
some forms comorbid anxiety disorders, characterized with low levels of both tonic and 
phasic firing. Maternal depression increases the vulnerability of depression in children, and 
increases the risk of HPA dysregulation. Maternal depression is likely to contribute to poor 
response to treatment both through psycho-social and biological mechanisms. A depressed 
mother is less likely to be able to meet all the organizational challenges of the treatment but 
may also induce a biological resistance to treatment, though increased HPA axis activity. 
Therefore, depression should be assessed in the mothers of children with ADHD as an 
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important determinant of the outcome. Depression should be assessed in children with 
ADHD to differentiate some symptoms that are caused by underlying depression 
undiagnosed and not caused by methylphenidate, such as psychomotor retardation.  
 
Further, biological measures could also become part of the assessment of children with 
ADHD in order to assess the level of activity of NE and DA brain pathways. Although 
much work is needed before any firm conclusion could be drawn, morning salivary cortisol 
or ACR could become part of the assessment of children with ADHD and help diagnosing 
subtype and orient treatment. This would allow more individualized and potent treatment.  
 
3.9 Limitations of the present study: 
The protocol stated that the morning saliva sample should be taken 15 minutes after 
awakening. However, some variability could have occurred in the exact timing of the saliva 
collection by the parents and we cannot exclude that the sample also reflect the awakening 
cortisol response. It is necessary to replicate the study with at least three samples in order to 
differentiate the morning level of cortisol and the cortisol response to awakening. It would 
be also important to have cortisol sample during the titration trials and in the maintenance 
phase, once the child is on the optimal dosage, in order to understand the acute and long 
term effects of stimulant both in responders and non responders. Previous result have 
suggested that cortisol level are not affected by long term treatment with stimulants, but 
this has to be examined as a function of the initial cortisol morning level and response to 
stress. Age is also a factor that has to be controlled. In this study, the blood draw was used 
as a psychological stressor. It would be interesting to use another psychological stressor 
such as the Trier Social Stress Test to compare the results obtained with a physical stressor.  
 
 4. Conclusion 
 
In conclusion, we studied the association of salivary cortisol upon waking and stress 
cortisol with the outcome of treatment of ADHD using methylphenidate. Venipuncture was 
the stress used to increase cortisol level.  
The results suggest that children with high morning cortisol are treatment resistant 
to methylphenidate. Morning cortisol might be a reliable marker for a depression 
endophenotype, which would predict a lack of response to stimulant. A greater benefit of a 
high dose of methylphenidate was observed for the high stress reactivity group but not the 
low stress reactivity group. Also, the presence of anxiety disorders comorbid with ADHD 
was related to a greater benefit from going to a high dose of methylphenidate.  
The results of this study stress the relation between ADHD, mood and anxiety 
disorder. The activity of the HPA axis might be used to separate the children with ADHD 
in subgroups with different response to medication affecting either dopamine or 
norepinephrine. 
 
 
 Bibliographie
Alessi SM, Greenwald M, Johanson CE, (2003). The prediction of individual 
differences in response to D-amphetamine in healthy adults. Behav Pharmacol, 14, 19-32. 
Aman, M. G., Buican, B., & Arnold, L. E. (2003). Methylphenidate treatment in 
children with borderline IQ and mental retardation: analysis of three aggregated studies. 
J.Child Adolesc.Psychopharmacol., 13, 29-40. 
Arnsten, A. F. & Dudley, A. G. (2005). Methylphenidate improves prefrontal 
cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: 
Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav.Brain
Funct., 1, 2. 
Aston-Jones, G. & Cohen, J. D. (2005). An integrative theory of locus coeruleus-
norepinephrine function: adaptive gain and optimal performance. Annu.Rev.Neurosci., 28, 
403-450. 
Asghari, V., Sanyal, S., Buchwaldt, S., Paterson, A., Jovanovic, V., & Van Tol, H. 
H. (1995). Modulation of intracellular cyclic AMP levels by different human dopamine D4 
receptor variants. J Neurochem., 65, 1157-1165. 
Barkley RA, (2004). Adolescent with attention deficit hyperactivity disorder: an 
overview of empirically based treatments. Journal of psychiatric practice, 10, 39-56. 
Barkley, R. A. (2000). Commentary on the multimodal treatment study of children 
with ADHD. J Abnorm.Child Psychol., 28, 595-599. 
Barrot M, Marinelli M, Abrous DN, et al. (2000). The dopaminergic hyper-
responsiveness of the shell of the nucleus accumbens is hormone-dependent. Eur J 
Neurosci, 12, 973-979 
 
  
85
 
Baehr, E. K., Eastman, C. I., Revelle, W., Olson, S. H., Wolfe, L. F., & Zee, P. C. 
(2003). Circadian phase-shifting effects of nocturnal exercise in older compared with young 
adults. Am.J Physiol Regul.Integr.Comp Physiol, 284, R1542-R1550. 
Barkley, R. A. (1976). Predicting the response of hyperkinetic children to stimulant 
drugs: a review. J.Abnorm.Child Psychol., 4, 327-348. 
Bateman B, Warner JO, Hutchinson E, et al. (2004). The effects of a double blind, 
placebo controlled artificial food coloring and benzoate preservative challenge on 
hyperactivity in a general population sample of preschool children. Archives of diseases in 
child hood, 89, 506-511. 
Bennett, G. G., Merritt, M. M., & Wolin, K. Y. (2004). Ethnicity, education, and the 
cortisol response to awakening: a preliminary investigation. Ethn.Health, 9, 337-347. 
Berridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F., Kelley, A. 
E., Schmeichel, B. et al. (2006). Methylphenidate preferentially increases catecholamine 
neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. 
Biol.Psychiatry, 60, 1111-1120. 
Bhagwagar, Z., Hafizi, S., & Cowen, P. J. (2003). Increase in concentration of 
waking salivary cortisol in recovered patients with depression. Am.J Psychiatry, 160, 1890-
1891. 
Biederman J, Faraone SV, (2005). Attention deficit hyperactivity disorder. Lancet, 
366, 237-248. 
Biederman J. Attention-deficit/hyperactivity disorder: A selective overview. Biol 
Psychiatry. 2005; 57:1215-1220. 
  
86
 
Birnbaum, S. G., Yuan, P. X., Wang, M., Vijayraghavan, S., Bloom, A. K., Davis, 
D. J. et al. (2004). Protein kinase C overactivity impairs prefrontal cortical regulation of 
working memory. Science, 306, 882-884. 
Booth, J. R., Burman, D. D., Meyer, J. R., Lei, Z., Trommer, B. L., Davenport, N. 
D. et al. (2005). Larger deficits in brain networks for response inhibition than for visual 
selective attention in attention deficit hyperactivity disorder (ADHD). J Child 
Psychol.Psychiatry, 46, 94-111. 
Bor W, Sanders MR, Markie-Dadds C., (2002). The effects of the triple P-positive-
parenting program on preschool children with co-occurring disruptive behaviour and 
attentional/hyperactive difficulties. Journal of child psychology and psychiatry, 30, 571-
578. 
Bowen R, Chavira DA, Bailey K, et al. (2008). Nature of anxiety comorbid with 
attention deficit hyperactivity disorder in children from a paediatric primary care setting. 
Psychiatry Research, 157, 201-209. 
Broadbear J, Winger G, Woods J., (1999). Glucocorticoid-reinforced responding in 
the rhesus monkey. Psychopharmacology, 147, 46-55. 
Broadbear JH, Winger G, Woods JH, (1999). Cocaine-reinforced responding in 
rhesus monkeys: pharmacological attenuation of the hypothalamic-pituitary-adrenal axis 
response. Journal Pharma Experimental therapeutics, 290, 1347-1355. 
Brookes, K. J., Mill, J., Guindalini, C., Curran, S., Xu, X., Knight, J. et al. (2006). A 
common haplotype of the dopamine transporter gene associated with attention-
deficit/hyperactivity disorder and interacting with maternal use of alcohol during 
pregnancy. Arch.Gen.Psychiatry, 63, 74-81. 
  
87
 
Buckley, T. M. & Schatzberg, A. F. (2005). On the interactions of the 
hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and 
circadian rhythm, exemplary sleep disorders. J.Clin.Endocrinol.Metab, 90, 3106-3114. 
Burke HM, Davis MC, Otte C, et al. (2005). Depression and cortisol responses to 
psychological stress: A meta-analysis. Psychoneuroendocrinology, 30, 846-856. 
Burkley TM, Schatzberg, (2005). Review: On the interactions of the hypothalamic-
pituitary-adrenal (HPA) axis and sleep: Normal HPA activity and circadian rhythm, 
exemplary sleep disorders. The journal of clinical endocrinology & metabolism, 90(5), 
3106-3114. 
 
Bymaster, F. P., Katner, J. S., Nelson, D. L., Hemrick-Luecke, S. K., Threlkeld, P. 
G., Heiligenstein, J. H. et al. (2002). Atomoxetine increases extracellular levels of 
norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy 
in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27, 699-711. 
Campbell UC, Carroll ME, (2001). Effects of ketoconazole on the acquisition of 
intravenous cocaine self-administration under different feeding conditions in rats. 
Psychopharmacology, 154, 311-318. 
Castellanos, F. X., Elia, J., Kruesi, M. J., Marsh, W. L., Gulotta, C. S., Potter, W. Z. 
et al. (1996). Cerebrospinal fluid homovanillic acid predicts behavioral response to 
stimulants in 45 boys with attention deficit/hyperactivity disorder. 
Neuropsychopharmacology, 14, 125-137. 
Chamberlain, S. R., Muller, U., Cleary, S., Robbins, T. W., & Sahakian, B. J. 
(2007). Atomoxetine increases salivary cortisol in healthy volunteers. J Psychopharmacol., 
21, 545-549. 
  
88
 
Champagne, D. L., Bagot, R. C., van, H. F., Ramakers, G., Meaney, M. J., de Kloet, 
E. R. et al. (2008). Maternal care and hippocampal plasticity: evidence for experience-
dependent structural plasticity, altered synaptic functioning, and differential responsiveness 
to glucocorticoids and stress. J Neurosci., 28, 6037-6045. 
Cheon, K. A., Kim, B. N., & Cho, S. C. (2007). Association of 4-repeat allele of the 
dopamine D4 receptor gene exon III polymorphism and response to methylphenidate 
treatment in Korean ADHD children. Neuropsychopharmacology, 32, 1377-1383. 
Cho K, Little HJ., (1999). Effects of corticosterone on excitatory amino acid 
responses in dopamine-sensitive neurons in the ventral tegmental area. Neuroscience, 88, 
837-845. 
Chong, R. Y., Uhart, M., McCaul, M. E., Johnson, E., & Wand, G. S. (2008). 
Whites have a more robust hypothalamic-pituitary-adrenal axis response to a psychological 
stressor than blacks. Psychoneuroendocrinology, 33, 246-254. 
Cohen, S., Schwartz, J. E., Epel, E., Kirschbaum, C., Sidney, S., & Seeman, T. 
(2006). Socioeconomic status, race, and diurnal cortisol decline in the Coronary Artery 
Risk Development in Young Adults (CARDIA) Study. Psychosom.Med., 68, 41-50. 
Dafny N, Yang PB., (2006). The role of age, genotype, sex, and route of acute and 
chronic administration of methylphenidate: A review of its locomotors effects. Brain
Research Bulletin, 68, 393-405. 
Daviss, W. B., Patel, N. C., Robb, A. S., McDermott, M. P., Bukstein, O. G., 
Pelham, W. E., Jr. et al. (2008). Clonidine for attention-deficit/hyperactivity disorder: II. 
ECG changes and adverse events analysis. J Am.Acad Child Adolesc Psychiatry, 47, 189-
198. 
  
89
 
Deuschle, M., Gotthardt, U., Schweiger, U., Weber, B., Korner, A., Schmider, J. et 
al. (1997). With aging in humans the activity of the hypothalamus-pituitary-adrenal system 
increases and its diurnal amplitude flattens. Life Sci., 61, 2239-2246. 
Dodt, C., Theine, K. J., Uthgenannt, D., Born, J., & Fehm, H. L. (1994). Basal 
secretory activity of the hypothalamo-pituitary-adrenocortical axis is enhanced in healthy 
elderly. An assessment during undisturbed night-time sleep. Eur.J Endocrinol., 131, 443-
450. 
DuPaul, G. J., Barkley, R. A., & McMurray, M. B. (1994). Response of children 
with ADHD to methylphenidate: interaction with internalizing symptoms. J.Am.Acad.Child
Adolesc.Psychiatry, 33, 894-903. 
Dura, T. T., Juste, R. M., Gonzalez, M. R., Gutierrez, T. M., Mauri, D. M., & Moya, 
B. M. (1996). [Sensitivity of the clonidine and guanfacine tests (alpha-2-adrenergic 
agonists) as pharmacologic stimulants of growth hormone. Effects on plasma cortisol]. 
An.Esp.Pediatr., 45, 575-578. 
Efron, D., Jarman, F., & Barker, M. (1997). Side effects of methylphenidate and 
dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, 
crossover trial. Pediatrics, 100, 662-666. 
El-Faddagh M, Laucht M, Maras A, et al. (2004). Association of dopamine D4 
receptor (DRD4) gene with attention deficit/hyperactivity disorder (ADHD) in a high risk 
community sample: a longitudinal study from birth to 11 years of age. J Neural Transm, 
111, 883-889. 
Elman I, Lukas SE, Karlsgodt KH, et al. (2003). Acute cortisol administration 
triggers craving in individuals with cocaine dependence. Psychopharmacol Bull, 37, 84-89 
  
90
 
Elman I, Lukas SE., (2005). Effects of cortisol and cocaine on plasma prolactin and 
growth hormone levels in cocaine-dependent volunteers. Addictive Behaviours, 30, 859-
864. 
Faraone SV, Doyle AE, Mick E, et al. (2001). Meta-analysis of the association 
between the 7 repeat allele of the dopamine D4 receptor gene and attention deficit 
hyperactivity disorder. Am J psychiatry, 158, 1052-1057. 
Faraone, S. V., Perlis, R. H., Doyle, A. E., Smoller, J. W., Goralnick, J. J., 
Holmgren, M. A. et al. (2005). Molecular genetics of attention-deficit/hyperactivity 
disorder. Biol.Psychiatry, 57, 1313-1323. 
Federenko IS, Nagamine M Hellhammer DH, et al. (2004). The heritability of the 
hypothalamus pituitary adrenal axis responses to psychological stress is context dependent. 
J Clin Endocrinol, 89, 6244-6250. 
Ghuman, J. K., Riddle, M. A., Vitiello, B., Greenhill, L. L., Chuang, S. Z., Wigal, 
S. B. et al. (2007). Comorbidity moderates response to methylphenidate in the Preschoolers 
with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J.Child 
Adolesc.Psychopharmacol., 17, 563-580. 
Giannopoulou, I., Carhart, R., Sauro, L. M., & Kanaley, J. A. (2003). 
Adrenocortical responses to submaximal exercise in postmenopausal black and white 
women. Metabolism, 52, 1643-1647. 
Gil-Ad, I., Topper, E., & Laron, Z. (1979). Oral clonidine as a growth hormone 
stimulation test. Lancet, 2, 278-279. 
Giordano, R., Bo, M., Pellegrino, M., Vezzari, M., Baldi, M., Picu, A. et al. (2005). 
Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to 
stimulation by mineralocorticoid receptor blockade. J Clin.Endocrinol.Metab, 90, 5656-
5662. 
  
91
 
Goeders, N. E. & Guerin, G. F. (1994). Non-contingent electric footshock facilitates 
the acquisition of intravenous cocaine self-administration in rats. Psychopharmacology
(Berl), 114, 63-70. 
Goeders, N. E. & Guerin, G. F. (1996a). Effects of surgical and pharmacological 
adrenalectomy on the initiation and maintenance of intravenous cocaine self-administration 
in rats. Brain Res, 722, 145-152. 
Goeders, N. E. & Guerin, G. F. (1996b). Role of corticosterone in intravenous 
cocaine self-administration in rats. Neuroendocrinology, 64, 337-348. 
Goeders, N. E., Peltier, R. L., & Guerin, G. F. (1998). Ketoconazole reduces low 
dose cocaine self-administration in rats. Drug Alcohol Depend., 53, 67-77. 
Goeders, N. E. & Guerin, G. F. (2000). Effects of the CRH receptor antagonist CP-
154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology, 23, 
577-586. 
Goeders NE., (2002). Stress and cocaine addiction. The journal of pharmacology 
and experimental therapeutics, 301, 785-789. 
 
Granon, S., Passetti, F., Thomas, K. L., Dalley, J. W., Everitt, B. J., & Robbins, T. 
W. (2000). Enhanced and impaired attentional performance after infusion of D1 
dopaminergic receptor agents into rat prefrontal cortex. J Neurosci., 20, 1208-1215. 
Gray, J. R. & Kagan, J. (2000). The challenge of predicting which children with 
Attention Deficit-Hyperactivity Disorder will respond positively to methylphenidate. 
Journal of Applied Developmental Psychology, 21, 471-489. 
  
92
 
Greenhill, L., Kollins, S., Abikoff, H., McCracken, J., Riddle, M., Swanson, J. et al. 
(2006). Efficacy and safety of immediate-release methylphenidate treatment for 
preschoolers with ADHD. J.Am.Acad.Child Adolesc.Psychiatry, 45, 1284-1293. 
Gunnar, M. R., Larson, M. C., Hertsgaard, L., Harris, M. L., & Brodersen, L. 
(1992). The stressfulness of separation among nine-month-old infants: effects of social 
context variables and infant temperament. Child Dev, 63, 290-303. 
Gunnar, M. R. & Nelson, C. A. (1994). Event-related potentials in year-old infants: 
relations with emotionality and cortisol. Child Dev, 65, 80-94. 
Gunnar, M. R., Brodersen, L., Krueger, K., & Rigatuso, J. (1996). Dampening of 
adrenocortical responses during infancy: normative changes and individual differences. 
Child Dev, 67, 877-889. 
Gunnar, M. R., Tout, K., de, H. M., Pierce, S., & Stansbury, K. (1997). 
Temperament, social competence, and adrenocortical activity in preschoolers. Dev 
Psychobiol., 31, 65-85. 
Gunnar, M. R. & Donzella, B. (2002). Social regulation of the cortisol levels in 
early human development. Psychoneuroendocrinology, 27, 199-220. 
 
Gust, D. A., Wilson, M. E., Stocker, T., Conrad, S., Plotsky, P. M., & Gordon, T. P. 
(2000). Activity of the hypothalamic-pituitary-adrenal axis is altered by aging and exposure 
to social stress in female rhesus monkeys. J Clin.Endocrinol.Metab, 85, 2556-2563. 
Hamarman S, Fossella J, Ulger C, et al. (2004). Dopamine receptor 4 (DRD4) 7-
repeat allele predicts methylphenidate dose response in children with attention deficit 
  
93
 
hyperactivity disorder: A pharmacogenetic study. Journal of Child and Adolescent 
Psychopharm, 14(4), 564-574. 
Haney, M., Maccari, S., Le, M. M., Simon, H., & Piazza, P. V. (1995). Social stress 
increases the acquisition of cocaine self-administration in male and female rats. Brain Res, 
698, 46-52. 
Harris DS, Reus VI, Wolkowitz OM, et al. (2003). Altering cortisol level does not 
change the pleasurable effects of methamphetamine in humans. 
Neuropsychopharmacology, 28, 1677-1684. 
Harris, D. S., Reus, V. I., Wolkowitz, O., Jacob, P., III, Everhart, E. T., Wilson, M. 
et al. (2006). Catecholamine response to methamphetamine is related to glucocorticoid 
levels but not to pleasurable subjective response. Pharmacopsychiatry, 39, 100-108. 
Hearn AJ, Gallagher P, Owen BM, et al. (2004). Effect of sub-chronic 
hydrocortisone on responses to amphetamine in normal male volunteers. 
Psychopharmacology, 171, 458-464. 
 Hennig, J. & Netter, P. (2002). Oral application of citalopram (20 mg) and its 
usefulness for neuroendocrine challenge tests. The International Journal of 
Neuropsychopharmacology5[1],67-71  
 Hennig, J., Lange, N., Haag, A., Rohrmann, S., & Netter, P. (2000). Reboxetine in a 
neuroendocrine challenge paradigm: evidence for high cortisol responses in healthy 
volunteers scoring high on subclinical depression. Int.J Neuropsychopharmacol., 3, 193-
201. 
Jensen PS, Arnold LE, Richter JE, et al. (1999). Moderators and mediators of 
treatment response for children with attention deficit hyperactivity disorder- the multimodal 
treatment study of children with attention deficit/ hyperactivity disorder. Archives of 
general psychiatry, 56, 1088-1096. 
  
94
 
Karande S., (2005). Attention deficit hyperactivity disorder- a review for family 
physicians. Indian J med Sci, 59(10), 546-555. 
Kirby K, Floriani BA, Bernstein H., (2001). Diagnosis and management of 
attention-deficit/hyperactivity disorder in children. Curr Opinion Ped, 13,190-199. 
Kojima, H., Terao, T., Iwakawa, M., Soya, A., Inoue, N., Shiraishi, Y. et al. (2003). 
Paroxetine as a 5-HT neuroendocrine probe. Psychopharmacology (Berl), 167, 97-102. 
Kosten T, Oliveto A, Sevarino K, et al (2002). Ketoconazole increases cocaine and 
opioid use in methadone maintained patients. Drug Alcohol dependence, 66,173-180. 
Kosten TA, Zhang XY, Kehoe P, (2003). Chronic neonatal isolation stress enhances 
cocaine-induced increases in ventral striatal dopamine levels in rat pups. Brain Res Dev 
Brain Res, 141, 109-116. 
Kuczenski, R. & Segal, D. S. (2002). Exposure of adolescent rats to oral 
methylphenidate: preferential effects on extracellular norepinephrine and absence of 
sensitization and cross-sensitization to methamphetamine. J Neurosci., 22, 7264-7271. 
Kudielka, B. M., Buske-Kirschbaum, A., Hellhammer, D. H., & Kirschbaum, C. 
(2004). HPA axis responses to laboratory psychosocial stress in healthy elderly adults, 
younger adults, and children: impact of age and gender. Psychoneuroendocrinology, 29, 
83-98. 
Kunz-Ebrecht, S. R., Kirschbaum, C., & Steptoe, A. (2004). Work stress, 
socioeconomic status and neuroendocrine activation over the working day. Soc.Sci.Med.,
58, 1523-1530. 
Kunz-Ebrecht, S. R., Kirschbaum, C., Marmot, M., & Steptoe, A. (2004). 
Differences in cortisol awakening response on work days and weekends in women and men 
from the Whitehall II cohort. Psychoneuroendocrinology, 29, 516-528. 
  
95
 
Lanfumey, L., Mongeau, R., Cohen-Salmon, C., & Hamon, M. (2008). 
Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related 
disorders. Neurosci.Biobehav.Rev., 32, 1174-1184. 
Lee B, Tiefenbacher S, Platt D, et al. (2003). Role of the hypothalamic-pituitary-
adrenal; axis in reinstatement of cocaine-seeking behaviour in squirrel monkeys. 
Psychopharmacology, 168, 177-183 
Lemaire, V., Deminiere, J. M., & Mormede, P. (1994). Chronic social stress 
conditions differentially modify vulnerability to amphetamine self-administration. Brain
Res, 649, 348-352. 
Li, D., Sham, P. C., Owen, M. J., & He, L. (2006). Meta-analysis shows significant 
association between dopamine system genes and attention deficit hyperactivity disorder 
(ADHD). Hum.Mol.Genet., 15, 2276-2284. 
Liu, D., Diorio, J., Tannenbaum, B., Caldji, C., Francis, D., Freedman, A. et al. 
(1997). Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-
adrenal responses to stress. Science, 277, 1659-1662. 
Madras BK, Miller GM, Fishman AJ, (2005). The dopamine transporter and 
attention deficit/hyperactivity disorder. Biol psychiatry, 57, 1397-1409. 
Maher, B. S., Marazita, M. L., Ferrell, R. E., & Vanyukov, M. M. (2002). 
Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. 
Psychiatr.Genet., 12, 207-215. 
Mantsch, J. R. & Goeders, N. E. (1999). Ketoconazole blocks the stress-induced 
reinstatement of cocaine-seeking behavior in rats: relationship to the discriminative 
stimulus effects of cocaine. Psychopharmacology (Berl), 142, 399-407. 
  
96
 
Marcason W. (2005). Can dietary intervention play a part in the treatment of 
attention deficit and hyperactivity disorder? Journal of the American Dietetic Association, 
105(7), 1161-1162. 
Marinelli M, Piazza PV, (2002). Interaction between glucocorticoid hormones, 
stress and psychostimulant drugs. European Journal of Neuroscience, 16, 387-394. 
 
McCann, D., Barrett, A., Cooper, A., Crumpler, D., Dalen, L., Grimshaw, K. et al. 
(2007). Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in 
the community: a randomised, double-blinded, placebo-controlled trial. Lancet, 370, 1560-
1567. 
McGough JJ, Smalley SL, McCracken JT, et al. (2005). Psychiatric comorbidity in 
adult attention deficit hyperactivity disorder: findings from multiplex families. Am J 
Psychiatry, 162, 1621-1627. 
Meinlschmidt, G. & Heim, C. (2005). Decreased cortisol awakening response after 
early loss experience. Psychoneuroendocrinology, 30, 568-576. 
Michelson D, Adler L, Spencer T, et al. (2003). Atomoxetine in adults with ADHD: 
two randomized, placebo-controlled studies. Biol Psychiatry, 53, 112-120. 
Michelson D, Allen AJ, Busner J, et al. (2002). Once-daily atomoxetine treatment 
for children and adolescent with attention deficit hyperactivity disorder: a randomized, 
placebo-controlled study. Am J Psychiatry, 159, 1896,1901. 
Michelson D, Faries D, Wernicke J, et al. (2001). Atomoxetine in the treatment of 
children and adolescent with attention deficit hyperactivity disorder: a randomized, placebo 
controlled, dose-response study. Pediatrics, 108, 1-9. 
Miczek, K. A. & Mutschler, N. H. (1996). Activational effects of social stress on IV 
cocaine self-administration in rats. Psychopharmacology (Berl), 128, 256-264. 
  
97
 
Oswald LM, Wong DF, McCaul M, et al. (2005). Relationships among ventral 
striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. 
Neuropsychopharmacology, 30, 821-832. 
Piazza PV, Rouge-Pont F, Deroche V, et al. (1996). Glucocorticoids have state 
dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Sci 
USA, 93, 8716-8720. 
Portella, M. J., Harmer, C. J., Flint, J., Cowen, P., & Goodwin, G. M. (2005). 
Enhanced early morning salivary cortisol in neuroticism. Am.J Psychiatry, 162, 807-809. 
Pruessner, M., Hellhammer, D. H., Pruessner, J. C., & Lupien, S. J. (2003). Self-
reported depressive symptoms and stress levels in healthy young men: associations with the 
cortisol response to awakening. Psychosom.Med., 65, 92-99. 
Pruessner JC, Champagne F, Meaney MJ, et al. (2004). Dopamine release in 
response to a psychological stress in humans and its relationship to early life maternal care : 
a positron emission topography study using [11C] raclopride. J Neurosci, 24, 2825-2831. 
Purper-Ouakil, D., Wohl, M., Mouren, M. C., Verpillat, P., Ades, J., & Gorwood, P. 
(2005). Meta-analysis of family-based association studies between the dopamine 
transporter gene and attention deficit hyperactivity disorder. Psychiatr.Genet., 15, 53-59. 
Ramsey, N. F. & Van Ree, J. M. (1993). Emotional but not physical stress enhances 
intravenous cocaine self-administration in drug-naive rats. Brain Res, 608, 216-222. 
Roberts, A. D., Wessely, S., Chalder, T., Papadopoulos, A., & Cleare, A. J. (2004). 
Salivary cortisol response to awakening in chronic fatigue syndrome. Br.J Psychiatry, 184, 
136-141. 
Rohleder, N., Joksimovic, L., Wolf, J. M., & Kirschbaum, C. (2004). 
Hypocortisolism and increased glucocorticoid sensitivity of pro-Inflammatory cytokine 
  
98
 
production in Bosnian war refugees with posttraumatic stress disorder. Biol.Psychiatry, 55, 
745-751. 
Schab, D. W. & Trinh, N. H. (2004). Do artificial food colors promote hyperactivity 
in children with hyperactive syndromes? A meta-analysis of double-blind placebo-
controlled trials. J Dev Behav.Pediatr., 25, 423-434. 
Schenk, S., Lacelle, G., Gorman, K., & Amit, Z. (1987). Cocaine self-
administration in rats influenced by environmental conditions: implications for the etiology 
of drug abuse. Neurosci.Lett., 81, 227-231. 
Schlotz, W., Hellhammer, J., Schulz, P., & Stone, A. A. (2004). Perceived work 
overload and chronic worrying predict weekend-weekday differences in the cortisol 
awakening response. Psychosom.Med., 66, 207-214. 
Schommer NC, Hellhammer DH, Kirschbaum C, (2003). Dissociation between 
reactivity of the hypothalamus-pituitary-adrenal axis and the sympathetic-adrenal-
medullary system to repeated psychological stress. Psychosom Med, 65, 450-460. 
 
Schulz, K. P., Fan, J., Tang, C. Y., Newcorn, J. H., Buchsbaum, M. S., Cheung, A. 
M. et al. (2004). Response inhibition in adolescents diagnosed with attention deficit 
hyperactivity disorder during childhood: an event-related FMRI study. Am.J Psychiatry, 
161, 1650-1657. 
Sinha R, Catapano D, O’Malley S, (1999). Stress-induced craving and stress 
response in cocaine dependent individuals. Psychopharmacology, 142, 343-351 
Smith, A. B., Taylor, E., Brammer, M., Toone, B., & Rubia, K. (2006). Task-
specific hypoactivation in prefrontal and temporoparietal brain regions during motor 
  
99
 
inhibition and task switching in medication-naive children and adolescents with attention 
deficit hyperactivity disorder. Am.J Psychiatry, 163, 1044-1051. 
Sonuga-Barke, E. J. (2002). Psychological heterogeneity in AD/HD--a dual 
pathway model of behaviour and cognition. Behav.Brain Res, 130, 29-36. 
Sonuga-Barke, E. J. (2003). The dual pathway model of AD/HD: an elaboration of 
neuro-developmental characteristics. Neurosci.Biobehav.Rev., 27, 593-604. 
Sonuga-Barke. E.J.S, (2004). On the reorganization of incentive structure to 
promote delay tolerance: a therapeutic possibility or ADHD. Neural plasticity, 11, 23-28. 
Spencer T, Heiligenstein JH, Bierderman J, et al. (2002). Results from 2 proof-of-
concept, placebo-controlled studies of atomoxetine in children with attention-deficit 
hyperactivity disorder. J Clin Psychiatry, 63(12), 1140-1147. 
Stein MA, Sarampote CS, Waldman ID, et al. (2003). A dose-response study of 
OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 
112, 404-413. 
 
 
Swanson JM, Kraemer HC, Hinshaw SP, et al. (2001). Clinical relevance of the 
primary findings of the MTA: success rates based on severity of ADHD and ODD 
symptoms at the end of treatment. Journal of the American Academy of child and 
adolescent psychiatry, 40, 168-179. 
Swanson JM, Arnold LE, Vitiello B, et al. (2002). Response to commentary on the 
multimodal treatment study of ADHD (MTA): mining the meaning of the MTA. Journal of 
abnormal child psychology, 30, 327-332. 
  
100
 
Swanson, J., Greenhill, L., Wigal, T., Kollins, S., Stehli, A., Davies, M. et al. 
(2006). Stimulant-related reductions of growth rates in the PATS. J.Am.Acad.Child
Adolesc.Psychiatry, 45, 1304-1313. 
Van Tol, H. H., Wu, C. M., Guan, H. C., Ohara, K., Bunzow, J. R., Civelli, O. et al. 
(1992). Multiple dopamine D4 receptor variants in the human population. Nature, 358, 
149-152. 
Lupien, S. J., de, L. M., de, S. S., Convit, A., Tarshish, C., Nair, N. P. et al. (1998). 
Cortisol levels during human aging predict hippocampal atrophy and memory deficits. 
Nat.Neurosci., 1, 69-73. 
Lupien, S. J., King, S., Meaney, M. J., & McEwen, B. S. (2000). Child's stress 
hormone levels correlate with mother's socioeconomic status and depressive state. 
Biol.Psychiatry, 48, 976-980. 
McGaugh, J. L. (2004). The amygdala modulates the consolidation of memories of 
emotionally arousing experiences. Annu.Rev.Neurosci., 27, 1-28. 
Monk, T. H. (2005). Aging human circadian rhythms: conventional wisdom may 
not always be right. J Biol.Rhythms, 20, 366-374. 
MTA Cooperative Group (1999). Moderators and mediators of treatment response 
for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study 
of children with Attention-deficit/hyperactivity disorder. Arch.Gen.Psychiatry, 56, 1088-
1096. 
Muller, U., von Cramon, D. Y., & Pollmann, S. (1998). D1- versus D2-receptor 
modulation of visuospatial working memory in humans. J Neurosci., 18, 2720-2728. 
  
101
 
Munoz-Hoyos, A., Fernandez-Garcia, J. M., Molina-Carballo, A., Macias, M., 
Escames, G., Ruiz-Cosano, C. et al. (2000). Effect of clonidine on plasma ACTH, cortisol 
and melatonin in children. J Pineal Res, 29, 48-53. 
Nachmias, M., Gunnar, M., Mangelsdorf, S., Parritz, R. H., & Buss, K. (1996). 
Behavioral inhibition and stress reactivity: the moderating role of attachment security. 
Child Dev, 67, 508-522. 
Nadeem, H. S., Attenburrow, M. J., & Cowen, P. J. (2004). Comparison of the 
effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses. 
Neuropsychopharmacology, 29, 1699-1703. 
Nichols, N. R., Zieba, M., & Bye, N. (2001). Do glucocorticoids contribute to brain 
aging? Brain Res Brain Res Rev., 37, 273-286. 
Nickel, T., Sonntag, A., Schill, J., Zobel, A. W., Ackl, N., Brunnauer, A. et al. 
(2003). Clinical and neurobiological effects of tianeptine and paroxetine in major 
depression. J Clin.Psychopharmacol., 23, 155-168. 
Nutt, D., Middleton, H., & Franklin, M. (1987). The neuroendocrine effects of oral 
imipramine. Psychoneuroendocrinology, 12, 367-375. 
Owens, E. B., Hinshaw, S. P., Kraemer, H. C., Arnold, L. E., Abikoff, H. B., 
Cantwell, D. P. et al. (2003). Which treatment for whom for ADHD? Moderators of 
treatment response in the MTA. J.Consult Clin.Psychol., 71, 540-552. 
Palumbo, D. R., Sallee, F. R., Pelham, W. E., Jr., Bukstein, O. G., Daviss, W. B., & 
McDermott, M. P. (2008). Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy 
and tolerability outcomes. J Am.Acad Child Adolesc Psychiatry, 47, 180-188. 
Posey, D. J. & McDougle, C. J. (2007). Guanfacine and guanfacine extended 
release: treatment for ADHD and related disorders. CNS.Drug Rev., 13, 465-474. 
  
102
 
Santosh, P. J., Taylor, E., Swanson, J., Wigal, T., Chuang, T., Davies, M. et al. 
(2005). Refining the diagnoses of inattention and overactivity syndromes: A reanalysis of 
the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based 
on ICD-10 criteria for hyperkinetic disorder. Clinical Neuroscience Research, 5, 307-314. 
Schule, C., Baghai, T., Schmidbauer, S., Bidlingmaier, M., Strasburger, C. J., & 
Laakmann, G. (2004). Reboxetine acutely stimulates cortisol, ACTH, growth hormone and 
prolactin secretion in healthy male subjects. Psychoneuroendocrinology, 29, 185-200. 
Schule, C., Baghai, T. C., Eser, D., Zwanzger, P., Jordan, M., Buechs, R. et al. 
(2006). Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment 
with reboxetine and mirtazapine in depressed patients. Psychopharmacology (Berl), 186, 
601-611. 
Singh, V. B., Corley, K. C., Phan, T. H., & Boadle-Biber, M. C. (1990). Increases in 
the activity of tryptophan hydroxylase from rat cortex and midbrain in response to acute or 
repeated sound stress are blocked by adrenalectomy and restored by dexamethasone 
treatment. Brain Res, 516, 66-76. 
Steptoe, A., Kunz-Ebrecht, S., Owen, N., Feldman, P. J., Willemsen, G., 
Kirschbaum, C. et al. (2003). Socioeconomic status and stress-related biological responses 
over the working day. Psychosom.Med., 65, 461-470. 
Tahir, E., Yazgan, Y., Cirakoglu, B., Ozbay, F., Waldman, I., & Asherson, P. J. 
(2000). Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity 
disorder (ADHD) in a sample of Turkish children. Mol.Psychiatry, 5, 396-404. 
Thorn, L., Hucklebridge, F., Evans, P., & Clow, A. (2006). Suspected non-
adherence and weekend versus week day differences in the awakening cortisol response. 
Psychoneuroendocrinology, 31, 1009-1018. 
  
103
 
Tidey, J. W. & Miczek, K. A. (1997). Acquisition of cocaine self-administration 
after social stress: role of accumbens dopamine. Psychopharmacology (Berl), 130, 203-212. 
Toren, P., Ratner, S., Weizman, A., Lask, M., Ben-Amitay, G., & Laor, N. (2007). 
Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: 
a long-term follow-up study. J.Child Adolesc.Psychopharmacol., 17, 803-812. 
Tourette's Syndrome Study Group (2002). Treatment of ADHD in children with 
tics: a randomized controlled trial. Neurology, 58, 527-536. 
Tucha O, Prell S, Mecklinger L, et al. (2006). Effects of methylphenidate on 
multiple components of attention in children with attention deficit hyperactivity disorder. 
Psychopharmacology, 185(3), 315-326. 
 
Van Cauter E., Leproult, R., & Kupfer, D. J. (1996). Effects of gender and age on 
the levels and circadian rhythmicity of plasma cortisol. J Clin.Endocrinol.Metab, 81, 2468-
2473. 
Van der Meulen, E. M., Bakker, S. C., Pauls, D. L., Oteman, N., Kruitwagen, C. L., 
Pearson, P. L. et al. (2005). High sibling correlation on methylphenidate response but no 
association with DAT1-10R homozygosity in Dutch sibpairs with ADHD. J Child 
Psychol.Psychiatry, 46, 1074-1080. 
Van Stegeren, A. H., Wolf, O. T., Everaerd, W., Scheltens, P., Barkhof, F., & 
Rombouts, S. A. (2007). Endogenous cortisol level interacts with noradrenergic activation 
in the human amygdala. Neurobiol.Learn.Mem., 87, 57-66. 
Vijayraghavan, S., Wang, M., Birnbaum, S. G., Williams, G. V., & Arnsten, A. F. 
(2007). Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in 
working memory. Nat.Neurosci., 10, 376-384. 
  
104
 
Vitiello, B., Abikoff, H. B., Chuang, S. Z., Kollins, S. H., McCracken, J. T., Riddle, 
M. A. et al. (2007). Effectiveness of methylphenidate in the 10-month continuation phase 
of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study 
(PATS). J.Child Adolesc.Psychopharmacol., 17, 593-604. 
Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L. et 
al. (2002). Relationship between blockade of dopamine transporters by oral 
methylphenidate and the increases in extracellular dopamine: therapeutic implications. 
Synapse, 43, 181-187. 
Volkow, N. D., Wang, G. J., Fowler, J. S., Telang, F., Maynard, L., Logan, J. et al. 
(2004). Evidence that methylphenidate enhances the saliency of a mathematical task by 
increasing dopamine in the human brain. Am.J Psychiatry, 161, 1173-1180. 
Volkow, N. D., Wang, G. J., Ma, Y., Fowler, J. S., Wong, C., Jayne, M. et al. 
(2006). Effects of expectation on the brain metabolic responses to methylphenidate and to 
its placebo in non-drug abusing subjects. Neuroimage., 32, 1782-1792. 
Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Gatley, S. J., Gifford, A. et al. 
(1999). Prediction of reinforcing responses to psychostimulants in humans by brain 
dopamine D2 receptor levels. Am.J Psychiatry, 156, 1440-1443. 
Volkow, N. D., Wang, G. J., Fowler, J. S., Thanos, P. P., Logan, J., Gatley, S. J. et 
al. (2002b). Brain DA D2 receptors predict reinforcing effects of stimulants in humans: 
replication study. Synapse, 46, 79-82. 
Wachtel SR, Charnot A, de Wit H, (2001). Acute hydrocortisone administration 
does not affect subjective responses to d-amphetamine in humans. Psychopharmacology, 
153, 380-388 
  
105
 
Waldman ID, Faraone SV, (2002). A meta-analysis of linkage and association 
between the dopamine transporter gene (DAT1) and childhood ADHD. Behaviour
Genetics, 32, 487-487. 
Wand GS, Oswald LM, McCaul ME, et al. (2007). Association of amphetamine-
induced striatal dopamine release and cortisol responses to psychological stress. 
Neuropsychopharmacology, 32, 2310-2320 
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A. et al. 
(2007). Alpha2A-adrenoceptors strengthen working memory networks by inhibiting 
cAMP-HCN channel signaling in prefrontal cortex. Cell, 129, 397-410. 
Ward A, Collins E, Haney M, et al. (1999). Blockade of cocaine-induced increases 
in adrenocorticotrophic hormone and cortisol does not attenuate the subjective effects of 
smoked cocaine in humans. Behavioural pharmacology., 10, 523-529. 
Ward AS, Collins ED, Haney M, et al. (1998). Blockade of cocaine-induced 
increases in adrenocorticotrophic hormone and cortisol does not attenuate the subjective 
effects of smoked cocaine in humans. Behavioural Pharmacol, 10, 523-529. 
 
Weaver, I. C., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, 
J. R. et al. (2004). Epigenetic programming by maternal behavior. Nat.Neurosci., 7, 847-
854. 
Wigal, T., Greenhill, L., Chuang, S., McGough, J., Vitiello, B., Skrobala, A. et al. 
(2006). Safety and tolerability of methylphenidate in preschool children with ADHD. 
J.Am.Acad.Child Adolesc.Psychiatry, 45, 1294-1303. 
Williams, G. V. & Goldman-Rakic, P. S. (1995). Modulation of memory fields by 
dopamine D1 receptors in prefrontal cortex. Nature, 376, 572-575. 
  
106
 
Wilhelm I, Born J, Kudielka M, et al. (2007). Is the cortisol awakening rise a 
response to awakening? Psychoneuroendocrinology, 32, 358-366. 
 
Winsberg, B. G. & Comings, D. E. (1999). Association of the dopamine transporter 
gene (DAT1) with poor methylphenidate response. J Am.Acad Child Adolesc Psychiatry, 
38, 1474-1477.  
 Yanovski, J. A., Yanovski, S. Z., Boyle, A. J., Gold, P. W., Sovik, K. N., Sebring, 
N. G. et al. (2000). Hypothalamic-pituitary-adrenal axis activity during exercise in African 
American and Caucasian women. J Clin.Endocrinol.Metab, 85, 2660-2663. 
Zahrt, J., Taylor, J. R., Mathew, R. G., & Arnsten, A. F. (1997). Supranormal 
stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial 
working memory performance. J Neurosci., 17, 8528-8535. 
Zeni, C. P., Guimaraes, A. P., Polanczyk, G. V., Genro, J. P., Roman, T., Hutz, M. 
H. et al. (2007). No significant association between response to methylphenidate and genes 
of the dopaminergic and serotonergic systems in a sample of Brazilian children with 
attention-deficit/hyperactivity disorder. Am.J Med.Genet.B Neuropsychiatr.Genet., 144B, 
391-394. 
 
 
D
A
T
E
:_
_
_
_
_
/
_
_
_
_
_
/
_
_
_
_
_
_
_
_
  
(j
o
u
r/
m
o
is
/a
n
n
ée
)
sw
an
 e
n
se
ig
n
an
t_
FL
H
_
0
9
-0
1
-0
7
1
N
°I
D
:
S
W
A
N
 –
 V
E
R
S
IO
N
 C
O
U
R
T
E
 -
 E
N
S
E
IG
N
A
N
T
C
o
ch
er
 l
es
 c
as
es
 c
o
rr
es
p
o
n
d
an
ts
 à
 l
a 
jo
u
rn
ée
 e
t 
la
 s
em
ai
n
e 
d
e 
l’é
va
lu
at
io
n
:
 
Lu
n
d
i 
M
ar
d
i 
 
M
er
cr
ed
i 
 
Je
u
d
i 
 
ve
n
d
re
d
i.
 
 
Pr
é-
te
st
  
S
em
ai
n
e 
1
  
 
S
em
ai
n
e 
2
  
S
em
ai
n
e 
3
 
S
em
ai
n
e 
4
. 
B
ea
u
co
u
p
  
en
 d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e 
E
n
d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
U
n
 p
eu
 
en
d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
D
an
s 
la
 
m
o
ye
n
n
e
U
n
 p
eu
 a
u
 
-d
es
su
s 
d
e 
la
m
o
ye
n
n
e 
A
u
-
d
es
su
s
d
e 
la
 
m
o
ye
n
n
e
B
ea
u
co
u
p
 
au
-
d
es
su
s 
d
e 
la
m
o
ye
n
n
e 
N
e
s’
ap
p
liq
u
e 
p
as
1
 
E
st
 c
ap
ab
le
 d
e 
se
 m
et
tr
e 
d
’a
cc
o
rd
 a
ve
c 
le
s 
ad
u
lt
es
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
 
E
st
 c
ap
ab
le
 d
e 
s’
am
u
se
r 
ca
lm
em
en
t 
(d
an
s 
le
s 
je
u
x 
ou
 
le
s 
ac
ti
vi
té
s 
d
e 
lo
is
ir
s)
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
3
 
E
st
 c
ap
ab
le
 d
e 
s'
o
rg
an
is
er
 d
an
s 
se
s 
tr
av
au
x 
o
u
 s
es
 a
ct
iv
it
és
. 
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
4
 
E
st
 c
ap
ab
le
 d
e 
s'
ar
rê
te
r 
et
 d
e 
re
st
er
 t
ra
n
q
u
ill
e.
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
5
 
E
st
 c
ap
ab
le
 d
e 
g
ar
d
er
 s
o
n
 s
an
g
 
fr
o
id
, 
d
e 
re
st
er
 c
al
m
e.
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
6
 
S
el
o
n
 l
e 
co
n
te
xt
e,
 e
st
 c
ap
ab
le
 
d
e 
re
st
er
 a
ss
is
 s
an
s 
se
 l
ev
er
 
(e
n
 c
la
ss
e 
ou
 a
ill
eu
rs
).
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
7
 
E
st
 c
ap
ab
le
 d
e 
se
 j
o
in
d
re
 s
an
s 
s’
im
p
o
se
r 
à 
u
n
e 
co
n
ve
rs
at
io
n
 
o
u
 à
 u
n
 j
eu
. 
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
8
 
R
ec
o
n
n
aî
t 
la
 r
es
p
o
n
sa
b
ili
té
 d
e 
se
s 
er
re
u
rs
 e
t 
d
e 
se
s 
m
au
va
is
es
 
co
n
d
u
it
es
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
9
 
É
co
u
te
 q
u
an
d
 o
n
 l
u
i 
p
ar
le
 
p
er
so
n
n
el
le
m
en
t.
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
0
 
E
st
 c
ap
ab
le
 d
e 
fa
ir
e 
at
te
n
ti
o
n
 
au
x 
d
ét
ai
ls
 e
t 
d
’é
vi
te
r 
d
e 
fa
ir
e 
d
es
 f
au
te
s 
d
’é
to
u
rd
er
ie
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
sw
an
 e
n
se
ig
n
an
t_
FL
H
_
0
9
-0
1
-0
7
2
N
°I
D
:
1
1
 
E
st
 c
ap
ab
le
 d
e 
su
iv
re
 l
es
 
co
n
si
g
n
es
 e
t 
d
e 
te
rm
in
er
 s
es
 
d
ev
o
ir
s/
tâ
ch
es
. 
  
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
2
 
E
st
 c
ap
ab
le
 d
’o
u
b
lie
r 
sa
 
ra
n
cu
n
e 
et
 d
e 
n
e 
p
as
 v
o
u
lo
ir
 s
e 
ve
n
g
er
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
3
 
E
st
 c
ap
ab
le
 d
e 
ve
ill
er
 s
u
r 
le
s 
ch
o
se
s 
n
éc
es
sa
ir
es
 à
 s
o
n
 t
ra
va
il 
(l
iv
re
s,
 c
ra
yo
n
s,
 e
tc
.)
 o
u
 à
 s
es
 
ac
ti
vi
té
s 
(j
o
u
et
s,
 e
tc
.)
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
4
N
e 
se
 l
ai
ss
e 
p
as
 f
ro
is
se
r,
 v
ex
er
 
o
u
 e
n
n
u
ye
r 
p
ar
 l
es
 a
u
tr
es
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
5
 
N
e 
se
 s
en
t 
p
as
 v
ic
ti
m
e 
d
'in
ju
st
ic
e 
et
 c
o
n
tr
ô
le
 s
a 
co
lè
re
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
B
ea
u
co
u
p
  
en
 d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
E
n
d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
U
n
 p
eu
 
en
d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
D
an
s 
la
 
m
o
ye
n
n
e
U
n
 p
eu
 a
u
 
-d
es
su
s 
d
e 
la
m
o
ye
n
n
e
A
u
-
d
es
su
s
d
e 
la
 
m
o
ye
n
n
e
B
ea
u
co
u
p
 
au
-
d
es
su
s 
d
e 
la
m
o
ye
n
n
e
N
e
s’
ap
p
liq
u
e 
p
as
1
6
 
E
st
 c
ap
ab
le
 d
e 
so
u
te
n
ir
 s
o
n
 
at
te
n
ti
o
n
 a
u
 t
ra
va
il 
o
u
 d
an
s 
le
s 
je
u
x.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
7
 
E
st
 c
ap
ab
le
 d
’e
n
tr
ep
re
n
d
re
 d
es
 
tâ
ch
es
 q
u
i 
n
éc
es
si
te
n
t 
u
n
 e
ff
o
rt
 
m
en
ta
l 
so
u
te
n
u
 (
à 
l'é
co
le
 o
u
 à
 
la
 m
ai
so
n
).
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
8
 
D
an
s 
la
 v
ie
 q
u
o
ti
d
ie
n
n
e,
 e
st
 
ca
p
ab
le
 d
e 
re
te
n
ir
 c
e 
q
u
'o
n
 l
u
i 
d
it
 o
u
 c
e 
q
u
'il
 d
o
it
 f
ai
re
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
9
 
S
el
o
n
 l
e 
co
n
te
xt
e,
 e
st
 c
ap
ab
le
 
d
e 
se
 r
et
en
ir
 d
e 
co
u
ri
r 
o
u
 d
e 
g
ri
m
p
er
, 
(n
'a
 p
as
 "
d
es
 f
o
u
rm
is
 
d
an
s 
le
s 
ja
m
b
es
")
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
0
 
É
vi
te
 d
e 
fa
ir
e 
d
él
ib
ér
ém
en
t 
d
es
 
ch
o
se
s 
q
u
i 
p
o
u
rr
ai
en
t 
fâ
ch
er
 l
es
 
au
tr
es
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
1
 
E
st
 c
ap
ab
le
 d
e 
se
 c
o
n
ce
n
tr
er
, 
d
e 
n
e 
p
as
 s
e 
la
is
se
r 
d
is
tr
ai
re
 
p
ar
 d
es
 s
ti
m
u
li 
ex
te
rn
es
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
sw
an
 e
n
se
ig
n
an
t_
FL
H
_
0
9
-0
1
-0
7
3
N
°I
D
:
2
2
 
A
tt
en
d
s 
q
u
'u
n
e 
q
u
es
ti
o
n
 s
o
it
 
en
ti
èr
em
en
t 
p
o
sé
e 
av
an
t 
d
'y
 
ré
p
o
n
d
re
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
3
 
A
cc
ep
te
 d
e 
su
iv
re
 l
es
 r
èg
le
s 
et
 
d
e 
ré
p
o
n
d
re
 a
u
x 
d
em
an
d
es
 d
es
 
ad
u
lt
es
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
4
 
E
st
 c
ap
ab
le
 d
e 
re
st
er
 a
ss
is
 s
an
s 
s'
ag
it
er
, 
en
 c
o
n
tr
ô
la
n
t 
le
s 
m
o
u
ve
m
en
ts
 d
e 
se
s 
m
ai
n
s 
et
 
se
s 
p
ie
d
s.
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
5
 
Q
u
an
d
 i
l 
p
ar
le
, 
es
t 
ca
p
ab
le
 d
e 
ré
g
le
r 
so
n
 d
éb
it
 s
u
iv
an
t 
le
 
co
n
te
xt
e.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
6
E
st
 c
ap
ab
le
 d
’a
tt
en
d
re
 s
o
n
 t
ou
r 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
IM
P
O
R
T
A
N
T
 :
 Y
 a
u
ra
it
-i
l 
u
n
 é
vè
n
em
en
t 
d
e 
la
 j
o
u
rn
ée
 q
u
i 
au
ra
it
 p
u
 i
n
fl
u
en
ce
r 
le
 c
o
m
p
o
rt
em
en
t 
d
e 
l’e
n
fa
n
t 
au
jo
u
rd
’h
u
i?
 
N
O
N
 
O
U
I,
 l
eq
u
el
 :
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 
D
A
T
E
:_
_
_
_
_
/
_
_
_
_
_
/
_
_
_
_
_
_
_
_
  
(j
o
u
r/
m
o
is
/a
n
n
ée
)
sw
an
 p
ar
en
ts
_
FL
H
_
0
9
-0
1
-0
7
1
N
°I
D
:
S
W
A
N
 –
 V
E
R
S
IO
N
 C
O
U
R
T
E
 -
 P
A
R
E
N
T
V
e
u
il
le
z 
in
d
iq
u
e
r 
q
u
i 
co
m
p
lè
te
 l
e
 q
u
e
st
io
n
n
a
ir
e
 :
 
m
èr
e 
p
èr
e 
tu
te
u
r 
lé
g
al
 
au
tr
e 
(s
p
éc
if
ie
r 
: 
 
 
 
 
_
_
 )
C
o
ch
er
 l
es
 c
as
es
 c
o
rr
es
p
o
n
d
an
ts
 à
 l
a 
jo
u
rn
ée
 e
t 
la
 s
em
ai
n
e 
d
e 
l’é
va
lu
at
io
n
: 
 
Lu
n
d
i 
 
M
ar
d
i 
 
M
er
cr
ed
i 
Je
u
d
i 
 
V
en
d
re
d
i 
S
am
ed
i 
D
im
an
ch
e.
 
 
Pr
é-
te
st
  
S
em
ai
n
e 
1
  
 
S
em
ai
n
e 
2
  
S
em
ai
n
e 
3
 
S
em
ai
n
e 
4
. 
B
ea
u
co
u
p
  
en
 d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e 
E
n
d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
U
n
 p
eu
 
en
d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
D
an
s 
la
 
m
o
ye
n
n
e
U
n
 p
eu
 a
u
 
-d
es
su
s 
d
e 
la
m
o
ye
n
n
e 
A
u
-
d
es
su
s
d
e 
la
 
m
o
ye
n
n
e
B
ea
u
co
u
p
 
au
-
d
es
su
s 
d
e 
la
m
o
ye
n
n
e 
N
e
s’
ap
p
liq
u
e 
p
as
1
 
E
st
 c
ap
ab
le
 d
e 
se
 m
et
tr
e 
d
’a
cc
o
rd
 a
ve
c 
le
s 
ad
u
lt
es
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
 
E
st
 c
ap
ab
le
 d
e 
s’
am
u
se
r 
ca
lm
em
en
t 
(d
an
s 
le
s 
je
u
x 
ou
 
le
s 
ac
ti
vi
té
s 
d
e 
lo
is
ir
s)
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
3
 
E
st
 c
ap
ab
le
 d
e 
s'
o
rg
an
is
er
 d
an
s 
se
s 
tr
av
au
x 
o
u
 s
es
 a
ct
iv
it
és
. 
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
4
 
E
st
 c
ap
ab
le
 d
e 
s'
ar
rê
te
r 
et
 d
e 
re
st
er
 t
ra
n
q
u
ill
e.
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
5
 
E
st
 c
ap
ab
le
 d
e 
g
ar
d
er
 s
o
n
 s
an
g
 
fr
o
id
, 
d
e 
re
st
er
 c
al
m
e.
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
6
 
S
el
o
n
 l
e 
co
n
te
xt
e,
 e
st
 c
ap
ab
le
 
d
e 
re
st
er
 a
ss
is
 s
an
s 
se
 l
ev
er
 
(e
n
 c
la
ss
e 
ou
 a
ill
eu
rs
).
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
7
 
E
st
 c
ap
ab
le
 d
e 
se
 j
o
in
d
re
 s
an
s 
s’
im
p
o
se
r 
à 
u
n
e 
co
n
ve
rs
at
io
n
 
o
u
 à
 u
n
 j
eu
. 
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
8
 
R
ec
o
n
n
aî
t 
la
 r
es
p
o
n
sa
b
ili
té
 d
e 
se
s 
er
re
u
rs
 e
t 
d
e 
se
s 
m
au
va
is
es
 
co
n
d
u
it
es
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
9
 
É
co
u
te
 q
u
an
d
 o
n
 l
u
i 
p
ar
le
 
p
er
so
n
n
el
le
m
en
t.
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
sw
an
 p
ar
en
ts
_
FL
H
_
0
9
-0
1
-0
7
2
N
°I
D
:
1
0
 
E
st
 c
ap
ab
le
 d
e 
fa
ir
e 
at
te
n
ti
o
n
 
au
x 
d
ét
ai
ls
 e
t 
d
’é
vi
te
r 
d
e 
fa
ir
e 
d
es
 f
au
te
s 
d
’é
to
u
rd
er
ie
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
1
 
E
st
 c
ap
ab
le
 d
e 
su
iv
re
 l
es
 
co
n
si
g
n
es
 e
t 
d
e 
te
rm
in
er
 s
es
 
d
ev
o
ir
s/
tâ
ch
es
. 
  
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
2
 
E
st
 c
ap
ab
le
 d
’o
u
b
lie
r 
sa
 
ra
n
cu
n
e 
et
 d
e 
n
e 
p
as
 v
o
u
lo
ir
 s
e 
ve
n
g
er
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
3
 
E
st
 c
ap
ab
le
 d
e 
ve
ill
er
 s
u
r 
le
s 
ch
o
se
s 
n
éc
es
sa
ir
es
 à
 s
o
n
 t
ra
va
il 
(l
iv
re
s,
 c
ra
yo
n
s,
 e
tc
.)
 o
u
 à
 s
es
 
ac
ti
vi
té
s 
(j
o
u
et
s,
 e
tc
.)
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
4
N
e 
se
 l
ai
ss
e 
p
as
 f
ro
is
se
r,
 v
ex
er
 
o
u
 e
n
n
u
ye
r 
p
ar
 l
es
 a
u
tr
es
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
B
ea
u
co
u
p
  
en
 d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
E
n
d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
U
n
 p
eu
 
en
d
es
so
u
s 
d
e 
la
 
m
o
ye
n
n
e
D
an
s 
la
 
m
o
ye
n
n
e
U
n
 p
eu
 a
u
 
-d
es
su
s 
d
e 
la
m
o
ye
n
n
e
A
u
-
d
es
su
s
d
e 
la
 
m
o
ye
n
n
e
B
ea
u
co
u
p
 
au
-
d
es
su
s 
d
e 
la
m
o
ye
n
n
e
N
e
s’
ap
p
liq
u
e 
p
as
1
5
 
N
e 
se
 s
en
t 
p
as
 v
ic
ti
m
e 
d
'in
ju
st
ic
e 
et
 c
o
n
tr
ô
le
 s
a 
co
lè
re
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
6
 
E
st
 c
ap
ab
le
 d
e 
so
u
te
n
ir
 s
o
n
 
at
te
n
ti
o
n
 a
u
 t
ra
va
il 
o
u
 d
an
s 
le
s 
je
u
x.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
7
 
E
st
 c
ap
ab
le
 d
’e
n
tr
ep
re
n
d
re
 d
es
 
tâ
ch
es
 q
u
i 
n
éc
es
si
te
n
t 
u
n
 e
ff
o
rt
 
m
en
ta
l 
so
u
te
n
u
 (
à 
l'é
co
le
 o
u
 à
 
la
 m
ai
so
n
).
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
8
 
D
an
s 
la
 v
ie
 q
u
o
ti
d
ie
n
n
e,
 e
st
 
ca
p
ab
le
 d
e 
re
te
n
ir
 c
e 
q
u
'o
n
 l
u
i 
d
it
 o
u
 c
e 
q
u
'il
 d
o
it
 f
ai
re
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
1
9
 
S
el
o
n
 l
e 
co
n
te
xt
e,
 e
st
 c
ap
ab
le
 
d
e 
se
 r
et
en
ir
 d
e 
co
u
ri
r 
o
u
 d
e 
g
ri
m
p
er
, 
(n
'a
 p
as
 "
d
es
 f
o
u
rm
is
 
d
an
s 
le
s 
ja
m
b
es
")
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
0
 
É
vi
te
 d
e 
fa
ir
e 
d
él
ib
ér
ém
en
t 
d
es
 
ch
o
se
s 
q
u
i 
p
o
u
rr
ai
en
t 
fâ
ch
er
 l
es
 
au
tr
es
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
sw
an
 p
ar
en
ts
_
FL
H
_
0
9
-0
1
-0
7
3
N
°I
D
:
2
1
 
E
st
 c
ap
ab
le
 d
e 
se
 c
o
n
ce
n
tr
er
, 
d
e 
n
e 
p
as
 s
e 
la
is
se
r 
d
is
tr
ai
re
 
p
ar
 d
es
 s
ti
m
u
li 
ex
te
rn
es
. 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
2
 
A
tt
en
d
s 
q
u
'u
n
e 
q
u
es
ti
o
n
 s
o
it
 
en
ti
èr
em
en
t 
p
o
sé
e 
av
an
t 
d
'y
 
ré
p
o
n
d
re
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
3
 
A
cc
ep
te
 d
e 
su
iv
re
 l
es
 r
èg
le
s 
et
 
d
e 
ré
p
o
n
d
re
 a
u
x 
d
em
an
d
es
 d
es
 
ad
u
lt
es
.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
4
 
E
st
 c
ap
ab
le
 d
e 
re
st
er
 a
ss
is
 s
an
s 
s'
ag
it
er
, 
en
 c
o
n
tr
ô
la
n
t 
le
s 
m
o
u
ve
m
en
ts
 d
e 
se
s 
m
ai
n
s 
et
 
se
s 
p
ie
d
s.
 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
5
 
Q
u
an
d
 i
l 
p
ar
le
, 
es
t 
ca
p
ab
le
 d
e 
ré
g
le
r 
so
n
 d
éb
it
 s
u
iv
an
t 
le
 
co
n
te
xt
e.
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
2
6
E
st
 c
ap
ab
le
 d
’a
tt
en
d
re
 s
o
n
 t
ou
r 
-3
 
-2
 
-1
 
0
 
1
 
2
 
3
 
9
 
IM
P
O
R
T
A
N
T
 :
 Y
 a
u
ra
it
-i
l 
u
n
 é
vè
n
em
en
t 
d
e 
la
 j
o
u
rn
ée
 q
u
i 
au
ra
it
 p
u
 i
n
fl
u
en
ce
r 
le
 c
o
m
p
o
rt
em
en
t 
d
e 
l’e
n
fa
n
t 
au
jo
u
rd
’h
u
i?
 
N
O
N
 
O
U
I,
 l
eq
u
el
 :
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
 
French Version of the Strengths and Weaknesses of ADHD
Symptoms and Normal Behaviors (SWAN-F) Questionnaire 
Philippe Robaey MD, PhD1,2; Devendra Amre MBBS, PhD1,4; Russell Schachar MD5;
Louise Simard PhD1,4
Abstract
Objective: To evaluate internal and external consistency of a French adaptation of the SWAN (a 7-point rating strength-based
scale, from far below to far above average) and its accuracy as a diagnostic test among children with Attention
Deficit/Hyperactivity Disorder (ADHD). Method: Parents of 88 children referred for ADHD were interviewed using the SWAN-
F, a structured interview (DISC-4.0) and the Conners’ Rating Scale. Internal consistency and divergent and convergent valid-
ity of the SWAN-F were examined using the DISC-4.0 and Conners’ Rating Scales as reference standards for four dimensions:
Inattention, Hyperactivity/Impulsivity, ADHD, Oppositional Defiant Disorder. Results: The internal consistency of SWAN-F was
within acceptable ranges for all dimensions (Cronbach’s alpha greater than 0.80). Scores of the SWAN-F subscales were
strongly associated with the DISC-4.0 diagnostic assignments and Conners’ Rating Scales, following logical patterns of cor-
respondence between diagnoses. Its accuracy as a diagnostic test was comparable to Conners’ Rating Scale, with a lower
rate of false positives. Conclusions: The information gathered with the SWAN-F is compatible with that obtained using the
DISC-4.0 and Conners’ Rating Scale. Strength-based rating scales have the potential to evaluate the normal distribution of
behaviors and to provide reliable cut-off defining abnormal behavior. 
Key words: Pharmacogenetic, Attention Deficit/Hyperactivity Disorder, Methylphenidate Treatment
Résumé
Introduction: Évaluer la cohérence du questionnaire SWAN-F lorsqu’il est administré à des enfants atteints de trouble du
déficit d’attention avec hyperactivité (TDAH). Méthodologie: Les parents of 88 enfants qui ont reçu un diagnostic de TDAH
ont rempli le SWAN-F, le DISC-4.0 et l’échelle d’évaluation Conners. Les sous-échelles du SWAN-F étaient basées sur une
cotation en sept points qui classait les symptômes du DSM-IV de « nettement inférieurs à la moyenne » à « nettement
supérieurs à la moyenne » chez des enfants d’âge identique. La cohérence, la validité discriminante et la validité conver-
gente du SWAN-F ont été analysées au moyen du DISC4.0 et des échelles d’évaluation Conners qui ont servi de référence
pour quatre dimensions: inattention, hyperactivité/impulsivité, TDAH, trouble oppositionnel. Résultats: Pour toutes les com-
posantes du SWAN-F, la consiistence interne se situaient dans la zone acceptable (le coefficient alpha de Cronbach était
supérieur à 0,80). Les scores des sous-échelles du SWAN-F étaient fortement associés avec les diagnostics du DISC4.0 et
aux scores de l’échelle d’évaluation Conners, correspondant logiquement aux diagnostics. Conclusions: Les données recueil-
lies au moyen du SWAN-F sont compatibles avec celles obtenues au moyen du DISC-4.0 et de l’échelle d’évaluation Conners.
Les échelles basées sur l'évaluation des forces pourraient être utilisées pour l’évaluation quantitative des symptômes dans
les études longitudinales et génétiques et pour mesurer la réponse au traitement.
Mots clés: pharmacogénétique; trouble du déficit d’attention avec hyperactivité; traitement au méthylphénidate
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Introduction
Most clinical rating scales quantify behav-
iors on a Likert scale anchored by standard
descriptors, e.g., going from “never” to “very
often”, through “sometimes” and “often”. When
a weakness frequency (or intensity) is rated
beyond “normal” limits, it becomes a symptom.
Symptoms can thus be observed in subjects
considered as healthy, as long as their number
is beyond threshold and as long as they do not
cause a significant impairment. For example,
each ADHD behavioral descriptor has to be inap-
propriate for the child developmental level to be
considered as a symptom. The diagnosis
requires a symptom count above threshold and
the associated impairment must be clinically
significant, not specific to a situation (American
Psychiatric Association, 1994). Normal variabil-
ity is thus crucial at each level of the diagnosis
process. However, in a pathological perspective,
normality is only defined by an absence or a low
level of symptoms. This perspective creates
problems as the distributions of symptoms are
highly skewed and truncated in the normal pop-
ulation and as statistical cutoffs are generally
based on the assumption of a normal distribu-
tion. For example, in an epidemiological sample,
nearly 80% of children had scores of 1 or 0 (Just
a Little or Not at All) for the ADHD items of the
SNAP-IV. As a consequence, small changes in
1Research Centre of Sainte-Justine Hospital, Montreal,
Quebec
2Department of Psychiatry, Children’s Hospital of
Eastern Ontario, Ottawa, Ontario
4Department of Pediatrics, University of Montreal,
Montreal, Quebec
5Department of Psychiatry, Hospital for Sick Children,
Toronto, Ontario
Corresponding email: probaey@cheo.on.ca
Submitted: February 21, 2007; Accepted: May 3, 2007
cutoffs can have quite dramatic effect in the
number of children above threshold (Swanson
et al, 2005). Conversely, patients who show a
low but near-threshold level of symptoms are
defined as in remission. As it is not possible to
determine where these children are placed
within the normal distribution before and after
treatment, therapeutic effects could also be
overestimated.
These problems led some researchers to
propose full-range rating scales. For example,
Waschbusch and Sparkes (2003) designed an
ADHD rating scale based on the assumption
that symptoms can be rated below or above
“normal” level. For example: “Does not seem
to listen when spoken to directly” is rated with
five anchor points from “much less” to “much
more” than other (normal) children of the same
age and sex. This attempt to break down the
“Just a Little” and “Not at All” rating into cate-
gories from “much less” to “less” to “same”
yielded a more normal distribution, although
still negatively skewed, the “much less” rating
being significantly overrepresented, especially
in teacher ratings. Also, the proportion of chil-
dren rated as “more” or “much more” sympto-
matic was strongly decreased (Waschbusch &
Sparkes, 2003). Such a symptom-based full-
range scale has the inherent difficulty of evalu-
ating the relative rate of occurrence of behav-
ioral descriptors that are by definition
infrequent. A “much less” rating is also quite
broad as it encompasses different levels of the
corresponding strength. On the other side, eval-
uating the opposite strengths is likely to be
easier and more reliable, as parents and teach-
ers observed them much more frequently and
generally define a weakness as a lack of
strength.
The SWAN (Strengths and Weaknesses of
ADHD-symptoms and Normal-behaviors ratings
Scale - SWAN) is a scale where the informant is
asked to assess the strength opposite to the
ADHD symptoms (Swanson et al, 2005).
Without changing the content, each item of the
SNAP-IV rating scale (Swanson et al, 2001) was
re-worded in order to capture the strength cor-
responding to the weakness. For example:
“Often does not seem to listen when spoken to
directly” becomes “Listen when spoken to
directly” and is rated from “far below average”
(-3) to “far above average” (+3) relative to chil-
dren of the same age. This approach yielded a
normal distribution of ADHD scores (Hay et al,
2007) with a small positive skewness, the
above average rating being somewhat overrep-
resented. The proportion of children rated as
symptomatic (below and far below average)
was also decreased.
The objectives of this study was to test
internal and external consistency of a French
adaptation of the SWAN and its accuracy as a
diagnostic test, by using a symptom-based
interview (DISC-4.0) and different problem-
based scales (Conner’s Parent and Teacher
Rating Scale) in a sample of children referred
for ADHD in a university-based specialized clinic
in Montreal, Canada. 
Methods
Participants
Children of 6-9 years of age (n=124)
referred by their physicians with a suspected
diagnosis of ADHD were recruited through the
Interdisciplinary Research Program on
Hyperactivity at Sainte-Justine Hospital
(Montreal, Canada). Children with an IQ of less
than 80 (Wechsler, 1991), born prematurely
(<35 weeks of gestation), with severe learning
or language disabilities and with neurological
diseases (e.g. epilepsy) were excluded.
Following Ethics Board approval, informed
consent was obtained from all participating
families. 
Measures
DISC-4.0: During the scheduled hospital
visit, the parent was administered a structured
computerized interview, the Diagnostic
Interview Schedule for Children 4.0 (DISC-4.0),
by a trained interviewer. The DISC-4.0 has been
translated into French by two independent
research teams in Montreal. These French ver-
sions have been compared systematically and
standardized to build the DISC-4.0 version
used in this study. The French DISC-4.0 has not
been specifically validated, but the test-retest
reliabilities of the English version of the DISC-
4.0 (Shaffer et al, 2000) and of the previous
French version (DISC2.3) (Breton et al, 1998)
are considered satisfactory. Diagnoses of
Attention Deficit Hyperactivity Disorder (ADHD),
Conduct Disorder (CD), and Oppositional
Defiant Disorder (ODD) were obtained from the
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DISC-4.0 computerized algorithms. The pres-
ence (or not) of each ADHD symptom and the
number of positive symptoms rated with the
DISC-4.0 were evaluated.
SWAN-F: The original SWAN is based on the
DSM-IV criteria and is available through
http://www.adhd.net/. In the SWAN, symptoms
from the DSM-IV criteria list were reworded
using a strength-based formulation; for
example, “often has difficulty sustaining atten-
tion in tasks or play activities” was modified to
“is able to sustain attention in tasks or play
activities”. We adapted the SWAN, as the origi-
nal version retained some symptom-based
explanations and translated it in French (using a
back-translation): see appendix. The SWAN-F
includes the items for the DSM symptoms for
Inattention (9 items), Hyperactivity/ Impulsivity
(9 items), Oppositional Defiant Disorder (8
items) but not the 3 additional “sluggish tempo”
items and a 30th item “Avoid quarrelling” of the
downloadable SWAN. Three Conduct Disorder
items and 5 prosocial items were also included,
but not analyzed.
The SWAN-F items are scored according to a
seven-point scale ranging from “far below
average” (-3) to “far above average” (+3) rela-
tive to children of the same age, a score of 0 is
“in the average”. For each child, scores for
SWAN-F Inattention (S-IN scores) and
Hyperactivity/Impulsivity (S-HY/IM scores) sub-
scales were calculated as the average of the
ratings obtained for the 9 inattention and the 9
hyperactivity/impulsivity items, respectively. The
overall SWAN-F ADHD score (S-ADHD scores)
was the average of the 18 ratings. Scores for
the SWAN-F Oppositional Defiant Disorder (S-
ODD scores) was estimated as the average of
the ratings obtained for the 8 ODD items. Two
to three weeks prior to the scheduled evaluation
at Sainte-Justine Hospital, the parent (84%
mothers) received and completed the SWAN-F.
Revised Conners’ Parents and Teachers
Rating Scales (CPRS-R and CTRS-R; Conners et
al, 1998a,b): The French version of the
Conners’ Parent and Teacher Revised Rating
Scales (long version) were administered to the
parent and the teacher of the child respectively.
As age or sex-corrected scores are not avail-
able for the SWAN or the SWAN-F, and as the
age range was small, the raw ratings of the
SWAN-F scales were compared with the raw
scores of the Conners’ subscales, rather than
the usual standardized T-scores. Conners’ sub-
scales were calculated as weighted addition
(total of the ratings x number of items in the
scale/number of completed items) of the
respective items rated from zero to three. 
General Information Questionnaire: Infor-
mation on epidemiological, socio-demographic
and medical variables was collected using a
structured questionnaire addressed to the
parent. Specifically, information on the age of
the child, sex, mother’s and father’s education,
Canadian origin and family income and struc-
ture was collected.
Wechsler Intelligence Scale for Children
third edition (WISC-III) (Wechsler, 1991): This
scale was used by the psychologist to assess
the IQ of the child to determine if the child met
inclusion/exclusion criteria for this study.
Data Analyses
Preliminary analyses involved studying the
association between SWAN-F scores and socio-
demographic variables such as age (in
months), sex, mother’s and father’s education
(less than college/college or university level),
Canadian origin (one or two parents born
outside Canada/both parent born in Canada),
family income (<35 000$CAN/≥35 000$CAN)
or family structure (both biological parents vs.
other: mono-parental/reconstituted). Internal
consistency of the SWAN-F subscales was
assessed by estimating the Cronbach’s alpha
and correlations coefficients of each item with
the corresponding scale (item-total correlation).
To investigate external consistency, student t-
tests were performed to compare mean SWAN-
F scores between children with and without
ADHD, ODD and CD, diagnosed using the DISC-
4.0. SWAN-F scores within specific ADHD sub-
types (DISC-4.0) were compared using one-way
ANOVA. Pearson correlation coefficients were
calculated to assess the association between
Conners’ and SWAN-F scores. Finally, using
DISC-4.0 ADHD diagnostic assignment as ref-
erence, Receiver Operating Characteristic
curves (or ROC curves) (Beck and Shultz,
1986) were generated to investigate the capac-
ity of the Conners’ Parent Rating Scale and
SWAN-F ADHD scores to discriminate ADHD
cases versus non-cases. SPSS 15.0 was used
for the analyses.
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Results
Among the 124 referred families, 94 (76%)
accepted to participate and 6 children were
excluded because they presented with an IQ of
less than 80. Thus, the study sample consisted
of 88 subjects; 68 (78%) boys and 20 (22%)
girls. The age distribution of the children was
as follow: 19%, 32%, 34% and 15% were 6, 7,
8 and 9 years of age, respectively. Both
parents were of Canadian origin for 76% of the
children. College education was completed by
61% of the fathers and 56% of the mothers. 
Among the 88 children investigated, 74
(84%) were diagnosed with ADHD according to
DISC-4.0. Of these, 26 (35%) were categorized
as Inattentive, 15 (20%) as Hyperactive/
Impulsive and 33 (45%) as Combined type. A
total of 57 (77%) cases presented at least one
other psychiatric disorder; 46 (62%) presented
with CD or ODD, 24 (32%) with at least one
Mood or Anxiety Disorder, 10 (14%) with Tic
or Tourette’s Disorder and 4 (5%) with
Elimination or Eating Disorders. Forty nine
subjects (56%) were currently being treated
with psychostimulants, this frequency was
similar among subjects classified as ADHD and
non-ADHD according to DISC-4.0.
The SWAN-F scores were normally distrib-
uted within subscales among the study popula-
tion. Multiple linear regression revealed no
association between any of the socio-demo-
graphic variables and the different SWAN-F
scores. However, the modes of the S-ADHD
scores distribution, were very similar (Mean=-
1.22; S.D. = .77 in boys and Mean=-1.15;
S.D.= .85 in girls), as the medians (-1.36 for
boys and-1.0 for girls), the modes of the S-
ADHD scores distribution were -2.06 in boys
and only -0.78 in girls.
Internal consistency
Internal consistency of SWAN-F was within
an acceptable range for all subscales (Table 1),
yielding coefficients above 0.80 (Nunnally &
Bernstein, 1994). A Cronbach’s alpha coeffi-
cient of 0.91 was observed for the S-ADHD
subscale (18 ADHD items). While all other item-
correlations with the S-IN subscale were above
0.53, the item “listen when spoken directly”
(DSM-IV 1c ADHD item; American Psychiatric
Association, 1994) had an item-total correla-
tion of 0.31. The “able to talk with a normal
flow” item (DSM-IV 2f ADHD item; American
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Table 1: Internal consistency of SWAN-F subscales (N=88)
Number of Cronbach’s Alpha Range of item-total
Subscales items coefficients correlation coefficients
S-IN 9 0.89 0.31-0.77
S-HY/IM 9 0.88 0.33-0.80
S-ADHD 18 0.91 0.28-0.71
S-ODD 8 0.88 0.56-0.77
Table 2: Comparison of mean SWAN-F scores between children with and without ADHD, ODD and CD
SWAN-F subscales
DISC-4.0 diagnosis
Mean Scores (Standard Deviation)
S-IN S-HY/IM S-ADHD S-ODD
Non-ADHD (n=14) -0.61 (0.72) 0.01 (0.90) -0.30 (0.67) -0.35 (0.97)
ADHD (n=74) -1.59 (0.84)*** -1.16 (0.90)*** -1.38 (0.74)*** -0.85 (1.04)
Non ODD (n=43) -1.27 (0.74) -0.56 (0.90) -0.91 (0.72) -0.12 (0.89)
ODD (n=45) -1.59 (1.00) -1.37 (0.93)*** -1.48 (0.83)** -1.38 (0.75)***
Non-CD (n=63) -1.34 (0.89) -0.77 (1.00) -1.06 (0.80) -0.55 (1.00)
CD (n=25) -1.66 (0.88) -1.48 (0.82)** -1.57 (0.78)** -1.31 (0.93)**
* p<0.05, ** p<0.01, ***p<0.001
Note: DISC-4.0 diagnosis: ADHD; Attention Deficit Hyperactivity Disorder, ODD; Oppositional Defiant Disorder, CD; Conduct Disorder. SWAN-F
scales: S-IN; Inattention, S-HY/IM; Hyperactivity/Impulsivity, S-ADHD; Attention Deficit Hyperactivity Disorder, S-ODD, Oppositional Defiant
Disorder. 
Psychiatric Association, 1994) had a coeffi-
cient of 0.33 when item-correlation with
S-HY/IM subscale was investigated.
Coefficients were greater than 0.51 for the
remaining items. The item-total correlations for
the S-ODD subscale were all above 0.64. 
External consistency 
Table 2 presents the mean SWAN-F scores
for children with and without ADHD, ODD and
CD, respectively. Significant differences in
mean SWAN-F scores between ADHD and non-
ADHD cases were observed for S-IN (t=4.08,
p<0.001), S-HY/IM (t=4.44, p<0.001) and
S-ADHD (t=5.06, p<0.001) subscales, with chil-
dren with ADHD presenting lower scores (more
impaired) then non-ADHD children. When ODD
and non-ODD children were compared, signifi-
cant differences between mean SWAN-F scores
were observed for all scales except the S-IN
subscale, with children with ODD presenting
lower scores (more impaired) than non-ODD
children. Finally, significant differences in mean
scores of the S-HY/IM, S-ADHD and S-ODD
were observed between children with and
without CD. Children with ODD and CD pre-
sented lower SWAN-F scores then non-impaired
children. 
ANOVA results evaluating the consistency
between SWAN-F scores and ADHD subtypes
are presented in Table 3. Predictably, mean
scores of the S-IN subscale were significantly
lower for children with Inattentive or Combined
subtypes compared to non-ADHD children and
children presenting with the Hyperactive/
Impulsive subtype. Consistently, mean scores
of the S-HY/IM subscale were significantly lower
for children with Hyperactive/Impulsive or
Combined subtypes compared to non-ADHD and
Inattentive children. These specific patterns
were no longer observed for the mean global
S-ADHD scores. S-ADHD scores were signifi-
cantly lower for children with the combined
subtype compared to children with each specific
subtype and for children with ADHD, whatever
the subtype, compared to non-ADHD children.
The mean SWAN-F ratings for each specific
DSM-IV item were compared between children
with or without the respective symptoms as
assessed with the DISC-4.0. The mean SWAN-
F ratings were significantly lower (p<0.05)
among children with the symptoms for 7 of the
9 Inattentive (“listen when spoken to directly”
p=.15, and “organize work and activities”;
p=.08 in a bilateral test) and all the Hypera-
more, significant negative correlations were
observed between the number of Inattentive
symptoms and the S-IN score (r= -0.57,
p<0.001) and the number of Hyperactivity/
Impulsivity symptoms and the S-HY/IM score
(r= -0.69, p<0.001): the more negative the
scores, the more numerous the symptoms.
When studying the relationship between
ratings of the SWAN-F and Conners’ Parent
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Table 3: Comparison of SWAN-F scores between ADHD subtypes. 
S-IN scores S-HY/IM scores S-ADHD scores
Group Group Group
DISC-4.0 diagnosis Mean (SD) differences Mean (SD) differences Mean (SD) differences
Non-ADHD vs, Non ADHD vs, Non ADHD vs, IN**,
Non-ADHD -0.61 IN***, 0.01 (0.90) HY/IM**, -0.30 (0.67) Non-ADHD
(n=14) (0.71) Non ADHD vs, Non ADHD vs, vs, HY/IM*, Non
COM** COM*** ADHD vs,COM***
ADHD subtypes 
(N=74)
Inattentive -1.76 -0.54 -1.15
(IN) (n=26) (0.64) IN vs, HY/IM** (0.81) IN vs. COM*** (0.65) IN vs, COM*
Hyperactive/Impulsive -0.92 -1.17
(HY/IM) (n=15) (1.18) HY/IM vs. COM** (0.93) -1.05 (0.92) HY/IM vs, COM*
Combined -1.77 -1.63
(COM) (n=33) (0.65) (0.66) -1.70 (0.59)
* p<0.05, ** p<0.01, ***p<0.001. 
Note: SWAN-F scales: S-IN; Inattention, S-HY/IM; Hyperactivity/Impulsivity, S-ADHD; Attention Deficit Hyperactivity Disorder.
Rating Scale, we observed significant correla-
tions for Conners’ Parent subscale scores and
all specific SWAN-F scores except the “listen
when spoken directly” item (Table 4). Among
the 45 teachers (51%) who completed the
Conners-Teacher scale, significant correlations
were observed between Conners’ Teacher and
Conners’ Parent scores for the Inattention
(r=0.36 p<0.05) and Hyperactivity/Impulsivity
(r=0.56 p<0.001) subscales. Furthermore, sig-
nificant correlations were also observed
between SWAN-F and Conners’ Teacher scores
for the Inattention (r= -0.30 p<0.05) and
Hyperactivity/Impulsivity (r= -0.32 p<0.05) sub-
scales. 
ROC curves were generated to evaluate the
discriminant capacity of the Conners’ Global
Index and S-ADHD subscale, using the DISC-
4.0 diagnosis assignment (gold standard) for
any type of ADHD as reference. The estimated
areas under the curves (AUC) were similar and
significantly different from 0.5 (no possible dis-
crimination) for the Conners’ Global Index’
(AUC= 0.79; CI 95%: 0.66-0.92) and SWAN-F
scores (AUC= 0.89; CI 95%: 0.81-0.97). For
the S-ADHD scores the optimal sensitivity
(0.86) and specificity (0.88) corresponded to a
cut-off of –0.60. For the Conners’ Global Index,
the optimal cut-off corresponded to a sensitiv-
ity of 0.75 and a specificity of 0.80. Increasing
the sensitivity to 0.85 by lowering the cut-off
resulted in a sudden drop in specificity (0.50),
an observation that suggests that the SWAN
could yield a lower false positive rate than the
Conners’ Rating Scale near cut-off. Results
were similar when using the DSM-IV global
symptom scale of the Conners’ Rating Scale:
optimal sensitivity and specificity were 0.80,
but any further increase in sensitivity generated
a sudden decrease in specificity. 
Discussion
Overall, the criteria used to assess the reli-
ability and accuracy of the SWAN-F in this study
sample showed that the SWAN-F was consistent
with the DISC-4.0 and the CPRS-R. SWAN-F
showed high internal consistency for all sub-
scales. Meaningful patterns of correspondence
were observed between S-IN, S-HY/IM and
S-ADHD scores and ADHD, ODD and CD diag-
noses, as well as with ADHD subtypes. Although
high correlations were observed for almost all
DSM-IV ADHD symptoms (item-by-item compar-
isons), the item “listen when spoken to directly”
showed low internal as well as external consis-
tency. The DSM-IV wording of the corresponding
criterion is “often does not seem to listen when
spoken directly”. The lower consistency may
result from a misunderstanding of the question
by the parents who scored the symptom as one
of “opposition” rather than “inattention”. “Does
not listen” (“N’écoute pas”) is often used to
mean “does not obey” in French. It may be
appropriate to modify the SWAN-F symptom
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Table 4: Item-by-item Pearson correlation coefficients between SWAN-F scores and Conners’
Parent Inattention or Hyperactivity/Impulsivity subscale scores.
Correlation between specific item SWAN-F scores and
Conners’ Parent Inattention scores Conners’Parent Hyperactivity/Impulsivity scores
a) attending to detail -0.44*** a) sitting still -0.65***
b) sustaining attention -0.51*** b) staying seated -0.68**
c) listening -0.14 c) modulating motor activity -0.56***
d) following through -0.52*** d) playing quietly -0.58***
e) organizing -0.60*** e) settling down -0.71***
f) engaging in sustained effort -0.61*** f) modulating verbal activity -0.47***
g) keeping track of things -0.59*** g) reflecting on questions -0.54***
h) ignoring extraneous stimuli -0.54*** h) awaiting turn -0.59***
i) remembering -0.47*** i) entering into others activities -0.66***
Inattention subscale -0.79*** Hyperactivity/impulsivity subscale -0.85***
*p<0.05, ** p<0.01, ***p<0.001
NB: all correlations are negative as impairment is rated as more negative in SWAN-F scores and more positive in Conners’ subscales
question to “Fais attention quand on lui parle
directement-Pay attention when spoken to
directly”. One Hyperactivity/Impulsivity item
worded “Quand il parle, est capable de régler
son débit suivant le contexte” in the SWAN-F -
for “modulate verbal activity (control excess
talking)” in the SWAN (corresponding to “often
talks excessively” as DSM-IV criterion) also
showed low internal consistency. This may be
related to the relative complexity of the item. A
simpler wording of this item (e.g., “Se retient de
trop parler, sur n’importe quoi- Keep them-
selves from talking too much, whatever the
topic”) could possibly increase the observed
internal and external consistencies. 
The SWAN was developed in response to
concerns that the SNAP-IV as well as the other
available symptom-based truncated checklist
may overestimate the number of youths with
ADHD, because of the skewed distribution. The
summary scores of the SWAN-F were normally
distributed even in a clinical sample and thus
departed from the J curve generated by one-
tailed ADHD rating scales. The use of normally
distributed ADHD ratings could also be of inter-
est for other clinical and research issues in
which the estimation of the normal variability
is central. 
For example, it may improve our under-
standing of the gender impact on ADHD expres-
sion. According to the polygenic multiple
threshold model, girls are less likely than boys
to be diagnosed with ADHD because girls
require greater liability to manifest ADHD than
boys. Mothers also perceived the DSM-IV
ADHD, ODD, and CD criteria as more descrip-
tive of boys (Ohan & Johnston, 2006). However,
in order to determine sex-specific cut-off, the
full sex-specific distribution should be known.
In an epidemiological sample of 872 boys and
812 girls, more girls than boys seemed to have
moderate symptomatic level using the SWAN
(Manly et al, 2005). By using a symptomatic
rating scale going from much less to much
more that other children, Waschbusch & King
(2006) found in an epidemiological sample of
781 boys and 710 girls that a small percentage
of girls with a higher than average ADHD and
ODD symptom count did not meet DSM–IV diag-
nostic threshold. In the present clinical sample,
we found no significant difference according to
gender for the mean SWAN-F scores. However,
the large difference in mode, more negative for
boys than for girls, suggests an over-represen-
tation of near-threshold ratings in girls, even in
a referred sample. Further research is thus
needed to explore the full distribution of scores
according to gender, and to develop age and
gender norms for the SWAN. 
The use of SWAN-F is also pertinent in
genetic studies. In a twin design, the structural
equation modeling is very sensitive to depar-
ture from normal distribution and truncated
measures are by definition skewed. In addition,
scoring individuals struggling with difficulties
as well as those performing well above average
increases the validity of the correlations within
twin pairs. The direct comparison of truncated
(Australian Twin Behaviour Rating Scale -
ATBRS) with full-range scores (SWAN) suggests
(Hay et al, 2007) that the proportion of children
rated as having problems is inflated by using a
problem-based truncated scale, as compared
to a full-range strength-based scale. As the “not
at all” descriptor is also used to describe a
much wider range of behaviors than the other
descriptors (normal but also different degrees
of strength), parents seem to re-distribute their
scores and to use more frequently the “nega-
tive” standard descriptors (from sometimes to
very often). Not only is the highly skewed dis-
tribution problematic in genetic studies, but
increasingly, association studies are using dis-
cordant or concordant pairs to detect linkages.
Full-range questionnaires are obviously more
appropriate to identify extremely discordant
pairs than truncated ones and may be
preferred (Cornish et al, 2005). The same rea-
soning holds for studies that look for an asso-
ciation between any biological or neuropsycho-
logical measures and behaviors by selecting
subjects at both ends of the distribution of
behavioral descriptors. For example, the SWAN
was used to select children at the extremes of
a “normal” ADHD continuum in a study on the
relationship between rightward visuo-spatial
bias and poor attention within the normal child
population using the Line Bisection test (Manly
et al, 2005).
Limitations 
Some limitations of the study should be
considered prior to interpretation. The accuracy
of the SWAN-F was evaluated among ADHD
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patients referred to clinicians as part of an
ongoing research program. Thus the population
was in many ways a “selected population” and
extrapolation of findings to the “general” or
similar “ADHD” populations may be inappropri-
ate. Further studies among larger unselected
populations will be necessary to further evalu-
ate the utility of the SWAN-F. Although, infor-
mation gathered with the SWAN-F significantly
correlated with that obtained by the Conners’
Teachers Rating Scale, the low response rate
among the teachers may have influenced the
results. In the present study, classification as
ADHD or non-ADHD was based on the findings
obtained using DISC-4.0. Diagnosis using DISC-
4.0 has inherent limitations. Information is col-
lected from only 1 informant and judging the
exactness of the information is not possible.
Clinical implications
To our knowledge, this is the first validation
study of the SWAN assessing internal and
external consistency in a referred sample.
Although, the investigation of their psychomet-
ric properties needs to be further pursued, the
SWAN and SWAN-F could nonetheless in their
present form have good potential for use in
clinical and research setting because they
retain the advantages of other rating scales:
simple to comprehend, rapidly completed, pro-
viding quantitative scores. In addition, as they
are based on strengths, they allow parents to
recognize them when they exist and thus may
decrease guilt and stigmatization associated
with reporting the child’s difficulties. Moreover,
these scales may allow limiting some bias in
clinical decision-making. A study by Lewczyk et
al (2003) showed that the poor concordance
among clinicians when diagnosing ADHD and
disruptive disorder partly resulted from the
concern to avoid false positives, even at the
cost of increasing the risk for false negatives.
The Conner’s Parent Rating Scale was reported
to have a sensitivity of 0.92 and a specificity of
0.94 (Conners et al, 1998a), in separating chil-
dren with a confirmed diagnosis of ADHD and
an epidemiological sample (mean age = 10.16
years; SD = 3.40). However, the present data
suggest that the accuracy could be lower in a
clinically referred sample (around 0.80), com-
parable to the SWAN. Moreover, if further
studies confirm the lower false positive rate
associated with the SWAN-F, it could constitute
a more reliable tool for clinicians than
symptom-based scales.
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